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Introduction 
Nutrition and immunity to infectious diseases are inseparable. One reason why infectious 
diseases such as malaria are more common in poor communities than in rich communities is 
that the former are more vulnerable to malnutrition. The diet of poor people in sub-Saharan 
Africa is based on cereal-based foods that have low contents of micronutrients (for example 
provitamin A) or that contain compounds that inhibit the intestinal uptake of trace metals 
such as zinc and iron. The aim of this first chapter is to review the effect of micronutrient 
deficiencies on the immune response to malaria, particularly with regards to their effect on 
cellular immunity. Although the focus of this review is on zinc, we will also consider other 
micronutrients because zinc deficiency in developing countries is commonly found in asso-
ciation with deficiencies in other micronutrients. 
 
1. Zinc nutrition 
1.1 Biological functions of zinc: Zinc is important for human well being because of its 
manifold biological functions in the body. It is a cofactor in many metalloenzymatic meta-
bolic pathways and  is required for the structure and activity of nearly 200-300 metalloen-
zymes, not only in humans but also in other  organisms [1, 2]. It has an antioxidant and cell 
membrane stabilisation activity that keeps the cells intact and functioning normally. Zinc is 
also known to play a critical role in body’s defence against infectious agents: it affects mul-
tiple aspects of the immune system, from the skin barrier to gene regulation in the lympho-
cytes [3]. As a result, zinc-deficient individuals are relatively vulnerable to a variety of 
pathogens. Zinc is fundamental in normal development and function of cells mediating both 
innate and acquired (specific) immunity. Zinc-deficient persons have disturbed functions of 
neutrophils and natural killer cells (non-specific immunity), and disturbed outgrowth and 
functions of cells of the adaptive immune response, affecting T lymphocyte numbers and 
activation, Th1 cytokine production, and B lymphocytes and antibody production, particu-
larly immunoglobulin G [4]. Zinc plays an important role in maintaining the proper balance 
between cell-mediated and humoral immunity by regulating patterns of cytokine secretion. 
These putative effects of zinc, together with its effects on the basic cellular functions such as 
DNA replication, RNA transcription, cell division, and cell activation makes its deficiency 
to be an issue of concern. Zinc is central in the formation of ‘zinc fingers’, i.e. loops within 
DNA-binding proteins that are required for recognizing and binding of these proteins to 
specific DNA regulatory sequences. Because many of these proteins act as transcription 
factors, zinc is required for DNA transcription. This role is particularly important in macro-
phages and other cells of the immune system that must divide rapidly in response to anti-
genic stimulation [4-6]. Zinc and iron are particularly required for the synthesis of deoxyri-
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bonucleotide precursors by ribonucleotide reductase and for the various nucleotidyl trans-
ferases. Apoptosis and thymic atrophy are also potentiated by zinc deficiency predisposing 
to probable impaired T-cell development and decreased T-cell counts with consequent CD4+ 
T-cell depletion.  
 
Micronutrients other than zinc are also critical for normal immune functioning [7].  Both the 
innate [8] and adaptive immune responses (cytokines and antibodies) are highly affected by 
deficiencies of micronutrients especially vitamin A, magnesium,  copper, iron and vitamin E 
[7]. Erickson et al [8] have stressed that these deficiencies particularly affect the functioning 
of macrophages, NK-cells and the polymorphonuclear cells, so that innate immune response 
is impaired. Because these innate response also determine the nature of the adaptive immune 
response, and particularly the balance between pro-inflammatory and regulatory immune 
responses, such deficiencies may be critical for the outcome of malarial infection. Thus an 
increased intake of such micronutrients may complement other interventions to control in-
fectious diseases. Table 1 shows the nutritional markers used in this thesis.  
 Table 1: Selected nutritional markers used in this thesis. 
Status Serum/plasma marker
 1
 Reference 
Zinc 
deficiency 
Zinc concentration <9.9 mmol/L (children aged <10 
years) 
Hotz and Brown 
[9] 
Low zinc 
status 
Zinc concentration <10.7 µmol/L Pilch and Senti 
[10] 
Iron 
deficiency 
Ferritin concentration <12 µg/L WHO [11] 
Iron 
deficiency 
anaemia 
Iron deficiency accompanied by anaemia (for children 
<5 y: haemoglobin concentration <110 g/L) 
WHO [11] 
Low 
magnesium 
status 
Magnesium concentration < 763 µmol/L, <777 µmol/L, 
<741 µmol/L, <740 µmol/L and <745 µmol/L for 
children aged 6-12 mo, 13-24 mo 25-36 mo, 37-48 mo 
and  >48 mo, respectively 
Adapted from 
Lowenstein and 
Stanton [12] 
Vitamin A 
deficiency 
Retinol concentration <0.70 µmol/L Sommer and 
Davidson [13] 
1 In the absence of inflammation 
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1.2  Zinc absorption and metabolism: Dietary zinc is taken up from the intestinal lumen by 
mucosal cells, where it is either integrated into intracellular zinc pools or rapidly transported 
across the basolateral membrane to the plasma compartment. In the plasma, the newly ab-
sorbed zinc is transported in portal systemic transport by albumin as the major carrier pro-
tein in a form of albumin-zinc complex [14].  
 
1.3 Causes and health effects of zinc deficiency: Plant foods contain phytic acid and phe-
nolic compounds, including some tannins from legumes, that interfere with the absorption of 
nutritional zinc. These compounds are collectively known as antinutrients. In addition, die-
tary calcium can decrease the absorption of zinc and iron [15]. Plant foods grown in zinc-
deficient soils are low in zinc content thus leading to dietary zinc deficiency. The varying 
grain zinc according to their source and not solely due to their genotype, indicates that the 
seed zinc content is controlled additively by both genotype and the environment of the 
mother plant, hence its availability from the food source when consumed by man. Balanced 
diets from variety of source that contain different nutrients at different levels will help to 
reduce risks of zinc deficiency. 
 
Overt zinc deficiency occurs in acrodermatitis enteropathica, a rare, autosomal recessive 
disorder, usually occurring in the first year of life [2, 16, 17] that results in severe zinc defi-
ciency as a consequence of impaired intestinal zinc absorption. This is associated with der-
matitis, poor wound healing, retarded growth and sexual development, and reduced taste 
acuity, abdominal pain, diarrhea, skin rash, and loss of appetite [18]. Recent studies have 
also identified a genetic mutation in women with low milk zinc concentration that results in 
transient neonatal zinc deficiency [19]. More frequently, however, individuals with zinc 
deficiency have no signs or symptoms even if it is associated with an impaired immune 
function and an increased burden of infectious diseases. Thus zinc supplementation has been 
shown to prevent diarrhoea and pneumonia in young children, whilst zinc supplementation 
during diarrhoea reduces the severity and duration of such illnesses [20, 21]. Its effect on 
child mortality remains inconclusive, although subgroup analyses suggest that it reduces 
mortality in children aged ≥12 months, with evidence of efficaciousness in infants aged <12 
months [20]. In children in Papua New Guinea and The Gambia, zinc supplementation also 
led to a reduced incidence of malaria [22, 23], although there was no evidence for such an 
effect in children in Burkina Faso [24]. Zinc supplementation can reduce infection with My-
cobacterium tuberculosis [25], and has been shown to greatly reduce the incidence of skin 
and wound infections in diverse populations including infants [26] and pregnant women 
Chapter 1 
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[27] . 
 
Studies on the effect of maternal zinc supplementation on infant birth weight and on infant 
and maternal health outcomes have ended with inconclusive results. In infants, however, an 
increased zinc intake may lead to improved mental and psychomotor development [28, 29]. 
Other consequences of zinc deficiency include impaired growth and loss of appetite. 
 
More trials need to be carried out to assess possible benefits and adverse effects in HIV. In 
the few studies that have been conducted so far in HIV-infected individuals, zinc intake was 
associated with decreased burden of opportunistic infections [30], an improved weight gain 
and increased CD4 cell counts [31]; however, these studies must be interpreted cautiously 
[30, 32]. Yeudall et al. [33] have studied and shown that multiple micronutrients, when in-
cluded in supplementation regimen, reduce incidences of common conditions like fever, 
diarrhoea, upper and lower respiratory infections. This suggests that precisely selected mul-
tiple nutrients rather than single micronutrient may be the preferred approach in African 
settings. 
 
1.4 Risk groups for zinc deficiency: In developing countries, the groups at highest risk for 
zinc deficiency are young children, and pregnant and lactating women. These groups also 
suffer the greatest burden of infectious diseases such as malaria. Preschool children are par-
ticularly vulnerable because of the large amounts of zinc required for rapid growth during 
this age.  Transient neonatal zinc deficiency in breast-fed infants, which cannot be corrected 
through maternal zinc supplementation, has been reported as a result of low zinc concentra-
tions in breastmilk [34-38]. However, breast milk normally has adequate zinc content to 
meet the requirement for infants up to 4–6 months of age [39]. Thus zinc deficiency usually 
starts at the age when children start receiving complementary foods, which are usually based 
on grains that contain antinutrients (see above). 
 
1.5 Assessment of zinc status: Although several methods are used to determine zinc status 
of individuals and populations, none is entirely satisfactory. A combination of zinc defi-
ciency characteristics (e.g. growth retardation, delayed sexual and skeletal maturity, skin 
lesions such as orificial and acrodermatitis, diarrhoea, alopecia, and behavioural changes) 
and severe hypozincemia makes the detection of severe human zinc deficiency relatively 
easy [40]. In severely zinc-deficient individuals, concentrations of zinc in the plasma are 
usually < 0.4 mg/L and often < 0.2 mg/L 
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In individuals with moderate zinc-deficiency, however, there are usually no manifestations; 
even if features exist, they are usually non-specific. Plasma zinc concentration is the most 
frequently used and best available method to determine zinc status, but it can be affected by 
a variety of other factors. Cut-off values defining deficiency are dependent on age, sex, 
pregnancy status and whether plasma samples were collected in a fasted state, either in the 
morning or in the afternoon/evening [9]. Infection-induced inflammation can reduce plasma 
zinc concentration; however, mean plasma zinc concentration may be a useful indicator of 
population zinc status for children in low-income nations despite the high prevalence of 
common childhood infections [41]. 
 
The zinc status of populations can also be assessed by determining the dietary intake of zinc 
and phytate. This can serve to estimate the dietary intake of zinc that is available for absorp-
tion, which can be compared with required amounts to assess the adequacy of intakes [9]. 
 
Zinc deficiency at population level can also be shown by determining the response to zinc 
interventions of growth or functional outcomes in randomised controlled trials [42]. Indi-
viduals with adequate zinc status down-regulate their absorption of zinc from food and may 
not respond to zinc-enriched staple foods to the extent shown by zinc-deficient individuals 
[43]. Serum extracellular superoxide dismutase can possibly be used as a biochemical indi-
Figure 1: Distribution of malaria worldwide; highlighted areas indicates regions worst 
affected by the disease. Source: WHO 
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cator of marginal zinc deficiency in humans [44] although further testing and validation is 
still needed to determine  the reliability of this indicator. Zinc clearance tests have also been 
used as diagnostic tests for marginal zinc deficiency in children of small stature [45]. 
 
1.6 Public health interventions to increase zinc intake: Despite the evidence of the health 
benefits of zinc supplementation, it has been difficult to translate these findings into health 
policies for African children. When planning the studies described in this thesis, the trials 
that had been conducted had been done almost exclusively in Asia, Latin America, the Pa-
cific, and developed countries. By contrast, the response to supplementation may be differ-
ent in Africa, where children’s health is challenged by different environmental factors. Ma-
laria is the prime example, with more than 90% of global deaths occurring in African chil-
dren, and up to 90% of African toddlers in many areas being infected but symptom-free. 
Few studies have been conducted on the protective effect of zinc against malaria, and their 
results are still contradictory and conflicting (see above). 
 
A group of leading economists recently recommended zinc supplementation as one of the 
most cost-effective interventions for reducing malnutrition and improving human welfare 
[46]. Nonetheless, adequate delivery of zinc supplements to populations in need is probably 
difficult to achieve. Preventive supplementation requires frequent contact with target groups 
that can possibly be achieved through integration with twice-yearly vitamin A supplementa-
tion programmes, immunization and growth monitoring programmes, or through social mar-
keting. Single-nutrient interventions are costly and in the long term possibly unsustainable 
[33]; this may be overcome at least in part by supplementation strategies that simultaneously 
address multiple micronutrient deficiencies. Another difficulties is the lack of suitable sup-
plementation vehicles for infants and toddlers, who have problems of swallowing tablets or 
capsules. There are several efforts currently being undertaken to develop and test low-cost 
supplementation vehicles in the form of chewable tablet-cookies and a nutrient-dense spread 
suitable for use in tropical environments [47-50]. 
 
Zinc supplements are now also recommended by the World Health Organization as part of a 
simple treatment for diarrhoea, in conjunction with oral dehydration salts. This use of zinc is 
safe and efficacious and may decrease the unnecessary use of antibiotics for non-dysentery 
diarrhoea [18, 51] and pneumonia. Short-term supplementation has the added benefit of 
improving health and overall immune status some weeks following treatment, and this strat-
egy may also boost the body’s immunological defence against other infections such as ma-
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laria and may be an effective way of decreasing childhood morbidity and mortality [18, 52]. 
Acceptance and affordability of the planned programs to the target populations is important; 
therefore the intervention practices should not differ much from the socio-cultural ways the 
target population is accustomed in terms of food practices. 
 
Several other innovative and complementary approaches are currently being developed. One 
is to breed and disseminate new staple crop varieties with high concentrations of micronutri-
ents. This can be achieved through selection and crossing of promising lines as part of a 
classical breeding programme; however, plants may also be genetically engineered to in-
crease the concentration of bioavailable zinc [53]. The approach has the potential to create 
an entirely new, safe, low-cost and self-sustaining approach to deliver zinc to poor farmer 
families [54]. Although the development and dissemination of such ‘biofortified’ crops re-
quires large initial research investments and sustained support by national and international 
policy makers, these interventions have low long-term recurrent costs. Because of technical 
constraints, and contrary to other methods of delivery such as supplementation or fortifica-
tion, the biofortification approach must focus on single nutrients or at most a few nutrients. 
This imposes a need to identify micronutrients that are critical to health and probably con-
sider area or regional requirements. Efforts to develop typically ‘African’ crops rich in zinc 
have so far been limited, and require increased support that is probably best obtained when 
showing compelling evidence of the health benefits of increasing zinc intake. 
 
Another option for increasing daily zinc intake is the mass fortification of centrally proc-
essed staple foods [55]. Zinc fortification has the potential to increase zinc intake and total 
zinc absorption, but there are no data to demonstrate the efficacy and effectiveness of this 
approach in improving the zinc status of young children [56]. Both the selection of appropri-
ate food vehicles and cost considerations should be taken into account in the formulation of 
fortification programmes [57]. 
 
Lastly, zinc nutrition can be improved by changing food preparation and processing meth-
ods to increase zinc bioavailability [52]. For example, soaking and fermentation can reduce 
the content of [31, 58] and can increase the bioavailability of zinc 
 
 
 
Chapter 1 
 17 
2.  Malaria 
2.1  Burden of disease: Malaria has been and still causes much morbidity and mortality in 
endemic areas. The disease occurs in hundred of countries and represents between 300 and 
500 million clinical cases per year. More than 40% of the world's population is at risk of 
malaria infection with 90% of cases and more than 95% of global deaths occurring in tropi-
cal countries, particularly sub-Saharan Africa [59]. Up to 90% of African toddlers in many 
areas are malaria-infected but symptom-free. In malaria-endemic regions of sub-Saharan 
Africa, the groups at greatest risk of malaria-associated mortality are children younger than 
five-years of age (one child dying of malaria in every 30 seconds) and pregnant women. 
However, in African children it has been found that the incidence of severe malaria declines 
markedly after the age of four years [60]. Malaria epidemics have devastated large popula-
tions and, together with HIV/AIDS and tuberculosis, is one of major public health chal-
lenges and a serious barrier to economic progress in many developing countries. 
 
2.3 Pathogenesis and manifestations: Illness in malaria is caused by the erythrocytic stage 
of the parasite. There are no symptoms associated with sporozoites, the developing liver 
stage of the parasite, the release of merozoites from the liver, or gametocytes.  The first 
symptoms and signs of malaria are associated with the rupture of erythrocytes when erythro-
cytic stage schizonts mature. This release of parasite materials like, glycosylphosphatidy-
linositol (GPI) moieties [63], malaria pigment [64] and plasmodium-derived nitric oxide 
synthase (NOS)-inducing soluble factors [65] apparently trigger a host immune response. 
The simultaneous rupture of the infected erythrocytes and the concomitant release of anti-
gens and waste products accounts for the intermittent fever paroxysms associated with ma-
laria. These by-products stimulate human mononuclear cells to release pro-inflammatory 
cytokines like tumour necrosis factor-alpha (TNF-α) and other pyrogenic cytokines [66-70]. 
Pro-inflammatory cytokines such as TNF-α suppress haematopoiesis, thus contributing to 
anaemia. The spleen and liver enlarge over time especially in febrile children with malaria 
[60].  
 
As stated earlier, cytokines, reactive oxygen intermediates, and other cellular products re-
leased during the immune response play a prominent role in pathogenesis, and are consid-
ered responsible for the fever, chills, sweats, weakness, and other systemic symptoms asso-
ciated with malaria. P. falciparum has additional unique characteristics that help to explain 
its distinct potential to cause severe or fatal disease. The parasite is very fast and prolific in 
replication and in higher numbers of parasites than other Plasmodium species. As P. falcipa-
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Box 1. Human malaria parasites  
Four species of protozoan parasites within the genus Plasmodium are known to cause malaria. 
These include P. falciparum, P. vivax, P. ovale and P. malariae. In Africa, the vast majority, 
widespread and most deadly malaria cases are due to P. falciparum. 
The malaria parasite, like other members of apicomplexa has a complex life cycle, pigeonholed 
by three distinct processes: sporogony, merogony and gametogony. The life cycle of P. falcipa-
rum involves an insect vector (mosquito) and a vertebrate host (human). The stage infective for 
humans is the uni-nucleate, lancet-shaped sporozoite (approximately 1×7 µm). Sporozoites are 
produced by sexual reproduction in the midgut of vector anopheline mosquitoes and migrate to 
the salivary gland. When an infected Anopheles mosquito bites a human, she may inject sporo-
zoites along with saliva into small blood vessels (Figure 2). Sporozoites are thought to enter 
liver parenchymal cells within 30–60 minutes of inoculation. In the liver cell, the parasite de-
velops into a spherical, multinucleate liver-stage schizont which contains 2,000 to 40,000 uni-
nucleate merozoites. This process of enormous amplification is called exo-erythrocytic 
schizogony. This exo-erythrocytic or liver phase of the disease usually takes between 5 and 21 
days, depending on the species of Plasmodium. However, in P. vivax and P. ovale infections, 
maturation of liver-stage schizonts may be delayed for as long as 1 to 2 years. These quiescent 
liver-phase parasites are called hypnozoites. Because P. vivax and P. ovale are relatively rare in 
Africa, these species will not be considered in the remainder of this review. 
Mature schizonts eventually rupture, releasing thousands of merozoites into the bloodstream. 
Each merozoite can infect a red blood cell by entering through receptor-mediated endocytosis 
[61]. Inside erythrocytes a series of asexual events (3–5 cycles) takes place involving erythro-
cytic schizogony with differentiation of late schizonts to individual merozoites. The merozoite 
develops to form either an erythrocytic stage (blood-stage) schizont (erythrocytic schizogony) 
or a spherical or banana-shaped, uninucleate gametocyte.  
The mature erythrocytic stage schizont contains 8 to 36 merozoites, each 5 to 10 µm long, 
which are released into the blood when the schizont ruptures. These merozoites proceed to 
infect another generation of erythrocytes. 
The time required for erythrocytic schizogony which determines the interval between the re-
lease of successive generations of merozoites varies with the species of plasmodium and is 
responsible for the classic periodicity of fever in malaria. The gametocyte, which is the sexual 
stage of the Plasmodium, is infectious for mosquitoes that ingest it while feeding on blood 
meal. Within the mosquito, the parasites develop over 2 to 3 weeks to mature ookinetes that 
traverse the gut epithelium to the salivary glands where they form an oocyst which then rup-
tures to release sporozoites that can infect humans. Only a fraction of the released sporozoites 
end up in the salivary glands [62], the rest can be introduced into uninfected individual during 
mosquito bite to initiate a new cycle. 
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rum parasites mature within red blood cells, they induce the formation of sticky knob-like 
protrusions on the surface of infected erythrocytes [71]. These knobs, bind to receptors on 
endothelial cells in capillaries and venules in multiple vital organs in the body [72] leading 
to cytoadherence and sequester formation. It is important to note that erythrocytes parasi-
tized by P. vivax do not readily bind to endothelium. Thus, despite very high plasma con-
centrations of TNF-a that may occur in vivax malaria, this infection does not lead to cerebral 
disease [73].  
 
The cytoadherence and sequestration of red cells within small vessels leads to microvascular 
pathology and obstruction to blood flow. Infected red cells also stick to uninfected red cells 
and form rosettes that clog the microcirculation [74]. Ultimately, secondary organ dysfunc-
tion and severe complications in the host can occur. In the brain this causes cerebral malaria; 
in the kidneys it may cause acute tubular necrosis and renal failure; and in the intestines it 
can cause ischemia and ulceration, leading to gastrointestinal bleeding and to bacteraemia 
secondary to the entry of intestinal bacteria into the systemic circulation. 
 
The severity of malaria associated anaemia tends to be related to the degree of parasitaemia. 
The pathogenesis of this anaemia appears to be multifactorial. Haemolysis or phagocytosis 
of parasitized erythrocytes and ineffective erythropoiesis are the most important factors, and 
phagocytosis of uninfected erythrocytes and an autoimmune haemolytic anaemia have also 
been implicated [72]. Consequently, children die from malaria essentially because of cere-
bral malaria, respiratory distress and anaemia/acidosis as prevailing syndromes [60]. Riley 
[73] has pointed out that cerebral malaria is predominantly an immune-mediated disease, 
and that immunological priming occurs during first infection, leading to immunopathology 
on re-infection. Massive intravascular haemolysis leading to haemoglobinuria and renal 
failure, frequently described in the past as blackwater fever, is also not uncommon. How-
ever, care should be taken not to confuse with haemolysis that may also occur after the use 
of certain antimalarial drugs (especially primaquine) in patients with glucose-6-phosphate 
dehydrogenase deficiency [75].  
 
2.4 Diagnosis and treatment: In African conditions, diagnosis of malaria in both children 
and adults is usually based on signs and symptoms common for the disease. Confirmatory 
tests for definitive diagnosis rely on observation of presence of parasites by microscopy or 
parasite antigens by rapid diagnostic tests (RDTs) but also by genotyping of DNA by poly-
merase chain reaction (PCR) [76-78]. However, in most African communities where malaria 
is endemic, physician evaluation, microscopy and currently RDTs are more available and 
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reliable tools. PCR is especially effective at detecting submicroscopic levels of parasitaemia 
[79, 80] but its application is usually restricted to large scale surveys rather than being used 
in clinical practice [81] because of the high costs of reagents, trained personnel and the labo-
ratory facilities required. 
 
Chemoprophylaxis is highly effective in reducing mortality and morbidity from malaria in 
young children and pregnant women living in endemic areas [82]  although it is difficult to 
sustain, may lead to rebounds when stopped, and, in some studies, has impaired the develop-
ment of naturally acquired immunity. For decades, chloroquine and other quinoline deriva-
tives have been the drugs of choice for treatment of falciparum malaria in endemic coun-
tries. Because of the spread and intensification of drug resistance,  the mainland of Tanzania 
was forced to change its policy in 2001 from chloroquine to sulphadoxine-pyrimethamine 
(SP) as the first-line drug for treatment of uncomplicated malaria in children, and subse-
quently, in 2006, to artemether/lumefantrine (AL).  Artemisinin-based combination thera-
pies (ACTs) such as AL are now recommended by the World Health Organization (WHO) 
in all countries experiencing resistance to conventional monotherapies (chloroquine, amo-
diaquine or sulfadoxine–pyrimethamine) [83]. The recent finding that intrarectal artesunate 
administration is efficacious and safe as an initial treatment for uncomplicated malaria in 
children [84] is helpful in individuals who cannot swallow drugs.  
 
2.5 Public health interventions to control malaria: Annual economic growth in countries 
with high malaria transmission has historically been lower than in countries without malaria. 
The disease may account for as much as 40% of public health expenditure, 30% to 50% of 
inpatient admissions, and up to 50% of outpatient visits [59] signifying that public health 
interventions against the disease are highly needed. Intervention programs currently imple-
mented target the vector mosquito (insecticides), the parasite (vaccines) and cure of patient 
(antimalarials) to ensure effective recovery from the disease. The Malaria Vaccine Technol-
ogy Roadmap [85] anticipates the development and licensing of a first-generation malaria 
vaccine that has a protective efficacy of more than 50% against severe disease and death by 
2015; as foreseen, a malaria vaccine with protective efficacy of more than 80% against clini-
cal disease and lasting longer than 4 years will have been developed and licensed by 2025. 
Whilst this strategy may serve to contribute to malaria control within 10-20 years, insecti-
cide-treated nets, intermittent preventive treatment in pregnancy and antimalarial drug com-
bination therapy remain the key interventions for prevention and treatment of malaria. Inter-
mittent preventive treatment, in which full therapeutic doses of a drug are given at defined 
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intervals [82], has the potential to provide some of the benefits of sustained chemoprophy-
laxis in pregnant women (IPTp) and young children (IPTi) and is a promising new approach 
to malaria control. Schellenberg et al. [86] have demonstrated a reduction of episodes of 
clinical malaria by 60% and episodes of severe anaemia by 50% in Tanzanian infants treated 
with SP at 2, 3, and 9 months of age, at the time of routine immunization. However, because 
SP resistance has already become widespread in Tanzania, it is necessary to consider the 
newly WHO recommended ACTs for effective malaria control in both infants and pregnant 
women. Supplementation of micronutrients, if shown to protect against disease, will best 
work if integrated with other interventions.  
 
3.  Immune mechanisms in malaria 
3.1 Overview of the role of immunity to malaria: The evolution of the immune system con-
sists of factors that provide innate and acquired immunity, and has evolved to become more 
specific, complex, efficient, and regulated. One of the principal functions of the human im-
mune system is to defend against infecting and other foreign agents by distinguishing self 
from non-self (foreign antigens) and to organize other protective responses from leukocytes. 
A dysregulated immune system can react to self antigens resulting into autoimmune diseases 
or failure to defend against infections. Much of the pathology associated with parasitic in-
fections such as  malaria, is immune-mediated. The immune mediators (e.g. cytokines) of 
protection can also cause disease, and the outcome of infection hinges on a delicate balance 
between appropriate and inappropriate induction of these mediators [70, 87].  
 
Helper CD4+ T-lymphocytes (Th-cells) play a critical role in the immune response to many 
human diseases, including malaria, working in close interaction with cells of innate immu-
nity. Such cells include macrophages and dendritic cells.  The outer membranes of dendritic 
cells (DC) contain innate receptors, the Toll-like receptors (TLRs), which sense microbes 
and microbial products and trigger dendritic cell maturation and cytokine production, thus 
effectively bridging the innate and adaptive immunity against the pathogen [88]. On the 
DCs, are also CD36 host receptors that recognize P. falciparum-infected erythrocytes bind-
ing and modulate their function. The CD36 mediates non-opsonic phagocytosis of infected 
erythrocytes [87, 89, 90]. Binding of pathogen associated molecular patterns (PAMPs) to 
relevant pathogen recognition receptors (PRR, like the TLRs or CD36) will result in activa-
tion of the NF-kB transcription factor complex and the subsequent production of pro-
inflammatory cytokines such as interleukin (IL)-12. Besides activation of the innate arm of 
the immune system this release of IL-12 will also polarise the antigen-specifically-activated 
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Figure 2. Plasmodium falciparum life cycle in the vertebrate host (man) and invertebrate 
host (the mosquito). Source: Malaguarnera and Musumeci [61]                                                                                                  
Th-cell repertoire into preferential Th1 development. Such overactive and polarised Th1 rep-
ertoire evokes IL-12 and IFN-γ-dependent protection against the blood-stage infection with 
the malaria parasite, Plasmodium falciparum. Regulatory T-cells, on the other hand, mediate 
active suppression of various immune responses [91]. These T-cells comprise classical Th2 
cells capable of inhibiting Th1 responses, but also alternative T-cell populations. One of the 
primary mechanisms of tolerance induction is via secretion of immunosuppressive cytokines 
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Malaguarnera and Musumeci [61]                                                                                                            
such as IL-10, IL-4 and transforming growth factor-beta (TGF-β). Regulatory T-cells have 
been isolated from in vitro cultures, which appeared to produce low levels of IL-2, no IL-4, 
but high levels of IL-10 and TGF-β, demonstrating the importance of cytokines in regulating 
and dampening the immune response. Although cytokine functions are complex involving 
protective and pathological consequences, the analysis of a set of these soluble proteins will 
allow direct and complete measurement of regulatory circuits of the human immune system 
[92, 93]. 
 
3.2 Innate immunity to malaria: Immunity plays a critical role in the pathogenesis of ma-
laria, as shown by two key observations [94]. First, in highly endemic, rural areas, it is com-
monly found that up to 90% of children are infected yet symptom-free. Secondly, hospital-
based studies in such areas show that severe, acutely life-threatening malaria and malaria-
associated deaths occur mostly at a very young age, when maternal antibodies obtained dur-
ing pregnancy have waned out, and chronic or repeated exposure to infections has not yet 
resulted in protective levels of acquired immunity. Thus in highly endemic areas, severe 
malaria is an increasingly rare phenomenon after the age of 5 – 10 years, whilst the preva-
lence of parasitaemia steadily declines after the age of 2 years. These observations and oth-
ers indicate that immunity against severe disease and subsequent death develops much faster 
than against pyrogens and parasites themselves. 
 
With the plasmodium parasite developing within the host hepatocyte being the major target 
of protective immunity at the exo-erythrocytic stage [95], the body’s immunologic defence 
mechanism develops against several liver-stage specific antigens, which along with those 
brought in with the invading sporozoite, are rapidly processed by the host cell and presented 
on the surface of infected hepatocytes in combination with MHC class I [96, 97]. Macro-
phages, including Kupffer cells, are antigen-presenting cells [98] and antigen presentation 
leads to recognition by cytotoxic T lymphocytes (CTLs) and killing of the infected cell or 
stimulation of NK and CD4+ T cells to produce IFN-γ, which can trigger a cascade of im-
mune reactions, eventually leading to death of intracellular parasite [96, 97]. Alternatively, 
the CTLs may directly be cytolytic to malaria-infected hepatocytes by releasing perforin and 
granzyme or by binding to apoptosis-inducing receptors on the infected cells [61, 95].  
Schwenk et al [99] proposed the exo-erythrocytic opsonization of P. falciparum liver-stage 
circumsporozoite proteins (spzs) by antigen-specific antibodies in both naturally infected 
individuals and in persons immunized with radiation-attenuated spzs to be an important step 
and a possible mechanism for macrophage phagocytic activity and contribution in confer-
ring a protective immunity against the infection. Evidence from other similar, previously 
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reported studies [100, 101] have revealed opsonization of spzs for uptake and destruction by 
monocyte/macrophages as a crucial process by which antibodies (Abs) contribute to protec-
tive immunity. All taken together, dendritic cells, NK-cells, NKT cells, macrophages and 
possibly γδT cells are proposed to play a great role as effectors of innate immune responses 
in human malaria infection. Evidence from in vitro studies have shown strong expansion of 
γδT cells during early phases of malaria infection supporting the idea that they contribute 
greatly in innate parasite control [102]. They can also modulate adaptive immunity through 
their ability to produce regulatory cytokines [87].  
 
Although the principal defence mechanism against protozoan parasites that survive within 
macrophages is cell-mediated immunity, particularly macrophage activation by Th1 cell-
derived cytokines [103], immunity to malaria is said to be both cellular and humoral [104], 
stage-specific [105] and includes both innate and adaptive immune responses. Following 
inoculation, the sporozoite stage in the liver comprises the first encounter with the host im-
mune system. The protective immunity relies on the release of pro-inflammatory cytokines 
such as IL-18, IL-12, IFN-γ, TNF-α, nitric oxide and reactive oxygen species by macro-
phages and NK cells [61, 106, 107]. Moreover, under the influence of the polarising capac-
ity of several of these cytokines, increased activity by CD8+ T-cells (CTL) will also result in 
an antigen-specific Th1 and cytolytic activity [108]. These early responses will be subse-
quently dampened by a later anti-inflammatory response based on the release of IL-4, IL-10, 
and TGF-β. Omer et al [70] for example, have reported low TGF-β concentration to have a 
pro-inflammatory role with an ability to recruit monocytes, T-cells and neutrophils towards 
the inflammation site early in an infection, through modulation of endothelial cell adhesion 
molecule expression in murine malaria. However, at high concentration, this multifunctional 
TGF-β has shown an anti-inflammatory role, suppressing production of TNF-α and NO 
from macrophages [109], inhibiting the production of IFN-γ and TNF-α from NK cells [110] 
as well as antagonising an IFN-γ-stimulated upregulation of major histocompatibility com-
plex (MHC) class II antigens [111]. These observations and results suggest that inhibition of 
rapid pro-inflammatory response and Th1 outgrowth such as may occur in zinc deficiency; 
potentially weakens the protective immune response towards human falciparum malaria. 
The fate and pathophysiological consequences of malaria, as stated earlier in this chapter, is 
pivoted largely on the balance in the pro- and anti-inflammatory immune responses and the 
regulation of innate immunity might be important component of adaptive responses.  
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Figure 3:  Possible targets of immune mechanisms at various stages of life cycle of human 
malaria parasite. The immune system react by activation, differentiation of T-cells leading 
to cytokine production and mainly cell-mediated response against liver-stage parasites. 
Antibodies, cytokines and free oxygen radicals are directed towards blood-stage parasites. 
Some of the merozoites develop (after escaping the immune attack), by a still unknown 
mechanism into male and female gametocytes which mature in the mosquito gut after being 
ingested by a blood sucking mosquito. In the gut, they fuse and develop sporozoites that may 
be injected into the blood stream of the new host through bite by the infected mosquito.  
Source: Hoffman and Miller [112] 
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3.3 Acquired immunity to malaria: Both innate and acquired immunity to malaria and other 
infections work synergistically being bridged with soluble mediator proteins, the cytokines. 
Specific antibodies are also thought to be involved in protective anti-malarial immunity de-
spite the fact that anti-malarial antibodies-induced immunity is not sterile [113]. The kind of 
immune response that develop against malaria is targeted towards reduction of clinical dis-
ease, lowering parasitaemia levels and is short lived unless there is repeated exposures like 
that occurs  in areas with intense transmission. In malaria endemic areas, repeated exposure 
to P. falciparum infection induces strong humoral immune responses characterised predomi-
nantly by immunoglobulins (Ig) M and G despite other isotypes. Large proportion of these 
immunoglobulins are non-malaria-specific reflecting polyclonal B-cell stimulation but a 
small proportion (5% or more) is what is important in malaria by keeping low parasitaemia 
and reducing clinical disease and is species and stage-specific reacting with a wide variety 
of parasite antigens [114]. Various transfer experiments conducted to date have indicated the 
significance of humoral immunity in providing a protection against malaria. In vitro studies 
have further shown that specific antibodies can inhibit both sporozoites motility [115] and 
sporozoites invasion of hepatocytes [116]. Additional evidence has shown that immunity to 
falciparum malaria is associated with protective antibodies of different classes and sub-
classes [117]. Depending on the dynamics of disease transmission and on the immune status 
of the individual, IgG1 and IgG3 antibodies have shown to be protective, while IgG2 and 
IgG4 subclasses generally compete and interfere with protection [113, 118, 119]. In other 
words, IgG2 and IgG4 are not considered protective. In general, IgG3 is the prevailing iso-
type associated with protection in humans. However, this isotype has only a short half-life in 
circulation (7 days, as compared to 24 days for IgG1). Hence, it would be beneficial to indi-
viduals to induce specific IgG1 antibodies, which potentially provide long-term efficient 
protection against the pathogen. In this context, cytokines such as IL-10, IFN-γ, IL-2 and 
TGF-β may be of profound importance, by virtue of their potential to induce isotype switch-
ing in B-cells to the induction of antigen-specific IgG1. Importantly, the precise production 
of these cytokines is thought to be affected by zinc deficiency, leading to decreased levels of 
innate immunity, but also decreased activity of NK cells and a decreased ability to mount a 
protective Th1-type immune response. 
 
3.4 T-cell responses to falciparum infection: Antibodies contribute to protective immunity 
to human malaria but priming of T-cells remains to be important for the development and 
maintenance of this important component of immunity [120-122], and T-cell-derived 
gamma interferon (IFN-γ) is said to be important in mediating the cellular effector mecha-
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Figure 4: Bridging the innate and acquired immune systems. Potential regulatory mecha-
nisms of adaptive immunity to blood-stage malaria by cytokines produced by cells of the 
innate immune response [87]. In response to parasite ligands recognized by pattern-
recognition receptors (PRRs), such as Toll-like receptors (TLRs) and CD36, or inflamma-
tory cytokines, such as interferon-γ (IFN-γ), dendritic cells (DCs) mature and migrate to the 
spleen which is the primary site of immune responses against blood-stage Plasmodium 
parasites. Maturation of DCs is associated with the upregulation of expression of MHC 
class II molecules, CD40, CD80, CD86 and adhesion molecules and the production of cyto-
kines including interleukin-12 (IL-12). IL-12 activates natural killer (NK) cells to produce 
IFN-γ and induces the differentiation of Th1 cells. The production of cytokines, particularly 
IFN-γ, by NK cells results in DC maturation and enhances the effect of parasite-derived 
maturation stimuli, facilitating the clonal expansion of antigen-specific naive CD4+ T-cells. 
IL-2 produced by antigen-specific Th1 cells further activates NK cells to produce IFN-γ, 
which induces DC maturation and activates macrophages, further amplifying the adaptive 
immune response. Cytokines such as IL-10 and TGF-β negatively regulate both innate and 
adaptive responses.  
Source: Stevenson & Riley [87] 
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nisms [123]. Macrophages and dentritic cells are important in the initiation of innate im-
mune response (figure 4) with capability for integrating signals from pathogens, cytokines 
and T-cells, leading to the generation of an adaptive immune response of the appropriate 
class [124]. In this way the innate immune response is translated into adaptive immune re-
sponse to confer effective immune protection. Napolitani et al [125] suggest the TLRs ex-
pressed constitutively or after being induced in different cell types, to determine the innate 
cells capacity to detect microbial products [126-128] and discrimination to either type I or 
type II immune responses. This differentiation of macrophages to produce either type I or 
type II cytokine responses depends on activation states. The macrophages can be classically 
activated (caMac) to produce type I cytokines like IL-1β, TNF-α and in acute infections, IL-
12 [129] that are also produced by Th1 cells. On the other hand macrophages can be alterna-
tively activated (aaMac) inducing differentiation of T-helper cells into Th2 cells giving rise 
to production of type II cytokines like IL-4 and IL-10. While caMac expression of nitric 
oxide synthase (NOS) induce production of nitric oxide (NO) and polarization towards Th1 
responses, aaMac promote expression of arginase and polarization towards Th2 responses 
[129, 130]. The outcome of protozoan infections is largely dependent on the timing and rela-
tive strengths between the two types of responses (type I and II) which are dictated by acti-
vation pathway that the macrophages follow [131]. In most parasitic infections including 
helminths [129, 132-134] the response through aaMac is dominant, polarizing immunity 
towards Th2 responses. Studies by Rodriguez-Sosa et al [133] have shown chronic helmin-
thes infections to induce aaMac expressing high levels of chemokine receptor 5 (CCR5) 
with low IL-12 production despite a bias towards Th2 responses in mice. In humans, aaMac 
have been shown to actively inhibit proliferation of peripheral blood mononuclear cells 
(PBMCs) and down-regulating CD4+ T-cell-mediated responses [135].   
 
The domination of early responses to Plasmodium falciparum infection by pro-
inflammatory cytokines like IL-1β, TNF-α, IFN-γ and IL-12 which sometimes results into 
the pathological consequences, is suggestive of a classical activation of macrophages. This 
type I cytokine dependent pro-inflammatory response induce classically activated macro-
phages during protozoan infection [131]. Investigation of the immediate cytokine response 
of non-immune human PBMCs following stimulation with P. falciparum-infected erythro-
cytes after rigorous exclusion of Mycoplasma contamination has been done in vitro [136]. 
The results suggested that, the early inflammatory response to malaria is critically depend-
ent on lymphocyte subpopulations that are specific to P. falciparum antigens and that the 
response greatly differs from that which is directed towards bacterial endotoxins. It has been 
observed also that although viability of cells is slightly reduced [137] both antigen-specific 
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CD4+ and CD8+ T-cell responses are not affected in cryopreserved human PBMCs [138], 
signifying that T-cells are important targets for ex vivo measurements that reflect the magni-
tude and quality of in vivo T-cell responses. Studies on viability and functional activity of 
cryopreserved mononuclear cells [139] have however, indicated an association between 
viability and T-cell responses in HIV-based experiments. These prospective observations 
have not yet been well established in cryopreserved human PBMCs from exposed and non-
exposed individuals; stimulated with live P. falciparum antigens ex vivo. 
 
3.5.0 Regulation of cytokine responses in malaria: Regulation of immune responses is cru-
cial in plasmodium infection. During malaria, pro-inflammatory cytokines are released in 
early response to infection and later the adaptive (anti-inflammatory) responses takes over. 
Cytokines play both protective and pathological roles and the outcome of the disease de-
pends on the balance between protection and pathology. Cytokines production is elicited by 
schizonts rupture that result into release of  merozoites and various parasite antigenic sub-
stances and products like malarial pigments (hemozoins), glycosylphosphatidyl inositol an-
chors (GPI) of parasite proteins and other soluble antigens. The release of both pro-
inflammatory and anti-inflammatory cytokines require regulation for optimal responses and 
resolution of infection. Regulatory T-cells modulates parasite clearance and immune-
mediated pathology during malaria infection [140, 141].  
 
3.5.1 Regulatory T-cells; background: Regulatory T-cells (Tr cells) are subpopulation of T-
cells that was known once as suppressor T-cells because they down-regulate immune re-
sponses for both foreign and self antigens. These cells have immunoregulatory properties 
and they actively participate in maintaining and control of various immune responses [142, 
143]. Generation and differentiation of regulatory T-cells is reported to be dependent on 
transforming growth factor-beta (TGF-β) and that IL-6 may completely inhibit this TGF-β-
induced generation of regulatory T-cells [144]. Report by Seki et al [145] points out that 
galactose-specific soluble lectin-9 (Gal-9) induces differentiation of naïve T-cells (Th0) to 
regulatory T-cells and suppresses differentiation to Th17 cells (potentially pro-inflammatory 
cells, involved in autoimmune diseases such as rheumatoid arthritis) in vitro.  
 
Regulatory T-cells are characterized by expression of CD4 and CD25 markers on their sur-
faces (CD4+CD25+) which are IL-2 receptors and are referred to as natural regulatory T-cell 
(nTregs) [146]. These cells are produced by the normal thymus as a functionally distinct 
subpopulation of T-cells and their development critically depends on a forkhead family tran-
scription factor, Foxp3 [147] whose expression is regulated by IL-2 [148]. These cells do 
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not themselves produce IL-2 and act in a contact-dependent manner, antigen non-specific, 
prevent cell activation of other T-cells, and are dependent on exogenous IL-2 for prolifera-
tion in vitro and in vivo [149]. With broad repertoire of antigen specificities, they can recog-
nize both self and nonself antigens and their generation is controlled at least in part, devel-
opmentally and genetically. Other  subtypes of regulatory T-cells with diverse phenotypes, 
antigen specificity, and modes of action have been described [150, 151]. Some other anti-
gen-induced regulatory T-cells population have been identified and referred to as adaptive 
regulatory (or acquired regulatory) T-cells as they are induced in the periphery after encoun-
ter with pathogens and foreign antigens [152, 153]. Regulatory T-cells type I (Tr1 cells) are 
regulatory T-cells that produce the immunosuppressive cytokines IL-10 and originate from 
naïve T-cells primed by IL-10 or from T-cells induced by tolerogenic dentritic cells express-
ing IL-10. Th3 cells are also regulatory T-cells subpopulations that produce TGF-β. Regula-
tory T-cells play a golden suppressive role in maintaining the balance between Th1 and Th2 
to result into disease resolution while preventing pathology. The immunosuppressive cyto-
kines TGF-β and IL-10 therefore play important role in the balancing of immune response to 
a non-pathological one. 
 
In malaria the balance between Th1 and Th2 has been critical and it is the lack of a balanced 
immune response that results into aggressive pathological outcomes. Musumeci et al [69] 
studies on modulation of immune response in Plasmodium falciparum malaria have re-
vealed the levels of IL-12 to reliably predict the progression of the disease and they are 
modulated by administration of IL-18 and/or TGF-β (a Th3 product). Oustanding reviews on 
malaria immunology have further stressed  on the role of regulatory T-cells by pointing out 
that development of Th1 response can be antagonised directly by IL-4 and TGF-β and indi-
rectly by IL-10, which inhibit the production of pro-inflammatory cytokines [61] with IL-
10, in addition inducing B-cell proliferation, which is essential for the development of pro-
tective malarial antibodies. In malaria endemic areas the population risk to severe disease 
decline with increasing exposure with initially Th1/IFN-γ pro-inflammatory response 
switching to a predominantly anti-inflammatory response [73]. The switching between these 
responses is said to probably be induced by TGF-β, which has shown to be associated with 
reduced pathology in murine malaria [70, 154, 155]. The anti-inflammatory cytokine regula-
tory role of IL-10 and TGF-β produced by both the cells of  innate (macrophages) and adap-
tive (T-cells) are the key immunoregulators [87, 141] complemented by IL-4 that play a role 
in control of parasitemia and alteration of severity of malaria [156]. This means that IL-4 
contributes largely in conferring protection to malaria by potentially influencing adaptive 
immunity especially due to its role in polarization of T-cells. The TGF-β immunoregulatory 
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role base on its potetial property of being pro-inflammatory (at low concentration) and anti-
inflammatory (at high concentration) [70] that may largely depend on the antigen stimulat-
ing its release. 
 
3.5.2 Th17- cells and possible contribution to malaria pathology: With advancement in sci-
ence over decades, the understanding of immune aspects of regulation, pathogenesis and 
host defense to various infectious agents have broadened. The recent proposed T-cell subset 
of Th subpopulation, Th17, and understanding of contribution to outcome or pathology of 
malaria could be of particular interest. Th17 lineage of cells expressing IL-17 cytokines have 
been proposed some two years ago [157-159] and have been found  to develop from precur-
sor cells independent of cytokines and transcription factors that mediate the pathways under-
gone by Th1 and Th2 cell development [157]. This unique developmental and differentiation 
property of IL-17 producing Th17 provide insights into mechanisms by which signals from 
cells of the innate immune system guide alternative pathways of Th1, Th2 or Th17 develop-
ment [158].   
 
Activation of precursor Th cells in the presence of TGF-β and IL-6 is thought to drive differ-
entiation of Th17 cells in the mouse. Apart from cytokine environment, it is not clear 
whether any other elements of the initial activation of Th17 cells differ from those of other 
Th cell subpopulations. It has been suggested that IL-23 is involved in the expansion of al-
ready established Th17 populations, although the cytokine alone does not induce differentia-
tion of naïve T-cell precursors into that cell type. Cytokines produced by Th17 cells includes 
IL-17, IL-21 and IL-22 and among them IL-21, has also been shown to initiate an alterna-
tive route for the activation of Th17 populations [160]. In humans, a combination of TGF-β 
and IL-1β and IL-23 induces Th17 differentiation from naive T-cells [161] with both IFNγ 
and IL-4 which are main stimulators of Th1 and Th2 differentiation respectively, negatively 
regulating the Th17 differentiation [162, 163]. Studies in mice have in addition, shown the 
suppressive role of IL-10 on Th17 cytokines secretion by macrophages and T-cells in vitro 
and that only IL-10 deficient macrophages can produce IL-17 [164]. Some proteins involved 
in the differentiation of Th cells to Th17 cells are signal transducer and activator of transcrip-
tion 3 (STAT3) and the retinoic acid receptor-related orphan receptors  alpha and gamma 
(ROR-α and ROR-γ) [165]. The primary role of Th17 cells lies on its involvement in autoim-
mune disease. A more natural role for Th17 cells is suggested by studies which have demon-
strated preferential induction of IL-17 in cases of host infection with various bacterial and 
fungal species. Th17 primarily produce two main members of the IL-17 family; IL-17A and 
IL-17F which are involved in the recruitment, activation, mobilization and migration of neu-
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trophils and macrophages; and linking with activation of T lymphocyte subsets [166]. This 
is of particular attention as IL-17 produced by Th17 cells is said to contribute in a variety of 
inflammatory immune-mediated diseases such as rheumatoid arthritis, psoriasis and inflam-
matory bowel disease [167]. The involvement of Th17 in human malaria is still not yet eluci-
dated although has been found to associate with inflammation in rodent malaria parasite, 
Plasmodium yoelii [141].   
 
4. Zinc deficiency and malaria 
4.1 Effects of zinc on immunity: The immuno-modulating effects of zinc supplementation 
can be distinguished in immune enhancing and inhibiting activities [3, 168]. As a conse-
quence, zinc deficiency may also result in a surfeit of immune effects. Zinc deficiency rap-
idly diminishes antibody- and cell-mediated responses against parasites and viruses in both 
humans and animals. Biochemically, zinc catalyses the thymic hormone, thymulin, which 
stimulates differentiation, proliferation and maturation of CD8+ cytotoxic T-cells, CD4+ 
Th1-type cells, and of suppressor T-cells that are implicated in the fight against pathogens. 
The T-cell system is particularly sensitive to zinc deficiency because the resulting thymic 
atrophy, impaired T-cell development and decreased T-cell counts with consequent CD4+ T-
cell depletion [169-175]. 
 
Zinc is said to be essential for proliferation and differentiation of immune cells, and for vari-
ous lymphocyte functions implicated in resistance to malaria, including production of Im-
munoglobulin G (IgG), interferon-gamma(INF-γ) and tumour necrosis factor-alpha (TNF-
α), and microbicidal activity of macrophages. The innate immune defence system, which 
precedes adaptive immune response, is said to particularly be affected by zinc deficiency, 
leading to impaired activity of this type of response to variety of pathogens. Zinc deficiency, 
may cause decreased numbers of neutrophilic granulocytes generated by the bone marrow, 
decreased chemotaxis by neutrophilic granulocytes, decreased phagocytosis by macro-
phages and neutrophils, and deficient killing by Natural Killer (NK) cells by negatively af-
fecting KIR (killer Immunoglobulin-like receptors) binding, and impaired generation of 
oxidative burst. These all possible consequences from zinc deficiencies necessitates for de-
liberate efforts to delineate the effects of zinc on production profile and action of cytokines 
and possibly the impact may have on the antibody responses. This was also proposed by 
Keen and Gershwin [171] and it becomes worthwhile when explored together with other 
micronutrients in relation to more striking diseases like malaria in developing countries.   
 
Zinc deficiency is also likely to affects the adaptive (antigen-specific) arm of the immune 
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system [176-178]. Studies in human model have shown a marked decrease in IFN-γ produc-
tion but not on the IL-4, IL-6 and IL-10 in zinc deficiency [179]. Even mild zinc deficiency 
has been accompanied by an imbalance of Th1 and Th2 cell functions, resulting in dysregu-
lated resistance to infections restored following zinc supplementation [3]. Sensitivity of the 
Th1/Th2 balance needs special attention because it has been shown in other in vitro studies in 
both human and mouse models that polarization to either Th1 or Th2 may result following 
treatment with suppressive drugs such as vitamin D3 and Dexamethasone [91]. Other stud-
ies on naïve CD4+ T-cells have shown that 1α,25-dihydroxyvitamin D3 (vitamin D3) have a 
direct inhibition of Th1 favouring Th2 responses in mice models [180]. These studies have 
an implication that micronutrients may play a critical function in maintaining the Th1/Th2 
balance and induction of regulatory T-cell (Tr) proliferation, differentiation and activation, 
particularly induction of IL-10 and TGF-β production both being implicated in providing a 
balanced immune protection during infections. Studying these various effects of nutrients in 
relation to immune response to infections in human models could be very rewarding as may 
complement efforts already in place to control tropical diseases like malaria in endemic ar-
eas. 
 
An imbalance between Th1 and Th2 cells, decreased recruitment of T naive cells, and de-
creased percentage of T cytolytic cells may account for decreased cell-mediated immune 
functions in zinc-deficient subjects. Studies  by  Beck et al [179] revealed zinc to be re-
quired for regeneration of new CD4+ T lymphocytes and maintenance of T cytolytic cells. 
By negatively affecting T-cell activation, zinc deficiency will result in decreased IL-2 pro-
duction and IL-2 receptor expression. Decreased production of IL-2 in zinc deficiency may 
be due to decreased activation of nuclear factor kappa B (NF-kB) and subsequent decreased 
gene expression of IL-2 and IL-2 receptors [174]. Due to the impaired phagocytosis, intra-
cellular killing and cytokine production, macrophages become less activated resulting in 
decreased levels of IL-1β production and impaired expression of MHC class II molecules, 
which will add to the decreased T-cell activation and decreased production of IFN-γ. The 
profile of decreased cytokine production by T-cells is indicative for a decreased Th1 subset 
differentiation with possible functional consequences. Decreased production of Th1 cyto-
kines and IFN-γ by leukocytes in the healthy elderly person is correlated with low zinc se-
rum level. Zinc induces monocytes to produce IL-1β, IL-6 and TNF-γ in peripheral blood 
mononuclear cells and separated monocytes. B-cell development and antibody production, 
particularly IgG, is compromised by zinc deficiency. In particular, B-cells are sensitive to 
the induction of apoptosis induced by zinc deficiency. 
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4.2 Zinc deficiency and malaria; epidemiological evidence: Evidence prevail that shows 
that zinc supplementation can result in dramatic reductions in morbidity and mortality from 
malaria [22-24] and improved growth [181, 182] in some populations of children. Two of 
the malaria studies have indicated zinc supplementation to reduce the malaria-attributable 
fevers while one showed insignificant protective effects. Additionally, several studies con-
ducted in Asia and Latin-America have shown that preventive use of zinc by continuous 
supplementation leads to dramatic reductions in the incidence of diarrhoea, whereas thera-
peutic use of zinc for adjunctive treatment of children with either acute or persistent diar-
rhoea has been found to reduce the duration of illness and the risk of treatment failure [183, 
184]. Combination of iron and zinc in some cases is suggested to provide protection from 
both malaria and diarrhoea [185]. 
 
A pooled analysis of four studies and a subsequent study, all conducted in Asia, found that 
zinc supplementation in children led to substantial reductions in the incidence of pneumonia 
[183]; however, other studies showed no or little effect on acute lower respiratory infections 
[41, 185], or even an increased incidence [186]. Further studies must be conducted to deter-
mine whether the discrepancies reported are possibly due to bias, or to site-specific factors 
that influence response to zinc supplementation, such as zinc status or deficiencies in other 
nutrients known to be essential for growth or immune functioning, or suspected to impair 
zinc absorption or utilisation. For example, findings from a study among Ethiopian infants 
suggest that stunting predicts the presence of zinc deficiency, and thus for the response to 
supplementation [187]. In the recent study carried in Tanzanian community of Pemba, Zan-
zibar, Sazawal et al [188], have in addition, pointed out that the response to zinc supplemen-
tation was dependent on the dose given and also that there are sex and age-related differ-
ences in the response to supplementation. 
 
The postulated mechanism for the deleterious effects of zinc deficiency is a reduction in 
immuno-competence, particularly in cellular immunity [107], which may be reversible by 
supplementation [168, 183]. Zinc is essential for tissues with rapid cellular differentiation 
and turnover such as occur in the immune system and the gastrointestinal tract [183], and for 
various lymphocyte functions implicated in resistance to malaria [178]. Thus further studies 
of specific immune responses involved may provide clues about mechanisms of acquired 
immunity to malaria, which is essential for the development of  malaria intervention pro-
grams with micronutrients inclusion to boost immune responses to the disease. This could 
later be used together with not yet to be discovered effective vaccines for perfect malaria 
control. 
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Despite the impact of nutrition on immune functions and contradicting findings relating zinc 
with immune functions, most studies relating nutrition to immune response to malaria have 
been done outside Africa albeit malaria-related deaths in children of this endemic area. In 
addition, several in vitro stimulation studies have used peripheral blood mononuclear cells 
(PBMCs) for proliferation, differentiation and cytokine production but most of them have 
used mouse models whose immune responses may be different from that in human beings. 
In addition, even where studies have used human PBMCs, freshly prepared cells have been 
used rather than frozen cells which could reflect African situations where the location of 
study sites necessitates late processing (isolation of cells from whole blood after collection) 
and pre-cooling cells before stimulation experiments. In this study we have used laboratory 
prepared live P. falciparum-infected human red blood cells (mimicking the real in vivo 
situation), to stimulate PBMCs in vitro and measured proliferation, differentiation and cyto-
kine production of various lymphocyte subsets.    
 
5.  Aims and outline of the thesis 
This study was conducted to assess the baseline nutritional status, particularly zinc, and de-
termine its association with indicators of immune response to malaria before supplementa-
tion with zinc and other micronutrients in stunted children aged 6 - 72 months (< 5 yrs) of 
Handeni, Tanzania. In chapter 1, we provide a comprehensive theoretical background of the 
interaction between dietary micronutrient deficiencies, activity of the immune system and 
development of protection against Plasmodium falciparum infection and malaria disease 
manifestation. In the intervention study, the effect of zinc and other micronutrients on the 
immune response to malaria antigens will be investigated in 672 children aged 6-60 months 
receiving for a period of 26 weeks, a daily oral supplement with either zinc or its placebo, 
and additionally a daily oral supplement with either multiple micronutrients other than zinc 
or its placebo for group differences in cellular and serological indicators of immune re-
sponse to asymptomatic malarial parasitaemia determined at the end of the intervention pe-
riod; and group differences in cellular and serological indicators of the immune response to 
symptomatic malaria due to newly acquired infections in the course of the intervention pe-
riod. 
 
Chloroquine has been abandoned in Tanzania as a useful antimalarial drug due to parasite 
resistance. The antifolate drug combination, sulphadoxine-pyrimethamine (SP) is nowadays 
used for first-line treatment of uncomplicated malaria in most malaria endemic-African 
countries. Surveillance for antifolate-resistant parasites in the field was important to keep 
tracking the spread and intensity of drug resistance. Monitoring drug resistance through 
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regular exploration of gene mutations pertaining to drug resistance bears critical importance. 
In chapter 2, drug resistance to SP and detection of possible confounding factors pertaining 
to development of resistance in falciparum malaria was evaluated. 
 
The best indicator of immunity against malaria is arguably the incidence of symptomatic 
malaria, although this does not explain the mechanisms involved. In addition, zinc defi-
ciency has been found to result into underperformance of the immune system to combat 
malaria and other infections. These insights provided the basis for our hypothesis that zinc 
supplementation will boost the capacity of the immune system to brandish a protective re-
sponse to falciparum malaria, both in a quantitative and qualitative sense. To achieve these 
goals, we adopted the available technical and conceptual advances to analyse the immune 
capacity without the need to wait for actual challenging the individuals with infectious or-
ganisms. With respect to the involvement and role of the immune system we compared the 
activity of the innate immune response to Plasmodium falciparum (chapter 3) and the level 
of T-cell response after in vitro stimulation with cultured Plasmodium falciparum-infected 
red blood cell preparations (chapter 4) and Plasmodium falciparum specific antibodies as 
serological indicators of immunity (chapter 5) in zinc-deficient and zinc-replete children in 
both parasitaemic and aparasitaemic subjects. To reflect the real field situation where facili-
ties for sample processing may be far from the sample collection site, we performed the 
experiment in PBMCs kept frozen in Liquid Nitrogen (-1800C) for a period of 6 months and 
assessed cells viability, differentiation and proliferation capacity. 
 
A unique characteristic feature of infections with Plasmodium falciparum is the ability of 
infected red blood cells (IRBCs) to adhere to vascular endothelium by cytoadherence, re-
sulting in accumulation of IRBCs in the deep microvasculature. CD36 is one of the host 
ligands that have been found to mediate endothelial binding of IRBCs and has been identi-
fied in most field isolates. A mutation in  the gene encoding for CD36 is known to influence 
the malaria-associated anaemia (MA) in an endemic area. In chapter 6, the role of CD36 
deficiency was assessed in the development of malaria-associated anaemia in children. The 
study specifically explored the frequency of CD36 deficiency among children in malaria 
endemic areas and associations between CD36 deficiency and status of malaria-associated 
anaemia in these children. 
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6.5 Ethical issues: Clearance to conduct this study was obtained from ethical review boards 
in The Netherlands, by the Kilimanjaro Christian Medical Centre (KCMC) and the Tanza-
nian National Institute for Medical Research (reference numbers for KCMC and the Na-
tional Health Research Ethics Review sub-Committee: 094 and NIMR/HQ/R.8a/VolIX/540, 
respectively).  
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Abstract  
Sulphadoxine–pyrimethamine (SP) has been and is currently used for treatment of uncom-
plicated Plasmodium falciparum malaria in many African countries. Nevertheless, the re-
sponse of parasites to SP treatment has shown significant variation between individuals. The 
genes for dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) were used as 
markers, to investigate parasite resistance to SP in 141 children aged less than 5 years. Para-
site DNA was extracted by Chelex method from blood samples collected and preserved on 
filter papers. Subsequently, polymerase chain reaction (PCR) and restriction fragment length 
polymorphism (PCR-RFLP) were applied to detect the SP resistance-associated point muta-
tions on dhfr and dhps. Commonly reported point mutations at codons 51, 59, 108 and 164 
in the dhfr and codons 437, 540 and 581 in the dhps domains were examined.  Children in-
fected with parasites harbouring a range of single to quintuple dhfr/dhps mutations were 
erratically cured with SP. However, the quintuple dhfr/dhps mutant genotypes were mostly 
associated with treatment failures. High proportion of SP resistance-associated point muta-
tions was detected in this study but the adequate clinical response (89.4%) observed clini-
cally at day 14 of follow up reflects the role of semi-immunity protection and parasite clear-
ance in the population. In monitoring drug resistance to SP, concurrent studies on possible 
confounding factors pertaining to development of resistance in falciparum malaria should be 
considered. The SP resistance potential detected in this study, cautions on its useful thera-
peutic life as an interim first-line drug against malaria in Tanzania and other malaria-
endemic countries.  
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Background 
Human malaria is caused by an Apicomlexan parasite of the genus Plasmodium. Four spe-
cies are known to cause human malaria namely, Plasmodium falciparum, Plasmodium 
vivax, Plasmodium ovale and Plasmodium malariae. Nevertheless, P. falciparum has been 
found to be the most lethal of all human malaria parasites. This parasite causes epidemics in 
malaria-endemic countries, resulting in large numbers of deaths. Widespread chloroquine 
resistance has forced many countries to use alternative drugs as antimalarials against falci-
parum malaria, such as the combination of sulphadoxine and pyrimethamine (SP). However, 
the parasite has been observed to develop resistance to this drug combination associated 
with point mutations in the genes for the enzymes involved in the obligatory parasite-folate 
biosynthesis pathway. Such mutations lead to the lowering of the drug binding affinity to 
the parasite enzymes [1-5]. Resistance to pyrimethamine is attributed to mutations in the 
gene for the parasite enzyme dihydrofolate reductase (dhfr), whereas sulphadoxine resis-
tance is associated with mutations in the gene for the parasite enzyme dihydropteroate syn-
thetase (dhps). The increased level of resistance has been found to be associated with in-
creased numbers of mutations in the genes for these two enzymes. Studies [6] have shown 
that multiple mutations in the genes for both enzymes result in exceedingly high SP treat-
ment failure. Detection of these mutations in field isolates has been proposed as an alterna-
tive strategy for rapid screening of antifolate drug resistance [7-12].  
 
In Tanzania, due to high resistance that developed against the previously effective, safe and 
relatively cheap antimarial drug, chloroquine, SP was introduced as the first-line drug 
against malaria by August, 2001. Unfortunately, the change of policy to SP by the govern-
ment has been challenged by the previously reported low [13] but fast spreading levels of 
resistant parasite strains against the drug [14]. SP resistance has been reported in variable 
magnitudes across the country [15-17]. Surveillance for these antifolate-resistant parasites in 
the field is still required to dissuade its spread over wide areas and possibly suggest effec-
tive implementation of new drug policy in Tanzania. The present study was thus carried out 
during the period of January 2002 to August 2004 to evaluate the frequency of point muta-
tions in dhfr and dhps among P. falciparum isolates from children of Mlimba division of 
Kilomero district of Tanzania. This could give a picture of the level of drug pressure in the 
field from the time when SP was introduced as an interim first-line drug for malaria treat-
ment in the country. Since there are currently, various drug combinations on trial for treat-
ment of uncomplicated falciparum malaria [18,19], the anticipation was to obtain findings 
which would give information on the current frequencies of SP resistant P. falciparum 
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strains and probably give advice to policy makers for opting to other new effective, cheap 
and safe antimalarial drug combinations. 
 
Materials and methods 
Study area : The study was conducted at Ifakara Health Research and Development Center 
(IHRDC) situated in Ifakara Town of Kilombero District, Morogoro, Tanzania. Samples 
were collected during the period of January to August 2002 from Mlimba, an area about 150 
km from IHRDC along Kilombero River where malaria is endemic with perennial transmis-
sion. The area is among nine sentinel sites for National Malaria Control Programme since 
1997 and its human population dynamics is being closely monitored on a monthly basis by 
the Ifakara Centre Demographic Surveillance System (IC-DSS) since 1996. Recruitment of 
patients and sample collection was done by the research team at Mlimba Health Centre.  
  
Study subjects: The ethical clearance was obtained from both National Institute for Medical 
Research (NIMR) and IHRDC Institutional Ethics Committee authorities. Parents or guardi-
ans of participating children accepted and gave informed consent for participation in the 
study. About 172 patients of both sexes with acute uncomplicated falciparum malaria and 
aged 6 – 60 months (< 5 years) were initially recruited in this study. However 31 (18%) of 
the recruited patients either were excluded from the study due to failure to comply with cri-
teria for participating in the study or were lost during follow up.  
 
Sample collection: Blood samples for parasite genotyping were collected on filter paper 
(3MM Whatman), labelled and identified, and kept in a dry clean container with desiccant 
for a minimum of three hours to dry. Dry filter paper blood samples were stored at room 
temperature until when needed for further analyses. The follow-up samples were obtained at 
days 3, 7 and day 14 after SP treatment. Additional follow-ups were done at any other day if 
the child was unwell. During all these visits, finger-prick blood was obtained for micros-
copy and later molecular analysis.  
 
Extraction of parasite DNA: P. falciparum genomic DNA was extracted from blood col-
lected on 3MM Whatmann filter paper by Chelex method as previously described [20]. The 
extracted DNA from each sample was used immediately for PCR and any remaining portion 
was stored at –20ºC in appropriately labelled storage tubes.  
 
Genotyping of parasite genomic DNA: Sample analysis was based on the standardised poly-
merase chain reaction and restriction fragment length polymorphism. For amplification of 
the dhfr and dhps coding regions, a nested PCR protocol was adopted followed by RFLP. 
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The regions of the dhfr and dhps genes surrounding the polymorphisms of interest in dhfr 
51, 59, 108 and 164 and dhps 437, 540 and 581 codons were analysed as described in detail 
elsewhere [7,21,22].  
 
Amplification of parasite DNA by PCR: In this multiplex parasite DNA amplification of the 
parasite genomic DNA, two primer pairs M1/M5 and R2 + R/ were used as forward and 
reverse primers in primary (nest I) PCR reaction for the dhfr and dhps domains respectively. 
In secondary (nest II) PCR reaction M3 + F/ and F + M4 were used as forward and reverse 
primers to amplify the four regions on dhfr where the point mutation is anticipated to occur 
[20]. On the other hand, K +K/ and L + L/ primers were used to amplify regions on the dhps 
gene where resistance-associated mutations are said to occur [7]. The details of primer se-
quences, annealing temperatures and controls are shown in table 1. In both nest I and nest II 
PCR, reaction volumes ranged from 20µl to 30µl. The final concentration of each reagent 
was 1x PCR reaction buffer (10x PCR buffer – MgCl2, Invitrogen), 1.5 mM MgCl2, 125µM 
dNTP (Promega, Madison, WI, USA), 250nM primers (QIAGEN, Operon) and 0.02 U/µl 
Taq Polymerase (Invitrogen). The master mix was prepared in a 1.5ml reaction tube with 
Molecular biology PCR water (Sigma) as a diluent and aliquots made in PCR tubes (0.2ml 
size). To each PCR tube, 5µl of DNA was added in primary reaction and 2µl was re-
amplified in the nested PCR reaction. The known purified genomic DNA from HB3, 3D7, 
W2, K1, T9/96, FCR3 and V1/S laboratory parasite clones were used as positive controls 
and NT (No template) was included as negative control. PCR was performed in a Program-
mable Thermo Controller, (PTC-100 (TM) MJ Research, Inc., Watertown, MA, USA). Sam-
ples with no detectable PCR products were re-examined at least twice starting from the 
DNA preparation before were declared negative. 
 
Restriction enzyme digestion: Site-specific restriction enzymes were used to digest the PCR 
amplicons. Seven different restriction enzymes were used in this study (table 1), namely 
TSP509I, XmnI, AluI, DraI (dhfr domain) and AvaII, FokI, BstUI (dhps domain) enzymes, 
respectively. Essentially 8µl of PCR products were incubated with restriction enzymes (New 
England Biolabs, Beverly, MA, USA) according to manufacturer’s protocol in 25µl final 
reaction volume. The dhfr and dhps variants were identified as previously described 
[7,21,23].   
 
Gel electrophoresis: Nested PCR amplicons were electrophoresed on 2% agarose gels be-
fore subsequent restriction fragment length polymorphism analysis. Electrophoresis of re-
striction digests was done on 10% polyacrylamide gel (PAA) as described by Sambrook et 
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al [24] at a constant voltage of 11.25v/cm gel for 2.30 hours, stained with ethidium bromide, 
visualized under UV light, photographed and electronically stored.. 
 
Statistical analysis: Data were analysed using the EPI Info Version 6.04 epidemiological 
software (Centres for Disease Control and Prevention, Atlanta, GA, USA). This made it 
possible to estimate the frequency of point mutations on dhfr and dhps responsible for para-
site resistance against SP thus determining the prevalence of these mutations. The preva-
lence of each point mutation was calculated as the percentage of baseline (D0) samples con-
taining point mutation at the particular codon on dhfr and dhps, respectively. Fragment sizes 
were compared with known restriction fragments (band sizes) obtained in previous studies 
with reference to 1Kb DNA marker [21,25]. 
 
Results  
Treatment outcomes: From clinical evaluation (clinical data provided by IHRDC), a total of 
172 children with acute uncomplicated malaria were recruited into the study and treated 
with SP. Out of these recruited patients, 141 (82%) successfully completed the study. Data 
from 31 (18%) patients who could not complete the 14 days follow-up were excluded from 
analysis. Of patients who completed the study successfully, treatment failures were depicted 
in 15 (10.6%) patients comprising of 6.7% early and 3.9% late treatment failures, respec-
tively. Adequate clinical response occurred in 126 (89.4%) of patients. Consequently, mo-
lecular analysis was performed on 141 samples from patients who completed the study. 
 
PCR amplification of dhfr and dhps: Different primers were used to amplify regions in dhfr 
and dhps containing various point mutations associated with resistance to SP, thus different 
DNA fragments with different band sizes were obtained (figure 1). The fragment sizes were 
estimated as previously described elsewhere [21]. F + M4 amplification produced DNA 
amplicons of about 326 bp (figure 1a) while DNA amplicons of approximately 522 bp band 
size were obtained following DNA amplification by M3 + F/ primers (figure 1b). PCR am-
plification using K + K/ (figure 1c) and L + L/ primers (figure 1d) produced fragments of 
438 and 161 bp, respectively on 2% agarose gel.  Of 141 samples analysed, 120 (85.1%), 
136 (96.5%), 132 (93.6%) and 133 (94.3%) were successfully amplified using M3+ F/, F + 
M4, K + K/ and L +L/ primers, respectively.  
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RFLP analysis: Figure 2 depicts representative PAA gels of the restriction digests used to 
detect the fragment patterns corresponding to the different variants at each codon on the dhfr 
and dhps domains. PCR amplification of dhfr with the primers F + M4 yields a PCR product 
sized 326 bp of the codon 108. The restriction enzyme AluI was used specifically to cut 
fragments discriminating the two alternative forms, wild-type (180 and 118 bp) and mutant 
(299 plus 27 bp) at that codon. The wild type indicates presence of serine (Ser) in the amino 
acid sequence of the enzyme system while the mutant form of the gene indicates the substi-
tution by asparagine (Asn). Restriction digestion of the same PCR fragment with XmnI was 
used to distinguish wild type (189 and 137 bp) and mutant (162, 137 + 27 bp fragments) 
variants on codon 59 of the gene. Mutation at this codon reflects substitution of amino acid 
cystine (Cys, wild type) by arginine (Arg, mutant).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Agarose gels of the PCR products ((a) F+M4; (b) M3+F/; (c) K+K/; (d) L+L/) of 
the tests for the polymorphisms of dhf and dhps. Fragment sizes are in bp. 
 55 
Chapter 2 
The M3 + F/ amplified PCR fragments (figure 1b) were digested with TSP509I and DraI to 
distinguish variants at codon 51 and 164, respectively. Digestion by TSP509I produced frag-
ments of sizes 153 and 120 bp indicative of presence of amino acid asparagine (wild type) 
and 217 and 120 bp indicating presence of amino acid isoleucine (Ile, mutant). On the other 
hand, digestion with DraI was expected to produce fragments of sizes 245, 171 and 106 bp 
(wild type) and 145, 143, 106 and 28 bp (mutant) distinguishing polymorphisms at codon 
164. In this context wild type denotes occurrence of isoleucine (Ile) and the mutant indicates 
occurrence of leucine (Le). The four restriction enzymes were used mutually to detect muta-
tions on the dhfr gene ascribed to resistance to antifolate, SP by the malaria parasite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Polyacrylamide gels of the restriction digest of the PCR products ((a) AluI and 
xmnI; (b) AluI and XmnI; (c) TSP609I and DraI; (d) BSTUI and AvaII; (e) FokI) of the tests 
for the polymorphisms of the dhfr and dhps genes.  Fragment sizes are in bp.  
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Tests for polymorphisms on dhps are shown in figures 2d and 2e. PCR products of approxi-
mately 438 bp (figure 1c) were obtained from amplification with the K and K/ primers. The 
variants at codon 437 were discriminated by restriction digestion using the restriction en-
zyme AvaII (figure 2d). In this case uncut fragment (438 bp) indicated wild type while mu-
tations at this site was shown by a cut fragment sized 404+ bp. Mutation at this codon is 
indicative of substitution of glycine (Gly) for alanine (Ala). The K + K/ amplified PCR 
products have been used to detect polymorphisms occurring at codon 540. A restriction en-
zyme, FokI produced fragments sized 405 bp (wild type) and 320 and 85 bp (mutant) dis-
criminating variants at that codon. The 405 bp fragment indicates presence of amino acid 
Lysine (Lys) while the 320 and 85 bp fragments reflect substitution of glutamate (Glu) for 
lysine at this codon.  
 
Following amplification with L + L/ primers, PCR products of size 161 bp were produced 
(figure 1d). These PCR fragments have been used to describe polymorphism on the dhps 
gene occurring at codon 581 using a restriction enzyme BstUI. This restriction enzyme pro-
duced restriction digests of sizes 105, 33 and 23 bp (wild type) and 138 and 23 bp (mutant) 
from the PCR products of size 161 bp (figure 2d). The former reflects presence of amino 
acid, alanine at this codon and the latter indicates substitution of glycine for alanine. 
 
Mutation analysis was variably successful at each codon in both dhfr and dhps genes and an 
average of 120 (85.1%) of 141 patients produced fruitful outcome. Four codons (51, 59, 108 
and 164) on dhfr and three codons (437, 540 and 581) on dhps were evaluated and the re-
sults are presented in figure 2. Mutations in the dhfr were highest for Asn-108 (66.9%) and 
progressively declined for dhfr Ile-51 (62.7%) and dhfr Arg-59 (48.8%). Mutations in dhps 
varied from dhps Gly-437 (43.7%), dhps Glu-540 (39.2%) and was lowest for dhps Gly-581 
(0.8%) alleles. In all pre-treatment and post-treatment samples, no mutant dhfr Leu-164 was 
depicted. The triple dhfr, double dhps and the quintuple mutants (carrying the dhfr triple 
mutant and the dhps double mutant) were also evaluated and were considerable (table 3). 
Mixed pattern was not uncommon in many samples examined (table 4). 
 
Discussion  
The 141 patients represent children aged less than five years, the age most vulnerable to 
falciparum malaria [26]. Parasite recurrence in SP treated individuals has been linked to 
many factors. Such factors include overwhelmed immunity, multiple concurrent infections 
and drug resistance [27]. Several previous studies have investigated the association between 
mutations in dhfr and dhps and the parasitological and/or clinical response to SP medication 
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at individual level [6,28-30]. Most of these studies produced tangible results regarding the 
use of dhfr and dhps genotypes as resistance marker genes for SP [31]. In this study, it was 
observed (clinical data) that SP treatment cleared infection in 89.4% of the patients who 
completed the study. This treatment success is partly concordant but higher than what has 
previously been reported (82%) in a similar study by Aubouy et al [25] in Bakoumba vil-
lage in Haut-Ogooué province of Southeast Gabon. According to that study, dhfr mutations 
that lead to high-level in vitro resistance to pyrimethamine plus one or two dhps mutations 
were reported to be not sufficient to induce in vivo failure of SP treatment in young chil-
dren. Nevertheless, the semi-immune population of over 60% previously reported in Tanza-
nia [32] is probable reminiscent for the observed high parasite clearance despite detection 
of high resistance-associated point mutations in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:   Proportions of point mutations on dhfr and dhps related to parasite resistance to 
 antifolates 
Resistance to Gene locus  Mutations (%) Wild type (%) Mixed (%) Total 
Pyrimethamine DHFR 51 74 (62.7%) 35 (29.7%) 9 (7.6%) 118 
 DHFR 59 59 (48.8%) 36 (29.8%) 26 (21.5%) 121 
 DHFR 108 81 (66.9%) 17 (14.1%) 23 (19.0%) 121 
 DHFR 164 0 (0.0%) 104 (100.0%) 0 (0.0%) 104 
Sulphadoxine DHPS 437 56 (43.7%) 71 (55.5%) 1 (0.8%) 128 
 DHPS 540 47 (39.2%) 65 (54.5%) 8 (6.3%) 120 
 DHPS 581 1 (0.8%) 126 (98.4%) 1 (0.8%) 128 
  318 454 68 840 
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Table 3: Various dhfr/dhps combinations obtained from restriction analysis to determine 
point mutations in genes responsible for SP resistance.  
tDHFR = Triple mutants on dhfr gene; dDHFR = Double mutants on dhfr gene; dDHPS = 
Double mutants on the dhps gene; sDHPS = Single mutant on the dhps gene; nDHPS = No 
mutation on the dhps gene. 
 
Slightly higher values of mutations on dhfr (66.9% and 62.7%) were detected at codons 108 
and 51, respectively as compared to those previously reported by Mshinda [33] of 50%. This 
is attributable to rapid, stepwise selection of mutations following use of antimalarial, SP or 
similar drugs in the area. This is simply because our study was carried 2 years after a similar 
study by Mshinda in 2000. Pharmacological case management of the disease occurring at 
informal level [26,34] with poor compliance with dosing schedules could be another basis 
for the high frequency of mutations detected in this study. In addition, sub-dosage levels of 
drug administration e.g. two patients sharing a single dose prescribed for a single patient 
(personal observation) may be a probable cause for the detected high proportion of muta-
tions. Extensive use of different types of antifolates with mechanism of action similar to SP 
like trimethoprim and sulphamethoxazole (TS) combination (e.g. septrin) in treating other 
infections over time, probably accounts for the increased selection of mutations ascribed to 
SP resistance [17].  
 
The mutation of about 66.9% observed in dhfr on codon 108 was higher than that reported 
by Jelinek et al. [35] in West Africa (54.0%) but slightly lower than that observed in Central 
Africa (72.4%), South Africa (68.9%) and East Africa (72.9%). This could be correlated to 
the high proportion of mixed genotype infections (mutant and wild type, 19.0%) detected at 
this codon in the present study. Pearce et al. [17] reported the increase of mixed genotypes 
Category Number  Percentage (%) Percent Cum. 
tDHFR 44 36.40 36.40 
dDHPS 18 14.90 51.30 
tDHFR/dDHPS 24 19.80 71.10 
dDHFR/dDHPS 10 8.30 79.40 
tDHFR/sDHPS 4 3.30 82.70 
dDHFR/sDHPS 7 5.80 88.50 
tDHFR/nDHPS 14 11.50 100.00 
Total 121 100.0  
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in codons whose mutations are associated with SP resistance in an area of high endemicity. 
This proportion of mixed genotypes could give rise to dhfr mutations of about 85.9% if at 
all these genotypes were additive. The dhfr point mutations at codons 51 and 59 were also 
higher than that previously reported by Jelinek et al. [35] in Africa and all together explains 
the significance of these mutations in causing higher SP resistance. As previously reported 
by Hastings et al. [36], mutations at codon 164 in dhfr, which is thought to confer highest 
SP resistance when it occurs, was not depicted in this study. Generally, mutations in the 
three codons in the dhfr domain were higher (table 2) than those on the dhps domain, sug-
gesting that mutations on dhfr precede those on dhps in conferring parasite resistance to SP 
[37].  
 
 Table 4:  Proportions of mixed infections detected in this study 
 
 
 
 
 
 
smDHFR = Mixed variants detected at a single codon on the dhfr domain; mDHPS = 
Mixed variants detected at a single codon on the dhps domain; dmDHFR = Mixed variants 
detected at two codons on the dhfr domain; dmDHPS = Mixed variants detected at two 
codons on the dhps domain; tmDHFR = Mixed variants detected at three codons on the dhfr 
domain; tmDHPS = Mixed variants detected at three codons on the dhps domain 
 
The point mutations in dhps depicted in this study are far higher than what was observed in 
previous studies in East and South Africa [35] and Eastern Iran [38]. This might be ex-
plained by the widespread use of septrin in Tanzania, which is said to indirectly select muta-
tions for SP resistance [17]. Takahashi et al. [39] further reported that the use of antifolates 
such as co-trimoxazole for prophylaxis or medication against other infections than malaria 
indirectly and predominantly select double mutations at dhps for resistance. Nevertheless, 
the dhps mutations observed in this study were relatively lower than that observed in Central 
Category Variants detected  Total No. of variants Percentage (%) 
smDHFR 27x1 27 39.7 
smDHPS 8x1 8 11.8 
dmDHFR 8x2 16 23.5 
dmDHPS 1x2 2 2.9 
tmDHFR 5x3 15 22.1 
tmDHPS 0x3 0 0.00 
Total  68 100 
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and West Africa by Jelinek et al [35], possibly due to geographical differences [16] and dif-
ferences in patterns of drug use between different areas [17]. However, Beswas [16] re-
ported the dhps mutations in Tanzania ranging between 30 – 34%, which is less than values 
observed in our study (39.2 – 43.7%) signifying that drug pressure increasingly selects these 
mutant alleles with time depending on frequent use of antifolates.   
 
Overall proportion of point mutations portrayed in this study reflects the existence of high 
resistance in the study area. Only 8.5% of infections carried pure wild type genotype and 
4.6% of the samples showed single mutant alleles. Quintuple mutations were highest 
(18.5%) followed by triple (16.2%) and double mutations (13.8%). Quadruple mutations 
occurred in 6.9% of samples. About 41 (31.5%) of infections had at least one mixed 
(mutant, wild type) genotypes attributable to endemicity of the disease [40], which may re-
sult into high transmission consequently augmenting high proportion of mixed clones per 
infection in the population.  
 
The co-occurrence of point mutations in both dhfr and dhps loci was also examined in this 
study (table 3) with about 44 (36.4%) of samples containing triple mutant on dhfr, which 
was relatively similar to that reported by Mshinda [33] in the same place (41%) but was 
almost twice to values reported by Mugittu et al [15] of 18.6%. However, the proportion 
could escalate if the mixed triple dhfr variants (22.1%) and mixed double dhfr variants 16 
(23.53%) detected in the present study (table 4) were counted inclusively. Nevertheless, the 
proportion of these mutations was less than that reported by Pearce et al [17] in Hai district 
Northern Tanzania (>70%) where resistance to SP is already unprecedentedly high due to 
widespread use of SP and spread of resistance from nearby area, Muheza into the area. 
Mugittu et al [15] reported a prevalence of 80.3% in Mkuzi, an area in Muheza District 
where pyrimethamine was used for prophylactic and/or therapeutic trials at different periods 
from 1950s to 1994 [41-43]. The difference in levels of SP resistance between Tanzanian 
communities is also attributable to the differences in patterns of drug use between communi-
ties within the country [17]. In Muheza District Hospital, for instance, SP was implemented 
as first-line drug in children less than 5 years of age since 1984 [44].  
 
The frequency of triple-dhfr/double-dhps mutants (quintuple mutation, 19.8%) depicted 
(table 3) is high as compared to previous studies in Mlimba and Idete [45] which was re-
ported as a rare event. However, the proportion of quintuple mutation in Mlimba was less 
than that reported by Pearce et al [17] in Hai and Pare areas of Northern Tanzania (30 – 
63%). The proportion of quintuple mutation was also less than that generally reported by 
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Jelinek et al [35] (42.9%) in East Africa, and that by Bwijo et al [46] in Maonga and Chim-
bala villages of Salima District, Malawi (78%). The lower frequency of quintuple mutations 
(19.8%) observed in this study as compared to other reported mutations in Tanzania and 
other areas of Africa could partly be attributable to the early development of resistance in 
those areas. In Malawi for instance, the study was carried 7 years after introduction of SP as 
a first-line drug while our study was carried shortly (2 years) after introduction of SP as an 
interim first-line drug in Tanzania, providing a relatively shorter time for selection of SP 
resistance mutations. In addition the low quintuple mutations can also be linked to the pro-
portion of genotypes at similar locus possessing mixed variants observed in this study. In 
previous studies, the mixed variants were not reported. The random selection of these muta-
tions might generally, be a consequent of country-wide use of SP as a second-line antimalar-
ial drug several years before it was implemented as an interim first-line drug by August 
2001.  
 
The prevalence of double dhps mutation (table 3), which is considered to be a prerequisite 
for resistance to sulphonamides [7], was found to be 6x that reported by Mugittu et al [15] in 
the same area. This proportion (19.8%) was also higher than that reported in Kyela and Ma-
sasi areas of Tanzania but nearly equal to that reported in Butimba but less than that re-
ported in Mkuzi areas of Tanzania by Mugittu et al This might be attributed to the effect of 
septrin, an antifolate extensively used in Tanzania as antibiotic agent, indirectly and prefer-
entially selecting double mutations on the dhps locus [39]. Similar effects can result from 
septrin, which is essentially similar to co-trimoxazole in composition as previously stated. 
Both are antifolates basically composed of trimethoprim-sulphamethoxazole (TS) with simi-
lar effects to SP [46,47]. Observation also showed that 52.1% of infections harboured at 
least one mutation on the dhps locus (table 3) reflecting that probably there is high effect or 
prevailing use of septrin in the area.  This can also be associated with long-term abuse of the 
drug, but also could be indicative of the differences in the generic drugs available in the 
country manufactured by different companies which might have different bioavailability and 
therapeutic values. The high proportion of double dhps mutations when coupled with triple 
mutations in dhfr can result into quintuple mutation to confer highest SP resistance. 
 
Mixed genotypes in either dhfr or dhps, or both, were depicted in at least 68 DNA samples 
(table 4). Detection of mixed genotypes in dhfr and dhps is important due to its influence on 
the overall proportion of point mutations in baseline samples which upon drug pressure, the 
wild type get cleared with mutant genotypes persisting in longitudinal follow up samples.  
Most recrudescent infection detected in follow up cases came from pure mutant and mixed 
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genotypes in baseline samples as parasites with wild type genotypes are sensitive and were 
subsequently cleared post-medication by the drug. The variable results obtained following 
PCR-RFLP of follow up samples (20%) have been previously observed [25]. Infection de-
tected during follow-up may be either an infection that previously failed to express due to 
presence of an abundant (detected) strain that masked the presence of minor resistant strain, 
thus being a recrudescent parasite. But on the other hand the detected mutant alleles during 
follow-up may be new infection with similar genotype as that detected pre-treatment.  
 
Conclusions and recommendations: In conclusions, the impact of quintuple mutation on SP 
resistance may be weighed down by host immunity in endemic areas although may not sug-
gest continued use of the drug for treatment of malaria. The impact of other drugs with simi-
lar mechanisms of action used as antibiotics in selecting mutations responsible for SP resis-
tance need be studied especially for co-trimoxazole, which is currently used as a prophylaxis 
against opportunistic infections in HIV-infected individuals. The information obtained in the 
present study will be of direct and immediate relevance to current HIV and malaria control 
policies in Tanzania and possibly in Africa and the universe. In addition, it will add to our 
basic knowledge of the molecular basis of antifolate-resistant malaria. There is a need for 
reviewing the policy on the use of SP as a first-line drug for treating malaria in Tanzania. In 
addition, despite several previous studies showing SP + Amodiaquin (SP+AQ) and 
SP+Artesunate (SP+AS) to cause a delay in emergence of resistance and rapid gametocyte 
clearance, the high SP resistance potential detected in this study suggests exclusion of SP 
component in future planned drug combinations for treatment of malaria. Alternative combi-
nation therapies like artemisinin-based drugs (e.g. artemisinin-lumefantrine) and short-
acting antimalarials such as chlorproguanil-dapsone combination (LapDap) and atovaquone-
proguanil (Malarone®) may be rewarding albeit thorough clinical trials are still needed to 
evaluate the effectiveness and possible harmful side effects of these proposed drugs. In de-
ployment of a new antimalarial drug for treating malaria, the effect of other drugs with simi-
lar mode of action to drug, used in treating other infections than malaria have to be consid-
ered to preclude the possibilities of early development of resistance to the target drug due to 
cross-resistance. The findings from this study imply that in vivo studies be further carried 
out to confirm that the high frequency of SP resistance alleles is indicative of treatment fail-
ure. Improvement of health services with adequate drugs and skilled medical staffs from 
village levels may reduce uncontrolled and inappropriate use of the drug, consequently re-
ducing the chances of selecting SP resistance mutations against malaria. 
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Abstract  
Deficiencies in vitamins and mineral elements are important causes of morbidity in develop-
ing countries, possibly because they lead to defective immune responses to infection. Our 
aim was to assess the effects of mineral element deficiencies on early innate cytokine re-
sponses to Plasmodium falciparum malaria. Peripheral blood mononuclear cells from 304 
Tanzanian children aged 6–72 months were stimulated with P. falciparum-infected erythro-
cytes obtained from in vitro cultures. The results showed a significant increase by 74% in 
TNF-α in malaria infected individuals with zinc deficiency (11% to 240%; 95% CI). Iron 
deficiency anaemia was  associated with increased TNF-α production in infected individuals 
and overall with increased IL-10 production, while magnesium deficiency induced increased 
production of IL-10 by 46% (13% to 144%) in uninfected donors. Most donors showed a 
profound response towards IL-1β production, drawing special attention for its possible pro-
tective role in early innate immune responses to malaria. In view of these results, our find-
ings show plasticity in cytokine profiles of mononuclear cells reacting to malaria infection 
under conditions of different micronutrient deficiencies. Our findings lay the foundations for 
future inclusion of a combination of precisely selected set of micronutrients rather than sin-
gle nutrients as part of malaria vaccine intervention programs in endemic countries.  
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Introduction 
In African populations, multiple micronutrient deficiencies, infections and immunodeficien-
cies commonly co-exist. Deficiencies in vitamins and mineral elements can impair immune 
responses to infectious diseases through multiple mechanisms, ranging from phagocytosis 
and innate immune responses to antibody formation and cell-mediated immunity. Zinc is an 
important micronutrient because it is essential for the development, differentiation and func-
tion of several critical types of immune cells [1, 2]. In vitro mitogen stimulation experiments 
indicate that marginal zinc deficiency can cause reduced counts of circulating leucocytes 
and reduced whole blood concentrations of cytokines, particularly IL-6 [3]. Zinc deficiency 
contributes to pneumonia, acute and chronic diarrhoea [4, 5], and possibly malaria [4-6], 
which together constitute the leading causes of death in African children. In addition, zinc 
deficiency may exacerbate the outcome of diseases such as HIV and tuberculosis that rely 
on macrophage killing of infected cells [7]. Deficiencies of copper [8], iron and vitamin B12 
have been associated with impaired neutrophil functions whereas deficiencies of folic acid 
are not [9]. 
 
A fast-acting innate immune response, mediated by cytokines such as interleukine-1β (IL-
1β), IL-12 and tumour necrosis factor-α (TNF-α), is crucial for host survival in the initial 
stages of Plasmodium falciparum infection [10]. Zinc is needed for monocytes and macro-
phages to produce IL-1β and for other peripheral blood mononuclear cells (PBMCs) to pro-
duce TNF-α. Zinc deficiency can lead to impaired phagocytosis and intracellular killing by 
macrophages and neutrophils. In addition, it can impair NK-cell function, cytokine produc-
tion, the generation of an oxidative burst as well as complement activity [2, 11-14] through 
decreased activation of various cellular responses and low concentrations of IL-1β. In addi-
tion, innate immune responses determine the type and efficiency of subsequent adaptive 
immune responses [10, 15, 16] at later stages of infection. 
 
This study was conducted to assess the impact of deficiencies of zinc and other mineral ele-
ments on early innate immune responses to P. falciparum infection. We assessed this by in 
vitro stimulation experiments, using PBMCs samples that were collected from Tanzanian 
children aged 6-72 months. We hypothesised that zinc deficiency alters the balance in cyto-
kine production and their association in early immune responses, and that deficiencies of 
zinc and other mineral elements induce a decreased ability of PBMCs to produce pro-
inflammatory cytokines, and the regulatory cytokine IL-10, when exposed to P. falciparum 
parasites. In addition, we investigated to what extent the magnitude of the PBMCs cytokine 
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response depended on the P. falciparum infection status of the child at the time that the 
blood was collected and PBMCs were isolated. 
 
Subjects and methods 
Study area and population: This study was conducted in a lowland area around Segera vil-
lage (S 05º 19.447’, E 38º 33.249’), Handeni District, north-eastern Tanzania, in May-July 
2006. Malaria is highly endemic in this area, with virtually all infections being due to P. 
falciparum. The residents in the study population mostly comprise poor farmer families 
growing maize and cassava for subsistence use. Such populations are prone to deficiencies 
of zinc and iron because they have cereal-based diets that are rich in natural dietary constitu-
ents that inhibit the absorption of these trace metals [17]. At the time of our study, only one 
health centre in Segera was available to serve all of the surrounding area. The study was 
approved by Ethics Review Committees in The Netherlands and Tanzania (reference num-
bers for KCMC and the National Health Research Ethics Review sub-Committee: 094 and 
NIMR/HQ/R.8a/VolIX/540, respectively). Informed consent was obtained from community 
leaders and local government officials, and from parents or guardians. 
 
Sampling methods and eligibility criteria: A census list was made with all resident children 
aged 6-72 months in the study area. Using this list, 16 children were randomly selected from 
19 communities, resulting in a total of 304 subjects. Further details are provided elsewhere 
[18]. 
 
Field procedures: All children were examined by a clinical officer, who also measured axil-
lary temperature by electronic thermometer. Subjects were eligible when they had no fever, 
and showed no signs of other severe disease or severe malnutrition (weight-for-height z-
score below -3 SD). Both dip stick test and microscopy ware used for diagnosis providing a 
wide chance for detecting asymptomatic malaria case [19, 20].  Venous blood (6 mL) was 
collected in containers suitable for mineral element analysis with sodium heparin as antico-
agulant (Becton-Dickinson, Franklin Lakes, NJ). Immediately upon collection, the cap was 
sprayed with ethanol and allowed to dry; approximately 1.3 mL blood was then drawn by 
sterile syringe. This aliquot was centrifuged and plasma samples were stored and trans-
ported to The Netherlands at -80 ºC for subsequent measurement of mineral element con-
centrations. The remainder of the blood sample was kept at 20-25 °C during transport the 
same day to the laboratory in Moshi, at approximately 300 km distance, for collection of 
additional plasma and PBMCs. Children were treated for common childhood infections and 
anaemia according to guidelines of Tanzanian Ministry of Health. 
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Determination of plasma concentrations of mineral elements: Plasma samples were diluted 
20 times in milliQ [21], and concentrations of zinc, magnesium and copper were measured 
by inductively-coupled plasma atomic emission spectrometry (ICP-AES) (Vista Axial, Var-
ian, Australia). To determine variability in outcomes, measurements were replicated five 
times. With mean values set at 100%, measurements varied between 97% to 102% for zinc, 
99% to 102% for magnesium, and 97% and 102% for copper. Because we found no evi-
dence for copper deficiency as assessed by plasma copper concentrations <7.1 µmol/L 
(unpublished data), we only report the results for zinc and magnesium in this paper. 
 
Determination of plasma indicators of iron stores and inflammation: After arrival at the 
laboratory in Moshi, blood samples were immediately centrifuged (300´g) at ambient tem-
peratures for 10 minutes. We collected plasma (1.2 mL) and replaced this immediately with 
an equal volume of Iscove’s modified Dulbecco's medium (IMDM) with GlutaMAX 
(Invitrogen Gibco-BRL, Life Technologies, Grand Island, NY, USA) for subsequent isola-
tion of peripheral blood mononuclear cells (see below). Plasma was stored in liquid nitro-
gen, and subsequently transported on dry ice to The Netherlands, where plasma concentra-
tions of ferritin and C-reactive protein were measured as indicators of iron stores and in-
flammation, respectively, by using a Behring nephelometer (BN ProSpec; Dade-Behring) in 
The Netherlands (Meander Medical Centre). 
 
PBMCs isolation: PBMCs were isolated by Ficoll density gradient centrifugation, cells were 
transferred to 10% v/v DMSO in fetal calf serum, cooled at -1oC/minute in an isopropyl-
loaded device (Nalgene, Rochester, NY, USA) and preserved in liquid nitrogen [22]. For a 
16-h period during transport to Wageningen University, The Netherlands, the PBMCs were 
kept on dry ice, and immediately thereafter stored again in liquid nitrogen until stimulation 
experiments (see below).  
 
Preparation of P. falciparum-parasitized and unparasitized erythrocytes: Human O and 
rhesus-negative erythrocytes from healthy blood donors (Sanquin, Nijmegen, The Nether-
lands) were cultured in medium to which live P. falciparum parasites (NF54 strain) pro-
duced in a continuous culture were added [23, 24]. After 2-4 days, when asexual parasitae-
mia reached ~8-10% of infected erythrocytes, the culture was concentrated by centrifugation 
at 625´g for 5 min; infected erythrocytes were separated on a 67% Percoll gradient as re-
ported elsewhere [25] and washed twice in phosphate-buffered saline (PBS). Purified in-
fected erythrocytes were preserved at a concentration of approximately 15´107/mL in 13% 
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glycerol/PBS in a freezing container at -80oC. Glycerol (50% w/v) was added to the infected 
erythrocytes to avoid mechanical damage of the cells through ice formation. Unparasitized 
erythrocytes were processed similarly but without adding parasites to serve as a control. 
Both in parasitized and unparasitized erythrocyte cultures, we confirmed the absence of my-
coplasma contamination by polymerase chain reaction. Both parasitized and unparasitized 
erythrocytes were counted by flow cytometry, and compared regarding their size and inter-
nal complexity to the counting beads and PBMCs. Aliquots were made and stored at -80oC 
until needed for PBMCs stimulation. 
 
PBMCs stimulation: Malaria antigens differ in their capabilities to stimulate PBMCs: intact 
parasitized red blood cells (pRBC) are capable of inducing more rapid and intense pro-
inflammatory responses from PBMCs than freeze-thaw lysates of P. falciparum [26]. To 
simulate in vivo malaria-specific responses as closely as possible, we used P. falciparum 
pRBC, with an adapted protocol for stimulation of PBMCs by Jeurink et al [22]. In brief, 
PBMCs were cultured at 106 cells/well in sterile polystyrene 48-well plates with flat-bottom 
wells (Corning Inc, Corning, NY, USA). Based on initial optimization experiments, aliquots 
of pRBC were thawed and cultured with PBMCs in IMDM with glutamax containing 
Yssel’s supplements [27] with 2% human AB serum, 1% penicillin/streptomycin and 1% 
fungizone (Gibco-BRL), at a PBMCs:pRBC ratio of 1:2. PBMCs were also cultured under 
similar conditions with unparasitized erythrocytes (uRBC) (2´106 cells/well) as a negative 
control, and with soluble antibodies to CD3 and soluble antibodies to CD28 (Cat. 
No.555336 and 555725, Becton-Dickinson, Alphen aan den Rijn, The Netherlands) as a 
positive control. Monoclonal anti-CD3 and anti-CD28 antibodies provide co-stimulatory 
signals and polyclonal stimulation required for maximal proliferation of T lymphocytes [22, 
28]. Cell culture plates were incubated at 37oC in a humidified atmosphere containing 5% 
CO2. After PBMCs culturing for 1 day, we aspirated 75 µL of the supernatant per well to 
measure cytokine concentrations. 
 
Measurement of cytokine concentrations: Concentrations of IL-1b, IL-10, IL-12p70 and 
TNF-a were determined on a FACSCanto II flow cytometer by cytometric bead array sys-
tem and analysed with FCAP software (all from Becton-Dickinson). 
 
Statistical analysis: Data were entered and analysed using SPSS for Windows (version 15.0. 
SPSS Inc., Chicago, IL, USA). Zinc deficiency and low zinc status were defined as plasma 
zinc concentrations <9.9 µmol/L and <10.7 µmol/L, respectively. Low magnesium status 
was defined by magnesium concentration < 750 µmol/L [29, 30]. Iron deficiency anaemia 
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was defined by co-existing iron deficiency (plasma ferritin concentration <12 µg/L) and 
anaemia (haemoglobin concentration <110 g/L). Cytokine concentrations were ln-
transformed to obtain normally-distributed values. Group differences in these values were 
analysed assuming t-distributions. Interactions between malaria and micronutrient indicators 
were assessed using multiple linear regression models on log-transformed cytokine data; the 
resulting effect sizes were exponentiated and expressed as percentage values. Linear regres-
sion analyses were also carried out to explore the associations between IL-1β, TNF-α and 
IL-10, and to what extent these associations were influenced by nutrient status and malaria 
infection status. The association between concentrations of TNF-α and IL-10 were consid-
ered as a measure of balance between the pro-inflammatory responses and the regulatory 
response. We only report the analyses of the cytokine responses to pRBC. As expected, the 
average response to uRBC (negative control) was less than to pRBC, whereas the average 
response to CD3/CD28 (positive control) was higher. Correction for these responses does 
not change the estimates of the associations between nutrient status and cytokine responses, 
or between malarial infection status and cytokine responses. 
 
Results 
General characteristics of the study population: We collected blood from 135 boys and 169 
girls; these had similar age distributions. We found the following prevalence values (n): low 
zinc status: 63.1% (188); zinc deficiency: 48.3% (144); low magnesium status: 65.1% (194); 
iron deficiency anaemia: 9.4% (26); malaria: 46.1% (140). Detailed characteristics of the 
study population by malarial infection status are summarised in table 1. In addition, the 
associations between nutrient status and supernatant cytokine concentrations, and between 
malaria infection status of the child at the time of blood collection and supernatant cytokine 
concentrations, following 24h of PBMCs stimulation with Plasmodium falciparum-infected 
erythrocytes are also summarized (figure 1). Adjustment for age class, sex and/or magne-
sium deficiency did not lead to marked changes in the associations between zinc deficiency 
and supernatant cytokine concentrations shown in figure 1; conversely, adjustment for age 
class, sex and/or zinc deficiency did not lead to marked changes in the associations between 
magnesium deficiency and those supernatant cytokine concentrations. 
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Figure 1:  Associations between nutrient status and supernatant cytokine concentrations, 
and between malaria infection status of the child at the time of blood collection and super-
natant cytokine concentrations, following 24h of PBMC stimulation with Plasmodium falci-
parum-infected erythrocytes. 
 
N: normal concentrations; L: low concentrations (plasma concentrations of zinc and mag-
nesium <9.9 µmol/L and <750 µmol/L, respectively); A: absence of iron deficiency anae-
mia; P: presence of iron deficiency anaemia (co-existing iron deficiency; plasma ferritin 
concentration <12 µg/L and anaemia; haemoglobin concentration <110 g/L). –ve: malaria 
negative; +ve: malaria positive. Percentages indicate paired group differences in super-
natant cytokine concentrations, expressed as percentages relative to values observed in 
groups with normal plasma zinc or magnesium concentrations. P-values were obtained by 
assessing by multivariate analysis to what extent the proportional change in cytokine con-
centration that is associated with nutrient or malaria status.  
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Association between nutrient indicators and in vitro innate cytokine production, by malaria 
infection status at the time of blood collection: When analysing IL-10 concentrations, we 
excluded all individuals with IL-10 concentrations below the detection limit. In some in-
stances, differences in cytokine concentrations between nutrient replete and deficient chil-
dren (figure 2) seemed to depend on malarial infection status at the time of blood collection 
(table 2). The profile of supernatant cytokine concentration appeared different between sub-
jects with deficiencies in zinc, magnesium and with iron deficiency anaemia. In the absence 
of malaria infection at the time of blood collection, zinc deficiency was associated with mar-
ginal reductions in concentrations of TNF-α, IL-1β and IL-10. Amongst donors with malaria 
infection at the time of blood collection, zinc status was not associated with altered concen-
trations of IL-1β or IL-10, but low plasma zinc concentrations were associated with an in-
crease in TNF-α concentration by 74% (11% to 240%, 95% CI). Malaria infection at the 
time of blood collection seemed to determine the magnitude of the association between low 
plasma zinc concentration and TNF-α concentration (9% reduction in children without ma-
laria, as compared to 74% increase in their peers with malaria; although the statistical evi-
dence for this difference was weak (P=0.15). 
 
Magnesium deficiency, on the other hand, was associated with increased concentrations of 
IL-10; this increase was 46% in children without malaria, as compared to only 6% in their 
peers with malaria (figure 2). Low magnesium concentrations seemed associated with re-
duced concentrations of TNF-α and IL-1β by -25% (95% CI: -64% to 55%; P = 0.79) and -
44% (-70% to 6%; P = 0.13), respectively, in children with malaria infection at the time of 
blood collection, although these differences may have been due to chance. These results are 
a reverse of the situation in zinc deficiency. The numbers of individuals with both iron defi-
ciency anaemia and malaria (table 1) were too low to compare groups meaningfully. 
 
Influence of malaria and nutrient indicators on associations between cytokine concentra-
tions: We found no evidence that the associations between concentrations of TNF-α and IL-
10 depended on zinc, magnesium or malaria status at time of blood collection, as indicated 
by differences in slopes of 17% (-44% to 147%; 95% CI, P=0.67) for zinc status, 10% (-
47% to 127%; 95% CI, P=0.80) for magnesium status, or 3% (-24% to 39%; 95% CI, P=84) 
for malaria (figure 3). There was some evidence, however, that iron deficiency anaemia 
(IDA) influenced the relationship between concentrations of TNF-α and IL-10, as indicated 
by the difference between slopes of 119% (35% to 637%; 95% CI, P=0.20). 
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Figure 2:  Associations between nutrient status and supernatant cytokine concentrations 
following 24h of PBMC stimulation with Plasmodium falciparum-infected erythrocytes, by 
malaria infection status of the child at the time of blood collection. 
 
N: Normal concentrations; L: low concentrations (plasma concentrations of zinc and mag-
nesium <9.9 µmol/L and <750 µmol/L, respectively). Data from children without and with 
malaria infection at the time of blood collection are indicated with open and shaded col-
umns, respectively. Percentages indicate group differences in supernatant cytokine concen-
trations, expressed as percentages relative to values observed in groups with normal plasma 
zinc or magnesium concentrations. P-values were obtained by assessing by multivariate 
analysis to what extent the proportional change in cytokine concentration that is associated 
with nutrient status is different between children with and without malarial infection. The 
number of individuals with iron deficiency and malaria (table 1) was too small to meaning-
fully compare among groups. 
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Additional linear regression analyses (figure 4) showed evidence that zinc status influenced 
the association between concentrations of IL-1β and IL-10, as indicated by differences in 
slopes of 118% (4% to 359%; 95% CI, P=0.04). There was no evidence that malaria infec-
tion influenced the association between concentrations of TNF-α and IL-1β (figure 4, ma-
laria panel), as indicated by a difference in the slopes of regression lines of 9% (-13% to 
35%; P=0.47). In summary, these results show no evidence of influence on associations 
among innate cytokines, by the various conditions of micronutrient malaria status at time of 
blood collection except for zinc status, for which there was some evidence that it influenced 
the association between IL-1β and IL-10. We found no evidence of influence of micronutri-
ent status and malaria on associations in other relationships. There were insufficient cases in 
all groups to explore and meaningfully compare the associations between IL-12 and other 
cytokines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Associations between supernatant concentrations of TNF-α and IL-10 following 
24h stimulation of peripheral blood mononuclear cells with Plasmodium falciparum-
infected erythrocytes, by micronutrient and malaria status at the time of blood collection,  
 
Black blocks = zinc or magnesium replete, no iron deficiency anaemia or no malaria; open 
blocks = zinc and magnesium deficiency, iron deficiency anaemia or positive results for 
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malaria tests at time of blood collection. P-values indicate probabilities of obtaining differ-
ences in associations between cytokine concentrations (as indicated by the slopes of the 
lines) as least as extreme as observed, assuming no differences. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Relationships between supernatant concentrations of TNF-α, IL-1β and IL-10 
following 24h stimulation of PBMCs with Plasmodium falciparum-infected erythrocytes, 
under different conditions of micronutrient and malaria status at the time of blood collec-
tion.  
 
Black blocks = zinc replete, magnesium replete, or no malaria; open blocks = zinc defi-
ciency or positive results for malaria test at time of blood collection.  
 
Discussion 
Effects of plasma concentrations of mineral elements on in vitro cytokine responses by 
PBMCs: Our biochemical data showed that most children in this study had nutrient deficien-
cies, particularly in zinc and magnesium and to a lesser extent iron deficiency anaemia. Zinc 
deficiency was associated with increased TNF-α responses in children with malaria infec-
tion at the time of blood collection but not in those without infection. TNF-α is a pro-
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inflammatory cytokine resulting in malaria pathology if not properly regulated. We also 
found that, in children with malarial infection, zinc deficiency is associated with increased 
production of IL-1β and IL-10, even if this increase did not bring the levels to those reached 
by individuals in the non-infected group. This is important because IL-10 is required to limit 
the production of pro-inflammatory cytokines, so they do not lead to pathological conse-
quences [31]. The low production of IL-10, however, could be due to the fact that the cyto-
kine is said to be produced late (in vivo) following infection relatively to the innate cyto-
kines. The initial production of TNF-α could also be the triggering factor by feedback 
mechanisms for production of IL-10 although Ramharter et al [32] reported increased re-
sponsiveness of in vivo primed cells as compared to malaria-naïve cells, with a tendency 
towards increased production of TNF-α. This can possibly explain the difference between 
subjects who were exposed or non-exposed at the time of blood collection, in response to in 
vitro stimulation in our study. These results show possible alterations in innate cytokine 
production particularly TNF-α and IL1-β due to the reported impaired macrophage functions 
and NK-cells activity in zinc deficiency [1, 2, 13, 33]. Interaction between these cells leads 
to the production of innate cytokines in the early stages of infections. 
 
The relatively higher cytokines levels in individuals with malarial infection as compared to 
their uninfected peers (figure 2), however, can be explained by the priming of the immune 
system by malaria. Exposure of T cells to malaria leads to priming, so that these cells pro-
duce greatly increased amounts of IFN-γ when subsequently exposed. This cytokine is nec-
essary for up-regulation of production of TNF-α and other pro-inflammatory cytokines in 
malaria infection [34, 35]. In this context, malaria-positive subjects are said to have γδT-
cells primed with the capacity for immunological memory and highly contributing to rapid 
and early pro-inflammatory cytokine production following re-infection [35]. The increase in 
innate cytokine production in zinc-deficient individuals with malarial infection can be the 
result of a shift towards a pro-inflammatory immune response due to zinc deficiency in 
combination with prior priming of these cells due to previous exposure to malaria. The ini-
tial contact with the pathogen directs towards production of pro-inflammatory cytokines to 
limit infection. Loharungsikul et al [36] proposed Toll-like receptors (TLRs) to play a role 
in innate immune recognition in which the differential expression of TLRs on antigen pre-
senting cells (APCs) could be regulated by the P. falciparum parasite. This could account 
for the increase in levels of TNF-α in malaria-positive individuals regardless of micronutri-
ent status (figure 1). Studies from murine malaria [37] have revealed glycosylphosphatidyl 
inositols (GPIs) that anchor P. falciparum merozoite surface protein 1 (MSP1) and mero-
zoite surface protein 2 (MSP2) to be the pathogen associated molecular patterns (PAMPs) 
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preferentially recognised by TLR-2 and TLR-4. The recognition and the interaction between 
these molecular patterns signal the induction of pro-inflammatory cytokine production. In 
addition, it is possible that parasite DNA attached to malarial pigment (hemozoin) produced 
in the course of infection further activates the innate immune response through TLR-9 en-
gagement [38]. The expression of TLRs has been found to differ between malaria-infected 
and uninfected individuals, with higher expression being observed in infected patients [24, 
39]. These recent studies have further indicated TLR-2 to be highly expressed in mononu-
clear cells, particularly monocytes of P. falciparum-infected children and that TLR-2 are 
well responsive following stimulation with pRBCs resulting into stronger signals with con-
sequential change in cytokine production profiles. 
 
The interesting result in this study is that the impact of magnesium deficiency on early cyto-
kine responses followed a different profile from that observed with zinc status. Magnesium 
deficiency seemed to be associated overall with low TNF-α concentrations, low concentra-
tions of IL-1β and higher concentrations of IL-10 in uninfected but not infected donors 
(figure 2). Low levels of pro-inflammatory cytokines in malaria are critical because they 
reduce the ability of the initial innate immune response to limit infection. Our results imply 
that magnesium deficiency directs early cytokine responses towards anti-inflammatory 
rather than pro-inflammatory cytokine responses, although further studies are still needed to 
confirm this hypothesis. The significantly increased IL-10 and variable alteration in levels 
of TNF-α and IL-1β in both malaria-negative and malaria-positive subjects with magnesium 
deficiency may explain the imbalance in cytokine production as a result of magnesium defi-
ciency modulated by malaria status.  
 
Methodological differences may explain contradictions between our findings and those from 
previous studies [5, 7, 9, 40]. We used parasitized erythrocytes to simulate the in vivo infec-
tion, whereas others used mitogens, lipopolysaccharides (LPS), phytohemagglutinin (PHA) 
and polyclonal stimulation. In addition, we used Ficoll-isolated PBMCs that had been stored 
for several months under frozen conditions, whereas whole blood stimulated within 15 min-
utes of collection was also used. McCall et al [24] stimulated freshly prepared PBMCs from 
adult naïve volunteers ex vivo with P. falciparum antigens. Our findings suggest that zinc 
and other micronutrients can protect against malaria infection by a different means such as 
targeting specific pathogenic processes of infection in vivo [41]. Nevertheless, the idea that 
zinc can also reduce production of pro-inflammatory cytokines by inhibiting signal trans-
duction in monocytes in healthy human subjects [42], particularly IL-1β and TNF-α [2, 43, 
424], should be further explored. The latter idea is also supported by in vitro studies [45, 46] 
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in other conditions than malaria. 
 
In our study and those conducted by others [47, 48], IL-12 concentrations were below the 
detection limits. The most probable reason is the time required for maximal priming of 
pathogen recognition receptors (e.g. TLRs) on PBMCs by P. falciparum-parasitized erythro-
cytes. McCall et al [24] have shown that pro-inflammatory priming effects of P. falciparum 
require up to 48 hours to develop maximally, whereas we measured cytokines after 24 hours 
of stimulation. This priming is lacking in our culture system despite the reported poor in 
vitro induction of IL-12 by P. falciparum [49]. There may be a possibility that the levels 
were below the detection limits as a result of IL-12B gene promoter polymorphisms that is 
reported to be associated with low IL-12 production and increased malaria mortalities in 
children [50]. This gene encodes for the IL-12p40 cytokine and has been determined in Tan-
zania. Early IL-12 activity is also liable to suppression by transforming growth factor 
(TGF)-β [51, 52] that has been reported to variably influence and result in weak IL-12 acti-
vation and production, at least in vivo. Most of our donors responded towards production of 
IL-1β rather than TNF-α and IL-10.  This is interesting since although different arguments 
reveal the pathological effect of IL-1β on cerebral malaria and severity of the disease in 
children [53], IL-1β together with other pro-inflammatory cytokines like IFN-γ and IL-6 is 
said to be protective against malaria by inducing parasite killing by monocytes, macro-
phages and neutrophils [54]. Production of IL-1β is induced by direct interaction between 
zinc and monocytes through activation of interleukine-1 receptor associated kinase (IRAK) 
which is dose-dependent [44]. Lower in vivo zinc levels, partially inhibit IRAK leading to 
diminished but not completely inhibited normal T-cells IL-β response. Results from this 
study may also reflect that stimulation of cryopreserved PBMCs by pRBCs results in a grad-
ual production of innate cytokines preceded by IL-1β from the monocytes.  
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Table 1. Characteristics of the study population, by malarial infection status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Association between innate cytokines under different conditions of micronutrients and ma-
laria status: The association between IL-1β and IL-10 was found to be influenced by zinc 
status (figure 4). The two innate cytokines TNF-α and IL-1β are a prerequisite in early re-
sponses to malaria infection and IL-10 is an important regulatory cytokine affected by nutri-
ent deficiencies and malaria infection status.  This is critical under tropical situations where 
both micronutrients deficiencies and malaria prevail, posing a challenge to the early immune 
response to infections. 
 
 
 
 
 
 
 
 
 
 Plasmodium- 
infected 
Plasmodium- 
uninfected 
P-value 
Sex   0.56 
Male 65 70  
Female 75 94  
Age class   0.03 
6-12 months 7 19  
12-24 months 18 31  
24-48 months 61 58  
48-72 months 54 55  
Zinc deficient 1   0.49 
Yes 63 81  
No 74 80  
Magnesium deficient 2   0.63 
Yes 87 107  
No 50 54  
Iron deficiency anaemia 3   <0.001 
Yes 2 24  
No 138 140  
 
1 
Plasma zinc concentration <9.9 µmol/L; 
2 
plasma magnesium concentration <750 µmol/L; 
3
 
anaemia (haemoglobin concentration <110 g/L) and iron deficient (plasma ferritin 
concentration <12 µg/L. 
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In conclusion, we have shown micronutrient deficiencies to variably influence some in vitro 
innate cytokine concentrations. Zinc deficiency in particular, was found to possibly influ-
ence  the in vitro production of various innate cytokines that particularly are modulated by 
malaria status. Magnesium deficiency, on the other hand, seemed to associate with higher 
concentrations of IL-10 in donors uninfected at time of blood collection. These results may 
be speculative indicators that while zinc deficiency and possibly iron deficiency anaemia 
might increase pro-inflammatory cytokines such as IL-1β and TNF-α, magnesium defi-
ciency may have greater influence on anti-inflammatory cytokines such as IL-10. With re-
gards to early innate cytokine responses to malaria, an ideal situation should be to supple-
ment children with a combination of a few precisely selected micronutrients rather than sin-
gle nutrients, although further studies involving larger sample sizes still need to be per-
formed. This study has indicated the effect of poor nutrition on innate immune responses in 
children from malaria endemic area and how malaria infection may modulate these relation-
ships. The findings have also shown plasticity in cytokine profiles of mononuclear cells 
reacting to malaria infection under conditions of different micronutrient deficiencies. Our 
findings therefore lay the foundations for future inclusion of selected micronutrients in ma-
laria vaccine intervention programs, particularly in developing countries, to boost immune 
response to malaria. 
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Abstract 
An appropriate balance between pro-inflammatory and anti-inflammatory cytokines that 
mediate innate and adaptive immune responses is required for effective protection against 
human malaria and to avoid immunopathology. In malaria endemic countries this immu-
nological balance may be influenced by micronutrient deficiencies. Here, we stimulated 
peripheral blood mononuclear cells from Tanzanian preschool children in vitro with Plas-
modium falciparum-infected red blood cells to determine T-cell responses to malaria under 
different conditions of nutrient deficiencies and malaria status. Our data indicate that zinc 
deficiency is associated with an increase in TNF-α response by 37%; 95% CI: 14% to 118% 
and IFN-γ response by 74%; 95% CI: 24% to 297%. Magnesium deficiency, on the other 
hand, was associated with an increase in production of IL-13 by 80%; 95% CI: 31% to 
371% and a reduction in IFN-γ production. These results reflect a shift in cytokine profile to 
a more type I cytokine profile and cell-cell mediated responses in zinc deficiency and a type 
II response in magnesium deficiency. Our data also reveal a non-specific decrease in cyto-
kine production in children due to iron deficiency anaemia that is largely associated with an 
malaria infection status. The pathological sequel of malaria potentially depend more on the 
balance between type I and type II cytokine responses than on absolute suppression of these 
cytokines and this balance may be influenced by a combination of micronutrient deficien-
cies and malaria status. In conclusion, it should be further assessed to what extent supple-
mentation with zinc, magnesium and iron is beneficial in children with deficiencies for these 
nutrients. 
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Introduction 
Frequent or chronic exposure to Plasmodium falciparum infection is thought to be a key 
element to immune protection against malaria in endemic areas [1]. Although the human 
immune system can kill parasites, it can also contribute to severe disease if not regulated 
and controlled to optimal levels [2, 3]. In African countries, micronutrient deficiencies are 
common and may modulate immunity and predispose to infections. This is particularly rele-
vant for young children who are most at risk of both malaria and micronutrient deficiencies. 
 
Deficiencies in mineral elements and vitamins can result in suppression of innate, T-cell 
mediated and humoral responses [4, 5]. Coordinating these responses are the cytokines 
which are produced interactively by several types of immune cells [2, 4]. The immune re-
sponse to malaria is specific for individual developmental stages of the parasite, and the 
balance in production of pro-inflammatory and anti-inflammatory cytokines seems to be 
critical for prognosis [5, 6]. Following presentation of malaria antigens by antigen-
presenting cells including dendritic cells, macrophages and occasionally B cells, naïve T 
helper (Th) cells proliferate and differentiate into specific Th cell subsets. The pattern of Th 
cell types, and the associated cytokine profile, probably depends on the type of antigen-
presenting cells and their cytokine milieu, and on regulatory T-cells that suppress the prolif-
eration and activity of B cells and Th cells by the production of IL-10 and transforming 
growth factor (TGF)-β. Imbalance in these responses can result in an inefficient adaptive 
immune response to clear infection, and may contribute to pathological consequences. Sev-
eral reports [7-15] have indicated possible roles of micronutrients on immune responses but 
either they have focused on other infections than malaria, or their effects have been evalu-
ated in individuals older than 5 years, the age with the highest vulnerability to malaria. 
 
We hypothesized that the adaptive cytokine response to Plasmodium falciparum is influ-
enced by micronutrient deficiencies that result in an imbalance between Th1 cells, with in-
terferon (IFN)-γ as a signature cytokine, and Th2 cells, characterized by the production of 
interleukin (IL)-4, IL-5 and to some extent IL-13. We isolated peripheral blood mononu-
clear cells (PBMCs) from Tanzanian children aged 6-72 months, and assessed in vitro the 
cytokine responses of these PBMCs upon exposure to erythrocytes parasitized by P. falcipa-
rum. We compared these responses between donors with and without micronutrient defi-
ciencies and in addition, we assessed to what extent the magnitude of PBMCs cytokine re-
sponses depended on P. falciparum infection status of the child at the time of blood collec-
tion. 
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Subjects and methods 
Study area and population: The field work for this study was conducted in a lowland area 
around Segera village (S 05º 19.447’, E 38º 33.249’), Handeni District, north-eastern Tanza-
nia, in May-July 2006. Malaria is highly endemic in this area, with virtually all infections 
being due to P. falciparum. The local population comprises mostly poor farmer families 
growing maize and cassava for subsistence use. The study was approved by both Ethics Re-
view Committees in The Netherlands and Tanzania (for Tanzania ethics review bodies, the 
reference numbers for KCMC and National Ethics Review Committee were 094 and NIMR/
HQ/R.8a/VolIX/540, respectively). Informed consent was obtained from community leaders 
and local government officials, and from parents or guardians. 
 
Sampling methods, eligibility criteria and preliminary laboratory analyses: The details of 
sampling method, field procedures, isolation of peripheral blood mononuclear cells 
(PBMCs) are provided elsewhere [16, 17]. In brief, children aged 6-72 months were re-
cruited in the study and were clinically examined before sample collection. Children were 
eligible to participate if they had no signs of severe febrile disease or severe malnutrition at 
the time of assessment. Dip stick test was used for diagnosis complimenting microscopy and 
providing a wide chance for detecting asymptomatic malaria infection [18, 19].  Whole 
blood samples from the study children were collected after overnight fasting. PBMC were 
isolated using Ficoll density gradient centrifugation. P. falciparum-parasitized and unparasi-
tized erythrocytes were prepared as described elsewhere [20, 21], and kept under frozen 
conditions until the stimulation experiments.  
 
Determination of plasma indicators of mineral element status: Plasma samples were diluted 
20 times in milliQ [22], and concentrations of zinc, magnesium and copper were measured 
by inductively-coupled plasma atomic emission spectrometry (ICP-AES) (Vista Axial, Var-
ian, Australia). To determine variability in outcomes, measurements were replicated five 
times: with mean values set at 100%, measurements varied between 97% to 102% for zinc, 
99% to 102% for magnesium, and 97% and 102% for copper. Plasma concentrations of fer-
ritin and C-reactive protein were measured as indicators of iron stores and inflammation, 
respectively by using a Behring nephelometer (BN ProSpec; Dade-Behring) in The Nether-
lands (Meander Medical Centre) and will be reported separately. 
 
PBMCs stimulation: PBMCs were cultured at 106 cells/well in sterile polystyrene 48-well 
plates with flat-bottom wells (Corning, Cat No. 3548, NY 1483, USA) in Yssel’s culture 
medium [23], which is a modification of Iscove’s modified Dulbecco’s medium (IMDM), 
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lacking the nutrients considered in this study. The medium is recommended for the culture 
of cells growing in suspension, such as human T and B cell lines and is especially recom-
mended for the generation and long-term culture of antigen-specific T cell and NK clones 
[24, 25]. Aliquots of P. falciparum-parasitized red blood cells (pRBC) were thawed, re-
suspended in Yssel’s+ medium [17] with 1% human AB+ serum plus 1% penicillin-
streptomycin and 1% fungizone (Gibco-BRL, Invitrogen, Grand Island NY, USA), and 
added to PBMCs in a ratio of 2:1 (2×106 pRBC to 1×106 PBMC). PBMC were also cultured 
under similar conditions with unparasitized erythrocytes (uRBC) (2´106 cells/well) as a 
negative control, and with soluble antibodies to CD3 and soluble antibodies to CD28 (Cat. 
No.555336 and 555725, Becton-Dickinson Pharmigen, Alphen aan den Rijn, The Nether-
lands) as a positive control. Cell culture plates were incubated at 37oC in a humidified at-
mosphere containing 5% CO2. Based on previous studies [26-28] and our own preliminary 
experiments (Mbugi E, Meijerink M et al, unpublished data), we expected 7 days of con-
tinuous stimulation to be optimal for observing differences in PMBCs responses to exposure 
with non-parasitized and parasitized RBCs. Thus after 6 days of culture, monensin was 
added to cells to allow for accumulation and subsequent staining of intracellular cytokines. 
At day 7 of culture, aliquots of supernatant were collected from parallel non-monensin 
treated cultures; concentrations of type I cytokines (IL-1β, IL-12p70, TNF-α, ILN-γ) and 
type II cytokines (IL-4, IL-5, IL-10, IL-13) in culture supernatants were measured using a 
Cytometric Bead Array System (FACSCanto, Becton-Dickinson). 
 
Proliferation and activity of leukocyte subsets: Proliferation assays were performed to deter-
mine the activity potential of cells and to determine whether selected individuals displayed 
intrinsic differences in their T-cell compartments. To distinguish PBMCs subsets, we 
stained cultured cells (5×105) for 30 min, at 4oC in the dark with a combination of fluoro-
phore-bound antibodies against CD4 (T helper cells), CD8 (cytotoxic T cells) and CD45 (all 
leucocytes) (Becton-Dickinson Pharmingen, Alphen aan den Rijn, The Netherlands). The 
cells were then centrifuged (500×g, 5 min, 4°C), washed, re-suspended in PBS for subse-
quent staining for Ki-67 protein. This protein is present during all active phases of the cell 
cycle, but not in resting cells [29]. After CD marker staining, cells were fixed and permeabi-
lised by incubation (15 min, 4°C, dark condition) with BD Cytofix/Cytoperm (catalogue no. 
554722, Becton-Dickinson Pharmingen). The cells were subsequently washed twice with 
BD Perm/Wash buffer™ (catalogue no.554723, Becton-Dickinson Pharmingen), centri-
fuged (300×g, 10 min, 4°C), re-suspended in BD Perm/Wash buffer and incubated with Ki-
67 detection antibodies (catalogue no. 556026, Becton-Dickinson Pharmingen) (30 min, 4°
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C, dark conditions). Thereafter, the cells were washed twice with perm/wash buffer and 
suspended in PBS with counting beads for subsequent flow cytometry. 
 
Intracellular cytokine staining: Cultured cells (5×105) were incubated (for 30 min, at 4°C in 
the dark ) with 20% human AB serum in PBS to block Fc receptor binding and stained with 
antibodies against CD4 and CD25 to detect activated Th cells, centrifuged (500×g, 5 min, 4°
C), fixed, permeabilized and washed as described above, and re-suspended in PBS for sub-
sequent intracellular staining for IL-10 and IL-4 using antibodies against these cytokines 
(BD Pharmigen, Alphen aan den Rijn, The Netherlands). After incubation with anti-IL-10 
and anti-IL-4 detection antibodies, the cells were washed twice with perm/wash buffer and 
re-suspended in PBS for analysis by flow cytometry. 
 
Flow cytometry: Analyses were performed on a FACSCanto II flow cytometer and analysed 
with FACSDivaTM software (both Becton-Dickinson Biosciences). 
 
Statistical analysis: Data were entered and analysed using SPSS for Windows (version 15.0. 
SPSS Inc., Chicago, IL, USA). Zinc deficiency and low zinc status were defined as plasma 
zinc concentrations <9.9 µmol/L and <10.7 µmol/L, respectively; low magnesium status was 
defined by magnesium concentration <750 µmol/L; iron deficiency anaemia was defined by 
coexisting iron deficiency (plasma ferritin concentration <12µg/L) and anaemia 
(haemoglobin concentration <110 g/L). Because we found no evidence for copper defi-
ciency as assessed by plasma copper concentrations  (<7.1 µmol/L) (data not shown), we 
currently only report the results for zinc, magnesium and iron deficiency anaemia. Cytokine 
concentrations were log-transformed to obtain normally distributed values. Group differ-
ences were analysed assuming t-distributions, and associations between continuous vari-
ables were assessed using linear regression analysis. Effects of log-transformed data were 
expressed in their natural units by exponentiation, and reported as the percentage difference 
relative to the reference value. We only report the analyses of the cytokine responses to 
pRBCs. As expected, the average response to uRBCs (negative control) was less than to 
pRBCs, whereas the average response to CD3/CD28 (positive control) was higher. Correc-
tion for these responses does not change the estimates of the associations between nutrient 
status and cytokine responses, or between malarial infection status and cytokine responses. 
 
Results 
Study population and characteristics: The study population consisted of 304 children; 301 
were within the eligible age range; for 3 children we found after recruitment that they were 
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older but these were retained in the analysis. Characteristics of the study population and 
crude associations between malarial infection and nutrient markers are provided elsewhere 
[16] and (Chapter 3). In short, the following prevalence values were found: malarial antigen 
as assessed by dipstick test: 45.2 %; low zinc status 63.1% (188); zinc deficiency: 48.3% 
(144); low magnesium status: 65.1% (194); iron deficiency anaemia: 9.4% (26); malaria: 
46.1% (140).  Malaria status at inclusion was found to associate with age and iron defi-
ciency anemia, but not with zinc or magnesium deficiency (Mbugi et al, chapter 3). 
 
Induction of cytokine production: Lower concentrations of cytokines were detected in uRBC 
than in pRBC indicating the differences in in vitro mitogenic activities on PBMC. Stimu-
lated PBMC responded more strongly with IFN-γ production as compared to other cyto-
kines. Production of IL-4 was lowest regardless of the micronutrient status. In general, the 
composition of cytokines in day 7 supernatants consisted of IFN-γ, TNF-α, IL-1β, IL-13, IL-
10, IL-12p70, IL-5 and IL-4, in declining order of concentration.  
 
Proliferation and intracellular cytokine staining: The average proportion of malaria extract-
specific proliferating cytotoxic T-cells (CD8+ Ki67+) and proliferating Th cells (CD4
+ 
Ki67+) relative to the general proliferating leucocytes were 4% and 21%, respectively. In 
figure 1 a representative example of a flow cytometric analysis of a malaria-specific CD4+ 
T-cell response in the PBMCs of a malaria-infected child is shown. Of the leukocytes re-
sponding to the malaria extract after 7 days of culture,  on average 20% of the leukocytes 
were activated Th cells (CD4+ CD25+; 23 % in figure 1), part of them may be naturally oc-
curring or probably inducible regulatory T-cells (Tr). Intracellular cytokine staining revealed 
that the proportion of CD4+/CD25+ cells producing both IL-4 and IL-10 (average 19%; 7.2% 
in figure 1) was higher than cells producing only IL-10 (average 4%; 2.5 % in figure 1) or 
only IL-4 (14 % in figure 1). This indicated that most anti-inflammatory cytokine response 
came from IL-4+IL-10+ double producing cells, rather than from single IL10+ cells.  
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Influence of nutrient deficiencies on cytokine responses to stimulation with malaria para-
sites: We next explored the association between nutrient deficiencies and cytokine re-
sponses assuming no interaction with malarial infection. The effect change in cytokine con-
centration under different conditions of micronutrients status are shown in tables 1 and 2, 
respectively. For this analysis only the data were used of individuals of which the PBMCs 
cultures  stimulated by malaria extract yielded detectable cytokine levels that are indicative 
of malaria-specific responding T-cells by induced proliferation and cytokine synthesis. Thus 
the number of individuals differ for every individual cytokine analyzed. Overall, zinc defi-
ciency was associated with increased supernatant concentrations of TNF-α and IFN-γ (by 
37% and 74%, respectively), and seemed associated with increased concentrations of IL-5 
and IL-13 (tables 1 and 2). Magnesium deficiency was associated with an 80% increase in 
IL-13 concentrations, and seemed associated with a 49% increase in IL-5 concentrations. 
Iron deficiency anaemia was associated with increased concentrations of IL-12 by 37%, and 
seemed associated with a 34% decrease in IL-5 concentrations. 
 
Interaction between nutrient deficiencies and malarial infection on cytokine response to 
stimulation: In some cases, malarial infection at the time of blood collection seemed to in-
fluence the associations between nutrient deficiencies and cytokine responses to stimulation. 
For example, in children without malaria, zinc deficiency was associated with an increase in 
supernatant concentration of IFN-γ by 114%; 95% CI: 41% to 677% as compared to an in-
crease of 40%; 95% CI: -53% to 314% in their peers with malaria infection. Similarly, in 
children without malarial infection, iron deficiency anaemia was associated with a decrease 
in IFN-γ concentration by 23% (95% CI: -78% to 177%) as compared to a 60% increase 
(95% CI: 45% to 368%) in their peers with malaria infection. In none of these cases, how-
ever, was such interaction supported by statistical evidence, as indicated by the high P-
values in figures 2 and 3. In other words, there is no evidence that the relationships between 
nutrient markers and cytokines depend on malarial infection. This reflects that nutritional 
deficiencies association with in vitro cytokine responses is independent of malaria status at 
time of blood collection.   
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Table 3: Effect change in linear relationships and differences in slopes of supernatant con-
centrations of cytokines measured after 7 days of stimulation with malaria antigens in chil-
dren with different nutritional and malaria status at time when blood was collected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IDA: Iron deficiency anaemia  
 
Relationship between IFN-γ and type II cytokines: Lastly, we explored the influence of nu-
trient deficiencies on the relationships between IFN-γ and some type II cytokines (table 3, 
figure 4). Overall, there was a clearly detectable positive linear relationship between IFN-γ 
and IL-5, IL-10 and IL-13. There was weak evidence however, that the slopes of regression 
lines differ with zinc, magnesium or malaria infection status. On the other hand, there was 
strong evidence that the slopes of regression lines for the association between IFN-γ and IL-
10 differed with iron deficiency anaemia status (P = 0.001). The change in slopes in the 
latter relationship was such that in iron deficiency anaemia there existed a negative linear 
relationship signifying that an increase in IFN-γ lead to a decrease in IL-10. There was no 
evidence that the slopes of regression lines for the association between IFN-γ and IL-10 
differed (figure 4) in zinc deficiency, magnesium deficiency and malaria infection. How-
ever, the results indicate that a smaller increase in concentration of IL-10 was associated 
with a relatively larger increase on IFN-γ (slopes). Subsequent analysis on whether deficien-
Predictors Cytokine pairs Change in 
slope  
95% CI 
Zinc  IFN-γ vs IL-5 32% -62% to 357% 
Zinc  IFN-γ vs IL-10 -12% -43% to 35% 
Zinc  IFN-γ vs IL-13 12% -52% to 157% 
Magnesium  IFN-γ vs IL-5 -38% -89% to 256% 
Magnesium  IFN-γ vs IL-10 -36% -61% to 5% 
Magnesium  IFN-γ vs IL-13 -20% -71% to 118% 
IDA  IFN-γ vs IL-5 -45% -81% to 58% 
IDA  IFN-γ vs IL-10 -48% -63% to -36% 
IDA  IFN-γ vs IL-13 -26% -66% to 58% 
Malaria  IFN-γ vs IL-5 174% -5% to 689% 
Malaria  IFN-γ vs IL-10 -23% -17% to 83% 
Malaria  IFN-γ vsIL-13 40% -34% to 197% 
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cies and malaria infection status influence the association among Th1 and Th2 cytokines, 
apart from IFN-γ (data not shown) revealed an overlap in slopes of linear associations. 
There was weak evidence that magnesium deficiency, zinc deficiency and malaria infection 
at time of blood collection influenced these associations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Representative example of the flowcytometric analysis of the IL-10 secreting 
CD4+CD25+ population of PBMCs stimulated with malaria extract for 7 days. A. Leuko-
cytes were identified by forward (FSC) and sideward (SSC) scatter. B. Of these leukocytes 
staining was performed with CD4-PE-Cy7-A and CD25-APC-Cy7-A labelled monoclonal 
antibodies from BD Pharmingen. C. The CD4+CD25+ double positive cells were stained 
intracellularly with IL-4 APC-A and IL-10 PE-A labelled monoclonal antibodies from BD 
Pharmingen. Panel 1 contains 14% IL-4 single positive CD4+CD25+ cells, panel 3 contains 
2.5% IL-10 single positive CD4+CD25+ cells, and panel 2 contains 7.2% IL-4+IL-10+ dou-
ble positive CD4+CD25+ cells.  
 
B 
C 
A 
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Figure 2: Associations between micronutrient status and supernatant type I cytokine con-
centrations following 7 days of PBMCs stimulation with Plasmodium falciparum-infected 
erythrocytes, by malaria infection status of the child at the time of blood collection. 
 
N: Normal concentrations; L: low concentrations; A: absent; P: present. Percentages indi-
cate paired group differences in cytokine concentrations. Data from children without and 
with malaria infection at the time of blood collection are indicated with open and shaded 
bars, respectively. P-values indicates the interaction between nutrition and malaria infec-
tion status.   
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Discussion 
Cytokine production: The results from this study reveal that pro-inflammatory cytokine do 
not only initiate immune response to infections but are also responsible to make it persistent 
and effective. We have revealed a cytokine concentration of IFN-γ, TNF-α, IL-1β, IL-13, 
IL-10, IL-12, IL-5 and IL-4 in declining order following a 7 days in vitro stimulation of 
PBMCs using pRBCs (tables 1 and 2). The cytokine concentration in the supernatant fol-
lowing in vitro stimulation cannot be extrapolated to number of responding cells but at least 
hints on what could happen in vivo amid natural infection. The relatively low concentrations 
of IL-12, IL-5 and IL-4 may reflect that probably these cytokines are needed in very minutes 
amounts, present only very temporarily or are gradually degraded or consumed by cells ear-
lier after response to infection. We anticipate that these cytokines are more active earlier 
than 7 days. Comparably, in both zinc replete and zinc deficient groups cells seemed to re-
spond better towards production of IFN-γ, TNF-α, IL-1β, IL-13 and IL-10 than other cyto-
kines in vitro. This might mean that these cytokines are crucial for continued elimination of 
the parasite at different stages of infection (pre-erythrocytic and erythrocytic stages) in vivo 
although this hypothesis may be unjustifiable based only on in vitro data.  
 
Effects of zinc and other micronutrients on cytokine production: In malaria endemic areas, 
repeated exposure to infection by P. falciparum results into naturally acquired immunity 
that fails to develop in areas where malaria is hypoendemic, epidemic or mesoendemic. This 
means that the potential mechanisms of protection and immunological memory depend 
among other factors, on the degree of exposure and pattern of malaria transmission [30]. 
Regardless of age, immunity to malaria is generally low in populations living in areas with 
low or unstable transmission. In such a situation, clinical malaria and possibly severe com-
plications can occur in both children and adults [31]. Although it appears not to be sterile, 
immunity to malaria is protective provided there is a constant exposure to infection and may 
be strengthened by good nutrition. This study provides in vitro results on the effect of some 
nutrients on the mediators of immune response to malaria in Tanzanian children. We have 
used intact P. falciparum infected erythrocytes (pRBC) to induce immuno-regulatory cyto-
kines [26, 32] reflecting the real in vivo situation. Among nutrients explored in this study, 
zinc, magnesium and iron deficiency anaemia was associated with variable concentrations 
of one or more cytokines from both Th1 and Th2 groups, that mediate the immune response 
to malaria. Prasad [33] reported zinc deficiency to cause an imbalance between Th1 and Th2 
functions in an experimental human model in which production of IFN-γ (product of Th1) 
was decreased and that no effects were predictable in production of IL-4 (and IL-10) 
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(products of Th2). Our findings contrast with previous findings by Prasad in the sense that 
zinc deficiency was associated with higher levels of IFN-γ, TNF-α and IL-12 (figure 2) but 
concur with the findings on IL-10 (figure 3). This is especially intriguing as it may imply 
that in zinc deficiency, the immune response to malaria shifts to more cellular-mediated 
immune response before tailing off. Previous results [13, 34, 35] have indicated that zinc 
deficiency is associated with a decreased ratio of CD4+ to CD8+ cells and is indicative of 
cytotoxic immune response. It could be that, in our study, of the activated CD4+ T-helper, 
Th1 cells were dominant in producing type I cytokines in cells from zinc deficient children. 
Our study partly agrees with available reports that zinc deficiency affects both cell-mediated 
immune responses and humoral responses [14] and that B cell proliferation is less dependent 
on zinc, albeit zinc deficiency may result in fewer naïve B cells for production of antibodies 
to new antigens [36].  
 
Magnesium deficiency was associated with an increase in the concentration of IL-13 among 
type II cytokines. Little work has been done on the role of magnesium in immune response 
to malaria and our results draw attention to the role of magnesium in cytokine production in 
reaction to malaria infection. Report [37] indicates that IL-13 and IL-4 are major cytokines 
driving the polarization of the immune response towards Th2. IL-13 is also believed to regu-
late immunoglobulin switching from IgG isotype to IgE, this is particularly important be-
cause it signifies that prolonged magnesium deficiency may predispose individuals to hyper-
sensitivity reactions. Type I cytokines dominate in cellular immune responses while type II 
cytokine dominance implies humoral immune response [38]. Our findings may reflect that 
magnesium deficiency is associated with an increase in IL-12 and IL-1β but these responses 
become weakened in malaria infection. On the other hand, the increase in IL-12 and IL-1β 
concentrations in zinc deficiency further go up in malaria infection (figure 2) which may 
imply that in zinc deficiency the potential for production of pro-inflammatory cytokines 
following malaria infection is high, rising the risk for development to pathology. To the 
contrary, in malaria-infected, magnesium deficient children, the concentrations of IL-12, IL-
1β  (type I) and IL-5, IL-10 and IL-13 (type II cytokines) do not increase to levels attained 
in  (figures 2 and 3) uninfected peers. In other words, the increase in cytokine concentra-
tions due to magnesium deficiency in malaria infection does not compensate for that ob-
served in uninfected. Thus although we speculate that in zinc deficiency, the immune sys-
tem is more likely to use cellular responses as a weapon to fight against malaria opting to 
antibody responses in case of magnesium deficiency, the responses in magnesium defi-
ciency might be weaker than in zinc deficiency.  
104  
Nutrition and T-cell cytokine responses  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Associations between micronutrient status and supernatant type II cytokine con-
centrations following 7 days of PBMCs stimulation with Plasmodium falciparum-infected 
erythrocytes, by malaria infection status of the child at the time of blood collection. 
 
N: Normal concentrations; L: low concentrations; A: absent; P: present. Percentages indi-
cate paired group differences in cytokine concentrations. Data from children without and 
with malaria infection at the time of blood collection are indicated with open and shaded 
bars, respectively. P-values indicates the interaction between nutrition status and malaria 
infection status (nutrient vs. malaria). 
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Figure 4: Relationships between supernatant concentrations of IFN-γ and IL-10 under dif-
ferent conditions of micronutrient and malaria status at the time of blood collection, follow-
ing 7 days stimulation of PBMCs with Plasmodium falciparum-infected erythrocytes.  
 
Regression lines and blocks in respective panels: closed blocks and solid lines = zinc re-
plete, magnesium replete, no iron deficiency anaemia and no malaria; open blocks and 
dashed lines = zinc deficiency, magnesium deficiency, iron deficiency anaemia and positive 
malaria tests at time when blood was collected. The differences in slopes for other relation-
ships are shown in Table 3. P-values have been calculated to indicates whether the interac-
tion between nutrition status and malaria infection status have impact on the association 
between IFN-γ and IL-10. 
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The role of iron in the induction of a protective immune response is still debatable. Our 
findings indicate variable effects of iron deficiency anaemia on cytokine concentration. 
While levels of TNF-α, IFN-γ and IL-β (type I) and IL-10 and IL-13 (type II) seemed de-
creased in iron deficiency anaemia, the levels of IL-12 and IL-5 appeared increased (figure 
3). These variable effects of iron deficiency on a range of both type I and type II cytokines 
are critical as these may lead to unstable cytokine response failing to inhibit the parasite. 
Reports on iron nutrition in children living in malaria endemic areas have indicated some 
association between IL-4 with all biochemical indices of iron [39]. In this study that was 
carried on the coast of Kenya, authors also report an increase in IL-10 serum mRNA expres-
sions in malaria blood-smear positive children, results which are concordant with our in 
vitro results on iron deficiency anaemia despite the weak evidence. 
 
Malaria infection status and the profile of cytokine production under conditions of nutrient 
deficiencies: Comparing within groups our findings show an increase in type I cytokines 
(TNF-α, IFN-γ and IL-β) in association with malaria infection in zinc deficient children as 
compared with zinc sufficient individuals, although this increase is less than amongst unin-
fected donors. However, an increase in IL-12 concentration seems to be independent of zinc 
deficiency (figure 2) signifying that malaria infection is associated with induction of in-
creased IL-12 production independent of zinc status. The levels of IL-12 at day 7 of stimula-
tion supports our previous results (Mbugi et al, submitted) that in malaria infection, IL-12 is 
produced later than 24 hrs of stimulation. With slightly decreased levels of IL-10 in associa-
tion with malaria infection in zinc deficient children, the findings possibly reflect that zinc 
deficiency primarily results in pathological consequences of type I cytokines due the re-
duced regulatory role of the cytokine IL-10. In magnesium deficiency, we found malaria 
infection to associate with both type I and type II responses but the increase is not sufficient 
to compensate for the levels attained in malaria negative individuals regardless of magne-
sium status (figures 3 and 4). These results may reveal that magnesium deficiency can lead 
to immune incompetence in response to malaria infection.  
 
Iron deficiency anaemia appeared to induce a similar increased trend in both types of cyto-
kine amongst malaria infected donors. The only exception was IL-12, which was reduced in 
association with iron deficiency anaemia although the levels were higher than those attained 
in children without malaria infection. The high levels of IFN-γ in iron deficiency anaemia 
may be an indication that protection from clinical malaria reported in iron deficiency [39, 
40] is probably through cell mediated immune responses. Interestingly, with the exception 
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of IL-12, this study found an increase in both type I and type II cytokines in association with 
iron deficiency anaemia in children with malaria infection (figures 2 and 3). Available re-
port [41] have speculated about the role of iron deficiency in limiting the severity of the 
inflammatory response. The argument corresponds with our findings and it could be a result 
of increased secretion of anti-inflammatory cytokine in response to increase in levels of pro-
inflammatory cytokines in malaria infection. However, the observation that the increase in 
cytokine production could not reach the levels in children without malaria may be due to a 
combined effect of nutrients deficiencies other than iron in co-existence. It is possible that in 
addition to the depletion of iron to the parasite that may occur in iron deficiency anaemia the 
host cells, including immune cells, are also depleted of iron [42] thus reducing the capacity 
for sufficient cytokine production The modulation of immune response by iron rests on its 
effects on the function of Th1 mediated response and supply of this nutrient to the parasite 
[43], in particular, withdrawal of iron is said to increase Th1 mediated immune function in 
vivo [42]. Our study found an association of iron deficiency anaemia with slightly reduced 
concentrations of IL-1β, IFN-γ and TNF-α in children without malaria but an increment in 
children with malaria infection. This reflects that iron deficiency anaemia may be associated 
with increase in concentration of Type I cytokines in malaria infection. From our study it 
transpires that iron deficiency anaemia is most likely associated with variable effects of both 
type I and type II cytokine responses (figures 2 and 3) rather than the reported discriminate 
effects between the two arms [44].    
 
Linear association between type I and type II cytokines: Associations between cytokine pro-
duction under different conditions of nutrients and malaria status may be predictive for dis-
ease outcome. We found relationships between type I and type II cytokines in micronutrient 
deficient and replete groups and they were variably influenced by the malaria status (table 
3). However, the significant difference in slopes in the association between IFN-γ and IL-10 
with respect to iron deficiency anaemia status, in particular the negative association seen in 
iron deficiency anaemia, emphasises that probably the response shifts in deficiency situa-
tions from one type of cytokine response to the other. Particularly the balance between IFN-
γ and IL-10 which is said to be critical in controlling malaria infection. This underscores the 
notion that micronutrients may have no grossly visible effects under normal situations but 
they do when the body is destabilized in terms of immune protection during infections. To 
emphasize, there is strong evidence that the association between IFN-γ and IL-10 is influ-
enced by iron deficiency anaemia: in children without iron deficiency anaemia, IFN-γ re-
sponses are positively associated with IL-10 responses, whereas this association seems ab-
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sent or weakly negative in children with iron deficiency anaemia (lower-left panel of figure 
3). This seems supported by weak evidence of similar interaction in the same direction when 
examining the influence of iron deficiency anaemia on the association between IFN-γ and 
IL-5, and between IFN-γ and IL-13 (table 3). These associations may reveal that the regula-
tory T-cell responses (and possibly the Th2-responses) in malaria are suppressed in iron defi-
ciency anaemia. In addition, there is substantial evidence that the relationship between IFN-
γ and IL-5 is influenced by the presence of malarial infection at the time of blood collection: 
the association between the responses in IFN-γ and IL-5 is steeper in children with malarial 
infection than in their peers without infection (table 3); this seems supported by weak evi-
dence of similar interaction in the same direction between IFN-γ and IL-13 (table 3). These 
data provide evidence that in malaria, previous malarial infection suppresses the Th2 
(regulatory) responses to the disease. As regards to zinc and magnesium deficiencies, there 
is no evidence that the respective deficiencies influence the associations between IFN-γ and 
Th2 cytokines (table 3). However, the findings that nutritional deficiencies and malaria 
status at time of blood collection are variably associated with Th2 responses independent of 
IFN-γ alerts to the importance of nutritional component in boosting immune response to 
malaria. These associations, despite weak evidence, are indicative of a probable imbalance 
in cytokine concentration that may be influenced by nutrient deficiencies and malaria infec-
tion at the time of blood collection, the consequences of which may lead to exaggerated 
malaria pathology due to cytokine imbalance. 
 
Not only zinc deficiency results into significant impact on cytokine responses to infections 
[7, 9, 14, 45-48] but also other nutrients, like magnesium and iron. The results show that 
zinc deficiency may have more impact on type I cytokine responses while magnesium has 
selective effects on type II responses. In addition, the results also seem to indicate that in 
iron deficiency anaemia, the prevalent cytokine response is more of type I than type II re-
sponses. A recent randomised controlled trial conducted in Burkina Faso has suggested that 
a combined vitamin A plus zinc supplementation reduced the risk of fever and clinical ma-
laria episodes among children aged 6 to 72 months [49], and this combination may be in-
cluded in control strategies to fight against malaria in African children. However, it does not 
exclude the contribution of other micronutrients that have not been reported in this paper 
which need to be further explored.  
 
Our study have shown weak evidence [50] of effect of nutrients deficiencies on association 
between cytokine concentration and malaria status at time of blood collection. This could be 
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due to small sample size to detect differences, the use of confidence intervals in our analysis 
however, gives a strong reflection of what could be happening as it shows a range within 
which the true effect is likely to lie. A larger sample size could allow detection of even mi-
nor differences leading to a proposal to a more larger study particularly in the intervention 
study. The protective immune response to malaria is said to target a broad antigenic reper-
toire that go beyond parasitic developmental stages [51]. Our study used parasitized erythro-
cytes to induce cytokine response in PBMCs providing intimation that sterile immune pro-
tection focusing on whole parasite vaccines could be rewarding [52].  
 
In conclusion, we have found that micronutrient deficiencies may variably be associated 
with impaired cytokine production. Zinc deficiency and iron deficiency anaemia have 
shown to be associated with remarkable increases in type I cytokine production, implying a 
shift in the balance of the immune towards pro-inflammatory and cellular type in these con-
ditions. It may mean that zinc deficiency and iron deficiency anaemia directly induce in-
creased production of pro-inflammatory cytokines or causes an imbalance in regulatory anti-
inflammatory cytokines as reflected by increased pro-inflammatory cytokines. Since these 
pro-inflammatory cytokines have been associated with pathological consequences like cere-
bral malaria, it should be further assessed to what extent supplementation with zinc and iron 
is beneficial in children with deficiencies for these nutrients. Consideration of micronutrient 
supplementation may also be of value if incorporated in vaccine programs in endemic areas 
to boost immune responses to malaria.  
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Abstract  
Immunoglobulin G (IgG) subclasses have been signaled to confer naturally acquired immu-
nity to Plasmodim falciparum malaria. Cytophilic IgG1 and IgG3 by their potential for 
opsonization, phagocytosis and antibody-dependent cellular inhibition in association with 
monocytes have been suggestive for the critical role in malaria. The potential for production 
of antibodies is influenced by micronutrient status. We explored the effect of micronutrients, 
particularly zinc status on the profiles of IgG subclasses in 304 Tanzania children aged ≤ 5 
yrs. An enzyme-linked immunosorbent assay was performed using whole asexual blood 
stage malaria antigens to determine plasma malaria-specific antibody titres. The findings 
reveal that zinc deficiency may influence the production of IgM, total IgG and several IgG 
subclasses in a malaria status-dependent manner. Of the four IgG subclasses, IgG3 and 
partly IgG2 displayed significant changes in the zinc deficient children with IgG3 predomi-
nating in subjects with malaria. Zinc, magnesium, iron deficiency anaemia and malaria 
status did not influence the association between IgG3 and IgG4. Under conditions of micro-
nutrient deficiency and malaria status, an imbalance in IgG subclasses production may occur 
resulting into predominantly higher levels of IgG3 and IgG2 that may not confer sufficient 
protection. The profile of both cytophilic and non cytophilic IgG subclasses have shown to 
be variably influenced by zinc status, the effects that vary with age at least in under fives. 
These results provide an insight for inclusion of micronutrients, particularly precise amounts 
of zinc, in future malaria interventional programs in endemic areas. 
 
 
 
 
 
 
 
 
 
 115 
Chapter 5 
Introduction 
The humoral immune response is mediated by naturally acquired antibodies against Plasmo-
dium falciparum blood-stage surface antigens and is vital in limiting parasite multiplication 
and the conferral of protection to clinical malaria. In malaria endemic areas the development 
of naturally acquired immunity to severe disease takes place in children at an age range of 1 
– 5  years [1, 2]. This ‘antiparasite’ immunity is not absolute and is acquired through re-
peated exposure to Plasmodium falciparum [3]. Many parasite antigens are known to occur 
at different stages of the parasite in the human host with the body generating antibodies 
against the prevailing antigenic proteins. Protective immunity to falciparum malaria, how-
ever, has particularly been associated with cytophilic antibodies of immunoglobulin G (IgG) 
subclasses [1, 3]. Ferrante and Rzepczyk [3] pointed out the switch from Immunoglobulin 
M (IgM) on B-cells to different isotypes and different IgG subclasses (IgG1, IgG2, IgG3 
and IgG4)  upon encounter with malaria antigens. Antigens can differentially modulate im-
munoglobulin heavy-chain switching through induction of different cytokine secretory pat-
terns by CD4+ T helper (Th) cells [3, 4]. The differential release of these cytokines (type I 
or type II) is influenced by nutritional status, particularly zinc [5, 6]. Studies by Tongren et 
al [7] reported the regulation of immunoglobulin class switching in murine malaria to be 
epitope-specific and that in human malaria, the IgG1/IgG3 class switching is independently 
regulated by the nature of antigen, cumulative exposure to the antigen and maturity of the 
immune system [8]. 
 
Several studies have highlighted the importance of naturally acquired antibody-mediated 
immunity through IgG subclasses to be crucial in limiting clinical malaria [3, 9-17] although 
these studies have targeted different parasite surface antigens. The levels of subclasses of 
IgG, in particular the proportion of cytophilic (IgG1 and IgG3) to non-cytophilic (IgG2 and 
IgG4) have been hypothesized to be more significant than the overall levels of antibodies in 
providing protection to the development of severe disease [1, 19, 20]. In addition, the fine 
specificity of antibodies towards specific antigenic epitopes on P. falciparum antigens is 
thought to be critical for the generation of an effective immune response [18, 19]. 
 
Poor nutrition in children may interfere with the development and function of the immune 
system. The immune regulatory mechanisms become impaired due to quantitatively and 
qualitatively altered immune cell populations [6, 20-23]. The whole immune response path-
way from innate to adaptive antibody response and cellular responses is said to be affected 
[6, 24-35] and in malaria endemic areas the impact of the disease may be aggravated. Most 
children become vulnerable to infections at weaning when the passive immunity acquired 
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from prenatal maternal antibodies and breast milk wanes and nutritional support is poor. It is 
likely that poor nutrition interferes with the immune response to malaria in African settings 
where both situations prevail. Several reviews and studies [31-36, 38-41] have  explored and 
the association between micronutrient particularly zinc deficiencies with infections but only 
few have specifically focused on the association with malaria [32, 36-38]. Even those stud-
ies that have extensively investigated the factors associated with a protective role of IgG 
subclasses, have been limited to individual effects of age, exposure, transmission intensity, 
ethnicity, geographical location of parasite and seasonality on the dynamics [11, 39] and 
fine specificity [14] of antibody-mediated protection to malaria. The fact that in some chil-
dren the B-cell response undergoes isotype switching to a more cytophilic antibody response 
to malaria early in life and who remain protected from the disease attacks for quite longer 
time periods than other children [8, 40] even when exposure is limited by seasonality [3, 
41], is indicative of the contribution of other factors like nutritional status in strengthening 
of an effective antibody response to malaria. 
 
We hypothesized that zinc and other micronutrients deficiencies induce relative alterations 
in the plasma profile of naturally acquired Plasmodium falciparum-specific antibody re-
sponses that these antibodies may influence the induction of a protective  immunity to mani-
festation of the clinical disease. To assess these associations, a direct enzyme-linked immu-
nosorbent assay (ELISA) was performed to determine the plasma levels of isotype-specific 
antibodies responding to asexual Plasmodium falciparum stage antigens which are differen-
tially involved in the parasite clearance and protection from clinical disease. Group differ-
ences were compared by determining the malaria infection status at the time when blood 
sample collection was done.  
 
Subjects and Method 
Study area and population: The cross-sectional study was conducted in the period of May-
July 2006 in a lowland area around Segera village (S 05º 19.447’, E 38º 33.249’), Handeni 
District, north-eastern Tanzania. Malaria is highly endemic in this area, with virtually all 
infections being due to P. falciparum. The residents in the study population comprise mostly 
poor farmer families growing maize and cassava for subsistence use. At the time of our 
study, only one health centre in Segera was available to serve all of the surrounding area. 
The study was approved by both Ethics Review Committees in The Netherlands and Tanza-
nia. Informed consent was obtained from community leaders and local government officials, 
and from parents or guardians. 
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Sampling methods and eligibility criteria: A census list was made with all resident children 
aged 6-60 months in the study area. Using this list, 16 children were randomly selected from 
each of 19 communities, resulting in a total of 304 children. Children were eligible when 
they had no fever, and showed no signs of other severe disease or severe malnutrition 
(weight-for-height z-score below -3 SD). Further details are provided elsewhere [42]. 
 
Field procedures: All children were examined by clinical officers, who also measured axil-
lary temperature by electronic thermometer. Information on the state of health such as ma-
laria, fever, sickness and reports on fever in the past 14 days was diligently recorded. Ve-
nous blood (6 mL) was collected in containers suitable for mineral element analysis with 
sodium heparin as anticoagulant (Becton-Dickinson, Franklin Lakes, NJ). Immediately upon 
collection, the cap was sprayed with ethanol and allowed to dry; approximately 1.3mL 
blood was then drawn in a sterile manner from the collected blood for different measure-
ments. Children were treated for common childhood infections and anaemia according to 
guidelines of Tanzanian Ministry of Health. 
 
After arrival of blood samples at the laboratory in Moshi, they were immediately centri-
fuged (300´g) at ambient temperatures for 10 minutes. Plasma (1.2 mL) was stored in liquid 
nitrogen, and subsequently transported on dry ice to The Netherlands to measure additional 
biochemical indicators of micronutrient status and inflammation. 
 
Parasite Enzyme-linked immunosorbent Assays (ELISA): Different ELISAs testing antibod-
ies against various specific parasite antigens are described elsewhere [1, 10, 12, 13, 43-45]. 
We developed our own direct ELISA test protocol that was used to determine the plasma 
concentration of isotype-specific antibodies responding to Plasmodium falciparum asexual 
blood stages. Parasite extract (asexual blood stage antigens) were used to coat the plates, 
and these were covered and incubated overnight at 40C. The parasite extract was obtained as 
a kind gift from Professor Robert Sauerwein from the Medical Parasitology Laboratory, 
Radboud University Medical Centre Nijmegen, The Netherlands. The plates were blocked 
with 150µL of 1% w/v bovine serum albumin, (BSA) (grade V, Sigma P4417, St Louis MO, 
USA) in PBS. After blocking the plates were washed three times with an extensive volume 
of 0.05% Tween 20 (v/v) (Sigma-Aldrich, Missouri, USA) in PBS. Plasma samples were 
diluted 5 (IgG total, IgG1, IgM) or 20 (IgG2, IgG3, IgG4) times in 0.2% w/v BSA and 
0.05% Tween 20 in PBS. Plasma samples were added to the wells at 50µL and malaria posi-
tive and negative samples were added as controls. The positive control consisted of a pooled 
sample of 25 highly immune Tanzanian individuals. Addition of plasma to the wells was 
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followed by incubation under cover for 3 hrs at room temperature. After incubation, the 
plates were washed 3x in 0.05% Tween 20 in an extensive volume. Thereafter, 50µL of 
horseradish peroxidise (HRP) conjugated sheep anti human antibody (The Binding Site, 
Birmingham, UK) was added. and incubated at room temperature in a shaker in the dark for 
1.5 hrs. The following concentrations were used: 1µg/ml for IgG total (AP003) and IgG1 
(AP006), 2µg/ml for IgM (AP012), IgG2 (AP007), IgG3 (AP008) and IgG4 (AP009). Plates 
were emptied and washed 6x in 0.05% Tween 20 and finally 100µL of substrate, (2.2’-
azino-di[3-ethylbenzthi-azoline sulfonate (6)]), ABTS (Roche Diagnostics, Mannheim, Ger-
many) was added and incubated in the dark for colour development. A plate reader (Anthos 
Photometer 2020, Anthos-labtec, Woerden, The Netherlands) was used to measure colour 
development at 405 nm. 
 
Statistical analysis: The data were entered and analysed using SPSS for Windows (version 
15.0. SPSS Inc., Chicago, IL, USA). Relative titres were calculated using the control sample 
which was added to each plate. For these calculations a standard curve was made. Antibody 
titre values were log-transformed to obtain normally distributed variables. A  linear regres-
sion model was used to calculate the effect change in antibody levels in zinc replete and 
deficient individuals. Linear regression analysis was also used to assess whether different 
IgG subclasses associations were influenced by conditions of zinc, magnesium, iron defi-
ciency anemia and malaria status. Cut off values were set for zinc (plasma zinc concentra-
tion <9.9 µmol/L), magnesium (plasma magnesium concentration < 750 µmol/L) and iron 
deficiency anaemia (iron deficiency, ferritin concentration <12 µg/L accompanied by anae-
mia, haemoglobin concentration <110 g/L). Average antibody titres were determined by 
comparison of means from which the standard error of the means were used to calculate 
confidence intervals and the absolute values were obtained by exponential transformation of 
previously log transformed values using Microsoft excel. The confidence intervals were 
used as these provide an estimate of the mean at a confidence range of 95%. The difference 
in antibody titres in relation to zinc status among groups was based on ‘healthy’ children 
(with neither of conditions) and effect change estimated for asymptomatic malaria (from 
malaria dipstick results); sick with malaria infection; sick with malaria infection and a his-
tory of fever in the past 14 days; and sick without malaria infection. The group differences 
were accounted for by the use of confidence intervals (95% CI and p-value < 0.05). A gen-
eralized linear model (GLM) was performed to determine whether the effect of zinc defi-
ciency on plasma IgG subclass was age-dependent. Lots were used as scaling weight vari-
ables to account for the diversity in malaria prevalence among lots. The analysis compared 
among age groups the differences in P. falciparum (schizont asexual blood stage parasites)-
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specific antibodies plasma reactivity. Three age classes were established; 0.5 – 1.5 yrs, 1.5 – 
3 yrs and 3 – 5 yrs. 
 
Results 
General effect change and plasma total IgM and IgG levels: We initially evaluated the ef-
fect change and relative antibody levels of IgM and total IgG class (tables 1 and 2). The 
relative antibody levels in the zinc replete group were moderately higher compared to the 
zinc deficient group. IgM levels were significantly increased relative to the reference group 
(healthy children) in children with asymptomatic malaria, 38% (95% CI; 16% to 65%) and 
those who were sick with malarial infection and reported fever in the past 14 days, 53% 
(95% CI 25% to 89%) in the zinc replete group. Significantly higher levels of IgM were 
detected in the zinc deficient group for asymptomatic children, sick with malaria and those 
who were sick with malaria and a report of fever in the past 14 days (table 1).  The results 
in total IgG levels followed similar trends to the levels of IgM for the zinc replete as well as 
the zinc deficient group (table 2). In both cases the increase in IgM and total IgG levels 
were statistically not significant in sick children without malaria infection. 
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Effect change in plasma levels of IgG subclasses: Evaluation of the general plasma changes 
in IgG subclasses in different malaria situations are shown in figure 1. There was a signifi-
cant change in antibody titres for all IgG subclasses (P < 0.05) in zinc replete children with 
asymptomatic malaria and those who were sick and had malaria infection. In these subjects, 
the changes in IgG3 and IgG4 levels were almost similar with IgG4 being slightly higher 
than IgG3 in children that were sick with malaria infection and those who were sick with 
malaria infection and a report of fever in previous 14 days. With zinc deficiency (figure 1), 
only the changes in IgG3 levels were significant for asymptomatic malaria, sick with ma-
laria infection and in sick children with malaria and who reported complaints of fever in the 
past 14 days (P < 0.05). On the other hand, IgG2 predominantly showed increased levels in 
sick children with malarial infection (P < 0.05). There was a marked difference with respect 
to zinc status in which only IgG3 and partly IgG2 predominated in zinc deficiency which 
may imply these IgG subclasses to remain as critical weapons to fight against malaria in 
deficiency situations. The insignificant change in IgG subclasses in sick children with no 
malaria infection strengthens the notion that the antibodies studied are specific for malaria 
antigens. 
 
Comparison of levels of plasma IgG subclasses with respect to zinc status: The levels of 
Plasmodium falciparum-specific IgG subclasses in plasma were assessed to determine 
whether there were differences within individual IgG subclasses as a result of zinc status 
(figure 2). With ‘healthy children’ children set as reference group, the levels of IgG1 were 
significantly increased in asymptomatic malaria (P = 0.007; 95% CI, 13% to 120%) and in 
children who were sick with malaria infection (P = 0.011; 95% CI, 13% to 146%). There 
was no significant increase in IgG1 in the zinc deficient group. Increase in IgG2 levels fol-
lowed a similar trend to IgG1 in zinc replete group but in the zinc deficient group, the IgG2 
levels were significantly higher in the sick children with malaria infection (P = 0.015; 95% 
CI, 10% to 141%). Levels of IgG3 were significantly increased in both zinc replete and zinc 
deficient group (P < 0.05) relative to healthy individuals, except in sick children without 
malaria (figure 2). The levels of IgG3 in the zinc deficient group sick children with malaria 
(P = 0.004; 95% CI, 30% to 289%) and those sick with malaria and a reported fever in the 
previous 14 days (P = 0.002; 95% CI, 38% to 333%) were significant and relatively higher 
than their counterparts in the zinc sufficient group. With the exception of children sick with-
out malaria, IgG4 levels were higher in zinc replete and the increase of IgG4 in the zinc 
deficient group in all cases was statistically insignificant (figure 2). 
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Table 3:  Change in IgM, IgG total and IgG subclasses due to age in zinc deficient children 
compared to reference healthy group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a = asymptomatic malaria infection 
b = sick with malaria infection 
c = sick with malaria infection and history of fever in the past 14 days 
d = sick without malaria infection 
– = reduction  
+ = increase 
∆ = insignificant change (P ≥ 0.10) 
∆-/d+ =  variable insignificant change with a change in sick without malaria increasing 
NB: Bolded values indicates borderline significant P-values 
Parameter Age Group (Years) 
 0.5 – 1.5 1.5 – 3.0 3.0 – 5.0 
IgM P < 0.001a- 
P = 0.036c- 
P = 0.019a- 
P = 0.029b- 
P < 0.001a- 
P = 0.021b- 
P = 0.002c- 
IgG total P < 0.000a- P = 0.031b- 
P = 0.05c- 
P = 0.003a- 
P = 0.027c- 
IgG1 P = 0.016a- ∆-  ∆- 
IgG2 P = 0.045b+ 
 
P = 0.049b+ 
P = 0.075
d+
 
∆-/d+ 
IgG3 P < 0.001a- 
P = 0.048c- 
P = 0.062
b-
 P = 0.002a- 
P = 0.022b- 
P = 0.004c- 
IgG4 P < 0.001a- 
P = 0.004c- 
∆-  ∆-  
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Association between IgG3 and IgG4 subclasses under different conditions of micronutrients 
and malaria status: Since the effect change and the levels of IgG subclasses showed a great 
potential for IgG3 and IgG4 to be in higher levels with respect to zinc status, we performed 
a linear regression analysis to determine whether these two immunoglobulin subclasses we 
associated under different conditions of micronutrient status (figure 3). The association be-
tween IgG3 and IgG4 were linear but the higher P-values reflected that the slopes of the 
regression lines in the four panels (figure 3) are not different. These results provide no evi-
dence that the associations between IgG3 and IgG4 are influenced by deficiencies in zinc, 
magnesium, iron deficiency anaemia or malaria status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Effect change in profile of relative plasma concentrations of malaria parasite-
specific IgG subclasses in different malaria situations with and without associated clinical 
features in zinc replete and zinc deficient children. Value on the y-axis are log transformed 
values of antibodies titres as detected in plasma. Bars with asterisk (*) indicates signifi-
cance at P < 0.05.  
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Effects of zinc deficiency on IgM, total IgG and malaria-specific IgG subclasses with age 
group: Using a generalised linear model, we assessed whether the influence of zinc defi-
ciency on the change of IgM, IgG total and IgG subclasses levels varied with age (table 3). 
Results showed zinc deficiency to significantly influence the change in antibody levels with 
variable conditions of malaria status and age groups. The reduction in levels of IgM and 
IgG3 had more impact in older children (3 – 5 yrs) as compared to other age groups. On the 
other hand, the impact of zinc deficiency on IgG1 and IgG4 was significant in the younger 
age (0.5 – 1.5yrs) with insignificant impact on the medium (1.5 – 3yrs) and the older age 
group. The interesting finding in this study is the increase in levels with zinc deficiency for 
IgG2 contrary to other IgG subclasses and that it was associated with sick children with ma-
laria and those sick without malaria in at least all age groups. This could mean that IgG2 is 
more profoundly associated with sickness than protection against malaria. The effect of zinc 
deficiency on IgG2 in sick children without malaria and on IgG3 in sick children with ma-
laria was borderline significant (table 3). 
 
Discussion 
In Plasmodium falciparum malaria protective immunity to clinical disease is mainly as-
cribed to immunoglobulin G subclasses. In human malaria, cytophilic IgG1 and IgG3 sub-
classes with high affinity to Fc receptors on monocytes, providing a crucial protection [1, 3, 
18] gradually increasing with age, to target antigen and duration of exposure [8]. Their pro-
tective potential solely rests on their ability to fix complement, and facilitating opsonization 
and phagocytosis that limits parasite multiplication in an antibody-dependent manner. The 
kinetics of the antibody isotype formation  are continually altered by reinfection [46] with 
the proportion of cytophilic IgG1 and IgG3 relative to non-cytophilic IgG2 and IgG4 con-
sidered more significant than the overall levels of antibodies in providing protection to se-
vere disease [1, 19, 20]. We hypothesized that micronutrients, zinc deficiency in particular, 
could contribute to alterations in the levels of these antibodies to influence protection 
against malaria since in African children the two entities commonly co-exist. This study 
provides the first findings in associating micronutrient deficiency with specific IgG sub-
classes that confer protection to malaria in endemic areas. 
 
Effect change and plasma total IgM and IgG levels: This study used whole asexual blood 
stage malaria antigens to reflect the real in vivo milieu and providing broader antigenic tar-
gets for optimal induction of malaria-specific antibody profiles [13]. Primary responses to 
infection were assessed by measuring plasma levels of IgM and total IgG (Tables 1 and 2) 
126  
Nutrition and antibody responses 
and the levels changed with malaria status and significant changes were associated with 
asymptomatic malaria, sick with malaria infection and sick with malaria infection together 
with a reported fever in the past 14 days especially in the zinc deficient group. The similar 
pattern of change in IgM and IgG levels support previous reports [3] of switching of IgM on 
B-cells to different isotypes and different IgG subclasses upon encounter with malaria anti-
gens. This implies that IgM primarily determines the magnitude of protection by specific 
antibodies to malaria pathogen. In addition, Dodoo et al. [47] have reported recently IgM to 
confer protection and reduce incidence of malaria in African children. The levels of total 
IgG particularly reacting to glutamate rich protein (GLURP) of the parasite antigenic sur-
face has been reported to be strongly associated with reduced malaria incidence in Africa 
[48]. The significant changes in zinc deficient group could be a reflection of persistent infec-
tion and concurrent new infection. 
 
Effect change in plasma levels of IgG subclasses: This study found significant change in all 
IgG subclasses in zinc replete group especially in asymptomatic children and those who 
were sick with malaria infection (figure 1). The change in levels for sick children with ma-
laria infection and a report of fever in the past 14 days was high only for IgG3 and IgG4. 
The predominantly significant change in IgG3 observed in this study concur with previous 
studies for the significant role of IgG3 in conferring protection to malaria [1, 8, 12, 14] and 
the trend that IgG1 and IgG2 are lower than IgG3 and IgG4, respectively in asymptomatic 
children is intriguing (figure 1). It may reflect the potential response that in asymptomatic 
malaria there is a shifting order of response dominance from IgG1 to IgG3 and IgG2 to 
IgG4 respectively to sustain protection, albeit studies need to be done to uncover this propo-
sition. The dynamics of these isotype dominance may be due to dynamics of infection in the 
area with re-infection playing a role to keep the levels high [46].  
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Figure 2: Relative plasma levels and effect change under different malaria and zinc status. 
For each immunoglobulin G subclass the panels compare the levels in zinc replete and zinc 
deficient situations at different states of malaria infections. Percentages indicate paired 
group effect change differences in the relative plasma levels of antibodies. Bolded values: 
significant at P ≤ 0.05.  
 
Higher changes in IgG4 levels in sick children with malaria and a report of fever in the pre-
vious 14 days may be explained by firstly, a long half-life of IgG4 (probably due to previous 
subclinical malaria infection) and secondly, the reports that IgG4 is more associated with 
disease than protection [49]. However, Nebie et al [48] have recently reported IgG3 and 
IgG4 to be associated with reduced risk of clinical malaria in African children. In zinc defi-
ciency, however, the higher incremental change of IgG3 in all malaria situations further 
endorses the significant role IgG3 in protecting against malaria and that probably under de-
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ficiencies, the role of this IgG subclass becomes more critical. The findings also contrasts 
previous propositions of downstream isotype switching from IgG3 to IgG1 later in the 
course of infection after displaying early comparable levels [3]. This is because in an area of 
intense malaria transmission, re-infection maintains the level of IgG3 isotype [17]. The sig-
nificant change in levels of IgG2 in sick children with malaria may be associated with dis-
ease by the explanation that probably it replaces IgG4 in such situations of micronutrients 
deficiencies. Generally, there is a clear difference in alteration of IgG subclasses plasma 
levels in the zinc deficient group which may be explained by the probable influence of zinc 
status. IgG subclasses reacts to various sets of asexual stage parasite antigenic proteins that 
may account for the variable effects of zinc deficiency on these antibodies. 
 
Comparison of levels of plasma IgG subclasses with respect to zinc status: Having assessed 
the effect change and levels of primary response by IgM and total IgG plasma levels and the 
effect change in IgG subclasses, we compared the levels of individual IgG subclasses with 
regard to zinc status (figure 2). Results showed higher levels of increase in the zinc replete 
group as compared to the zinc deficient group for at least each immunoglobulin subclass. 
This signifies the importance of these IgG subclass coexistence in conferring protection to 
malaria and that may be influenced by zinc status due to relatively lower increases in the 
deficient group. While the increase in IgG3 and IgG4 seemed to predominate in zinc replete 
group, IgG3 and partly IgG2 were predominant in the zinc deficient group. The trend of 
response for IgG1 and IgG2  and that for IgG3 and IgG4 were also similar in the zinc replete 
group but not in the zinc deficient group. Available reports [48] indicate that, in the course 
of conferring protection to malaria, the IgG subclasses target different surface parasite anti-
genic proteins with IgG3 and IgG4 responding against (glutamate rich protein (GLURP) and 
IgG1 against apical membrane protein 1 (AMA1). In addition, cytophilic IgG1 and IgG3 
have been shown to be differentially regulated over time [50] with IgG3 remaining abundant 
[45]. This could further explain the association between IgG3 and IgG4 in the zinc replete 
group that was lost in the zinc deficient group. This may support previous findings that the 
proportion of these IgG subclasses is more important than their levels in conferring protec-
tion against the disease [1, 49, 51]. This proportion seemed to be disturbed under conditions 
of zinc deficiency. The increase in IgG3 levels can also be explained by its short half-life. 
IgG3 disappears fast (serum half life of 7 days) so that high amount can not be measured in 
healthy control, but there may be many IgG3 producing B-cells which rapidly start to pro-
duce IgG3 following infection.  
 
 129 
Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Relationship between malaria specific plasma IgG3 and IgG4 under different 
situations of nutrition and malaria status. There were no significant differences between 
slopes in all four conditions being compared as indicated by P-values.  
 
Footnote: scatter spots (black): zinc and magnesium replete, absence of iron deficiency 
anaemia and absence of malaria infection; scatter spots (grey): zinc, magnesium deficiency 
and iron deficiency anaemia and malaria infection. The black and dashed lines are their 
corresponding regression lines.  
 
In the zinc deficient group the predominance of IgG3 and that of IgG2 at least in sick chil-
dren with malaria infection, reflect that probably under zinc deficiency these IgG subclasses 
are critical in providing protection against the disease. Garraud et al [52] reported the asso-
ciation between IgG2 and IgG3 in conferring protection to malaria and that certain individu-
als possess rare mutated allele encoding an FcR that can bind IgG2 along with IgG3 and 
IgG1. Other mechanisms have also been suggested [49, 53]. Another possibility is that, an 
isotype imbalance [49] occurred in zinc deficiency and thus the resulting IgG2 and IgG3 
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proportions may note be protective. These results are in contrast of previous findings by 
Groux and Gysin [54] that IgG1 and IgG3 were always predominant in serum. It may be 
that, in malaria infection as reported previously either of the cytophilic IgG subclass (IgG1 
or IgG3) should be associated with a non cytophilic (IgG2 or IgG4) for perfect protection. 
Kinyanjui et al [46] reported the half-lives of these IgG subclasses to probably be shorter 
than what is known [3] with the half-life of IgG3 being shortest of all. The prevailing high 
levels of IgG3 in both zinc replete and zinc deficient group may be attribute to continued 
exposure to low but persistent malaria infections in an endemic area [1]. Rzepczyk et al [17] 
reported skewing of IgG response towards a short-lived IgG3 in response to P. falciparum 
infection and that plasma levels could be maintained through persistent infection or new 
infection.  
 
Association between IgG3 and IgG4 subclasses under different conditions of micronutrients 
and malaria status: Assessment of whether the association between IgG3 and IgG4 are in-
fluenced by nutritional status indicated no impact of zinc deficiency, magnesium deficiency, 
iron deficiency anaemia or malaria status (figure 3). This implies that deficiency in micro-
nutrients may influence production and consequently proportions of protective antibodies to 
malaria but not their association that may be programmed inherently by the body’s immune 
system which has high fidelity. 
 
Effects of zinc deficiency: Does age make the difference?: Several reports have evaluated the 
profile of antibody response to asexual blood stages of the malaria parasite. Some have in 
principle proposed the gradual change in the naturally acquired antibody responses with age 
[1, 3, 8, 40]. This study adds more information on zinc deficiency variably influencing the 
profile of antibody protection to malaria. Zinc deficiency seemed to significantly and nega-
tively influence the profile of IgM and IgG in all age groups implying that the primary re-
sponse is generally influenced by zinc deficiency regardless of children’s age differences. 
Children of 0.5 – 1.5yrs have shown to be prone to lowered IgG1 and IgG4 production in 
zinc deficiency while the impact on IgG2 and IgG3 is significant in all age groups with 
IgG2 increasing with zinc deficiency in contrast to IgG3. As suggested by previous studies, 
IgG3 levels seem to be prevalent in all age groups implying its critical role in conferring 
protection across all young ages (within < 5yrs children). Deficiency in zinc may be more 
alarming in endemic areas due to its impact on the largely believed immunoprotective IgG3 
subclass and possibly other IgG subclasses that have been shown in this study. 
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Our findings have shown preliminarily the variable effects that zinc may have on the pro-
files of IgM, IgG total and IgG subclasses, and that this effect seems to vary with age. IgG3 
have been shown to be critically affected across all age groups as per this study classifica-
tion. Inclusion of appropriately selected micronutrients could be a way forward towards 
boosting the production of protective IgG subclasses in endemic areas. Previously we found 
a profound impact of zinc and other micronutrients on the cytokine arm of the immune re-
sponses, both in the innate and anti-inflammatory cytokine profiles. This evidence brings us 
to firmly suggest for inclusion of micronutrients in future malaria vaccine programs pending 
thorough and extensive studies on these interactions are further done to strengthen the 
proposition. Special attention should be on the isotype switching under conditions of micro-
nutrient deficiencies, malaria status and age. 
 
Acknowledgement: Financial support was received from the Netherlands Organization for 
Scientific Research, NWO/WOTRO (grant numbers W 93-413, WAO 93-441, and PRIOR) 
and UN Children's Fund (UNICEF). We gratefully acknowledge the participating children, 
parents and the assistance given by community leaders, volunteers and colleagues in Tanza-
nia and The Netherlands. Professor Robert Sauerwein is acknowledged for providing the 
parasite extract antigens for ELISA. This paper was published with support of the Executive 
Director of KCMC, Moshi and the Director-General of the National Institute for Medical 
Research, Dar es Salaam, Tanzania. 
 
References 
1. Ndungu FM, Bull PC, Ross A, Lowe BS, Kabiru E, Marsh K: Naturally acquired immunoglobulin (Ig)G 
subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection 
for IgG1 and disease for IgG2 Parasite Immunol 2002, 24(2):77-82. 
2. Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, Tanner M, Alonso PL: Age 
interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical 
presentation. PLoS Medicine 2007, 4(7):e242. 
3. Ferrante A, Rzepczyk CM: Atypical IgG subclass antibody responses to Plasmodium falciparum asexual 
stage antigens. Parasitol Today 1997, 13(4):145-148. 
4. Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD: Isotype Switching by Human B Cells Is Division-
Associated and Regulated by Cytokines. J Immunol 2002, 169(8):4298-4306. 
5. Ibs K-H, Rink L: Zinc-Altered Immune Function. J Nutr 2003, 133(5):1452S-1456S. 
6. Shankar AH, Prasad AS: Zinc and immune function: the biological basis of altered resistance to infection. Am 
J Clin Nutr 1998, 68(2):447S-463S. 
7. Tongren JE, Corran PH, Jarra W, Langhorne J, Riley EM: Epitope-Specific Regulation of Immunoglobulin 
Class Switching in Mice Immunized with Malarial Merozoite Surface Proteins. Infect Immun 2005, 73
(12):8119-8129. 
8. Tongren JE, Drakeley CJ, McDonald SLR, Reyburn HG, Manjurano A, Nkya WMM, Lemnge MM, Gowda 
132  
Nutrition and antibody responses 
CD, Todd JE, Corran PH et al: Target Antigen, Age, and Duration of Antigen Exposure Independently Regu-
late Immunoglobulin G Subclass Switching in Malaria. Infect Immun 2006, 74(1):257-264. 
9. Dodoo D, Theisen M, Kurtzhals JAL, Akanmori BD, Koram KA, Jepsen S, Nkrumah FK, Theander TG, 
Hviid L: Naturally Acquired Antibodies to the Glutamate-Rich Protein Are Associated with Protection 
against Plasmodium falciparum Malaria. J Infect Dis 2000, 181(3):1202-1205. 
10. Okech B, Mujuzi G, Ogwal A, Shirai H, Horii T, Egwang TG: High titers of IgG antibodies against Plasmo-
dium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in 
Ugandan children. Am J Trop Med Hyg 2006, 74(2):191-197. 
11. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, Holder AA, Riley EM: Fine 
Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts 
Protection from Malaria Infection and High-Density Parasitemia. Infect Immun 2004, 72(3):1557-1567. 
12. Okech BA, Nalunkuma A, Okello D, Pang XL, Suzue K, Li J, Horii T, Egwang TG: Natural human immu-
noglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda. Am J Trop Med 
Hyg 2001, 65(6):912-917. 
13. Osier FHA, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KKA, Lowe B, Mwangi T, Bull PC, Thomas 
AW et al: Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite 
Antigens Are Associated with Protection from Clinical Malaria. Infect Immun 2008, 76(5):2240-2248. 
14. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, Trape J-F, Theisen M, Balde A, Pérignon J-L, 
Druilhe P: Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies 
to merozoite surface protein 3. PLoS Med 2007, 4(11):e320..  
15. Vestergaard LS, Lusingu JP, Nielsen MA, Mmbando BP, Dodoo D, Akanmori BD, Alifrangis M, Bygbjerg 
IC, Lemnge MM, Staalsoe T et al: Differences in Human Antibody Reactivity to Plasmodium falciparum 
Variant Surface Antigens Are Dependent on Age and Malaria Transmission Intensity in Northeastern Tanza-
nia. Infect Immun 2008, 76(6):2706-2714. 
16. Gray JC, Corran PH, Mangia E, Gaunt MW, Li Q, Tetteh KKA, Polley SD, Conway DJ, Holder AA, Ba-
carese-Hamilton T et al: Profiling the Antibody Immune Response against Blood Stage Malaria Vaccine 
Candidates. Clin Chem 2007, 53(7):1244-1253. 
17. Rzepczyk CM, Hale K, Woodroffe N, Bobogare A, Csurhes P, Ishii A, Ferrante A: Humoral immune re-
sponses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced 
skewing towards antibodies of the immunoglobulin G3 subclass. Infect Immun 1997, 65(3):1098-1100. 
18. Nájera O, González C, Toledo G, López L, Cortés E, Betancourt M, Ortiz R: CD45RA and CD45RO iso-
forms in infected malnourished and infected well-nourished children. Clin Exp Immunol 2001, 126(3):461-
465. 
19. Savino W: The thymus gland is a target in malnutrition. Eur J Clin Nutr 2002, 56(Suppl 3):S46-S49. 
20. Fraker PJ, King LE: Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr 2004, 24
(1):277-298. 
21. Guerrant RL, Lima AAM, Davidson F: Micronutrients and Infection: Interactions and Implications with 
Enteric and Other Infections and Future Priorities. J Infect Dis 2000, 182(s1):S134-S138. 
22. Kirkpatrick BD, Daniels MM, Jean SS, Pape JW, Karp C, Littenberg B, Fitzgerald DW, Lederman HM, Na-
taro JP, Sears CL: Cryptosporidiosis Stimulates an Inflammatory Intestinal Response in Malnourished Haitian 
Children. J Infect Dis 2002, 186(1):94-101. 
23. Rivera MT, De Souza AP, Araujo-Jorge TC, De Castro SL, Vanderpas J: Trace elements, innate immune 
response and parasites. Clin Chem Lab Med 2003, 41(8):1020-1025. 
24. Cunningham-Rundles S, McNeeley DF, Moon A: Mechanisms of nutrient modulation of the immune re-
 133 
Chapter 5 
sponse. J Allergy Clin Immunol 2005, 115:1119-1128. 
25. Keen CL, Gershwin ME: Zinc deficiency and immune function. Annu Rev Nutr 1990, 10:415-431. 
26. Prasad AS: Effects of Zinc Deficiency on Th1 and Th2 Cytokine Shifts. J Infect Dis 2000, 182(S1):S62-S68. 
27. Prasad AS: Zinc deficiency. BMJ 2003, 326(7386):409-410. 
28. Prasad AS: Zinc: Mechanisms of Host Defense. J Nutr 2007, 137(5):1345-1349. 
29. Prasad AS: Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol 2008, 43
(5):370-377. 
30. Prasad AS: Zinc in human health: effect of zinc on immune cells. Mol Med 2008, 14(5-6):353-357. 
31. Prasad AS, Beck FWJ, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, Cardozo LJ: Zinc supplementation 
decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. 
Am J Clin Nutr 2007, 85(3):837-844. 
32. Shankar AH, Genton B, Baisor M, Paino J, Tamja S, Adiguma T, Wu L, Rare L, Bannon D, Tielsch JM et al: 
The influence of zinc supplementation on morbidity due to Plasmodium falciparum: a randomized trial in 
preschool children in Papua New Guinea. Am J Trop Med Hyg 2000, 62(6):663-669. 
33. Shankar AH, Genton B, Semba RD, Baisor M, Paino J, Tamja S, Adiguma T, Wu L, Rare L, Tielsch JM et al: 
Effect of vitamin A supplementation on morbidity due to Plasmodium falciparum in young children in Papua 
New Guinea: a randomised trial. Lancet 1999, 354(9174):203 - 209. 
34. Wintergerst ES, Maggini S, Hornig DH: Immune-Enhancing Role of Vitamin C and Zinc and Effect on Clini-
cal Conditions. Ann Nutr Metab 2006, 50(2):85-94. 
35. Wintergerst ES, Maggini S, Hornig DH: Contribution of selected vitamins and trace elements to immune 
function. Ann Nutr Metab 2007, 51(4 ):301-323. 
36. Bates C, Evans PH, Dardenne M, Prentice A, Lunn PG, Northrop-Clewes CA, Hoare S, Cole TJ, Horan SJ, 
Longman SC: A trial of zinc supplementation in young rural Gambian children. Br J Nutr 1993, 69:243-255. 
37. Muller O, Becher H, van Zweeden AB, Ye Y, Diallo DA, Konate AT, Gbangou A, Kouyate B, Garenne M: 
Effect of zinc supplementation on malaria and other causes of morbidity in west African children: randomised 
double blind placebo controlled trial. BMJ 2001, 322(7302):1567. 
38. Shankar AH: Malaria and Nutrition. In: Nutrition and Health in Developing Countries. 2008: 229-274. 
39. Corran PH, O'Donnell RA, Todd J, Uthaipibull C, Holder AA, Crabb BS, Riley EM: The Fine Specificity, but 
Not the Invasion Inhibitory Activity, of 19-Kilodalton Merozoite Surface Protein 1-Specific Antibodies Is 
Associated with Resistance to Malarial Parasitemia in a Cross-Sectional Survey in The Gambia. Infect Immun 
2004, 72(10):6185-6189. 
40. Kinyanjui SM, Bull P, Newbold CI, Marsh K: Kinetics of antibody responses to Plasmodium falciparum-
infected erythrocyte variant surface antigens. J Infect Dis 2003, 187(4):667-674. 
41. Torres K, Clark E, Hernandez J, Soto-Cornejo K, Gamboa D, Branch O: Antibody response dynamics to the 
Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD 
(MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission. Malar J 2008, 7(1):173. 
42. Veenemans J, Andang’o PEA, Mbugi EV, Kraaijenhagen RJ, Mwaniki DL, Mockenhaupt FP, Roewer S, 
Olomi RM, Shao JF, van der Meer JWM et al: α+-Thalassemia protects against anemia associated with as-
ymptomatic malaria: evidence from community-based surveys in Tanzania and Kenya. J Infect Dis 2008, 198
(3):401-408. 
43. Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, Mwangi TW, Marsh K: High 
levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with re-
duced risk of clinical malaria in coastal Kenya. Vaccine 2006, 24(19):4233-4246. 
44. Polley SD, Mwangi T, Kocken CHM, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, 
134  
Nutrition and antibody responses 
Mwambingu G et al: Human antibodies to recombinant protein constructs of Plasmodium falciparum apical 
membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004, 23(5):718-
728. 
45. Osier FHA, Polley SD, Mwangi T, Lowe B, Conway DJ, Marsh K: Naturally acquired antibodies to polymor-
phic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. Parasite Immunol 2007, 
29(8):387-394. 
46. Kinyanjui S, Conway D, Lanar D, Marsh K: IgG antibody responses to Plasmodium falciparum merozoite 
antigens in Kenyan children have a short half-life. Malaria Journal 2007, 6(1):82. 
47. Dodoo D, Aikins A, Kusi K, Lamptey H, Remarque E, Milligan P, Bosomprah S, Chilengi R, Osei YD, 
Akanmori B et al: Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP 
with protection from clinical malaria in Ghanaian children. Malar J 2008, 7(1):142. 
48. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konate AT, Chilengi R, Theisen M, 
Dodoo D et al: Humoral Responses to Plasmodium falciparum Blood-Stage Antigens and Association with 
Incidence of Clinical Malaria in Children Living in an Area of Seasonal Malaria Transmission in Burkina 
Faso, West Africa. Infect Immun 2008, 76(2):759-766. 
49. Bouharoun-Tayoun H, Druilhe P: Plasmodium falciparum malaria: evidence for an isotype imbalance which 
may be responsible for delayed acquisition of protective immunity. Infect Immun 1992, 60(4):1473-1481. 
50. Diallo TO, Spiegel A, Diouf A, Lochouarn L, Kaslow DC, Tall A, Perraut R, Garraud O: Differential evolu-
tion of immunoglobulin G1/G3 antibody responses to Plasmodium falciparum MSP1(19) over time in ma-
laria-immune adult Senegalese patients. Am J Trop Med Hyg 2002, 66(2):137-139. 
51. Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Toure Balde A, Diatta B, Seignot P, Roussilhon C: Prog-
nostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble recep-
tors in West African patients with severe malaria. Infect Immun 1997, 65(8):3271-3276. 
52. Garraud O, Mahanty S, Perraut R: Malaria-specific antibody subclasses in immune individuals: a key source 
of information for vaccine design. Trends Immunol 2003, 24:30-35. 
53. Vafa M, Israelsson E, Maiga B, Dolo A, Doumbo OK, Troye-Blomberg M: Relationship between immu-
noglobulin isotype response to Plasmodium falciparum blood stage antigens and parasitological indexes as 
well as splenomegaly in sympatric ethnic groups living in Mali. Acta Tropica 2009, 109(1):12-16. 
54. Groux H, Gysin J: Opsonization as an effector mechanism in human protection against asexual blood stages 
of Plasmodium falciparum: Functional role of IgG subclasses. Res Immunol 1990, 141(5):529-542. 
 
 
 
 
 
 
 
 
 CHAPTER  
              6 
CD36 deficiency protects against malarial anaemia in children by 
reducing Plasmodium falciparum-infected red blood cells adher-
ence to vascular endothelium 
135 
Jaffu Chilongola, Sakurani Balthazary, Maximillian Mpina, Mar-
tin Mhando, and Erasto Mbugi 
Trop Med Int Health, 2009; 14(7):9810-9816  
136  
CD36 deficiency protects against malaria anaemia 
Abstract 
CD36 is a receptor that occurs on the surface of activated immune cells, vascular endothelial 
cells and participates in phagocytosis and lipid metabolism. This receptor is known to be the 
major endothelial receptor molecule for field isolates of Plasmodium falciparum. A T1264G 
mutation in exon X of the gene leads to deficiency of CD36. This study aimed at determin-
ing associations between CD36 deficiency, P. falciparum in vitro adherence on purified 
CD36 and anaemia among children in an endemic area. Genotypes were determined by 
nested polymerase chain reaction of isolated DNA from filter blood spots followed by Re-
striction Fragment Length Polymorphism (RFLP). Plasmodium falciparum adherence as-
says were performed on immobilized purified CD36. The data indicate that CD36 is an im-
portant cytoadherence receptor that mediates adherence to most P. falciparum field isolates. 
Our findings also suggest that mutations causing CD36 deficiency may confer significant 
protection against malarial anaemia (MA) in children (χ2 = 8.58, P < 0.01). The protective 
role that CD36 deficiency may confer against MA in children seems to be mediated through 
reduced cytoadherence of infected red blood cells to vascular endothelium.  
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Introduction 
A unique characteristic feature of infections with Plasmodium falciparum is the ability of 
infected red blood cells (IRBCs) to adhere to vascular endothelium by cytoadherence. The 
result of cytoadherence is accumulation of IRBCs in the deep microvasculature. This phe-
nomenon is called 'sequestration' and is associated with disease outcomes [1-3]. In some 
instances, parasite populations with a predisposition to adhere to certain receptors are more 
commonly associated with certain disease outcomes, such as cerebral malaria and placental 
malaria [4-6], although the precise role of parasite–receptor interactions in determining dis-
ease severity remains to be understood. Sequestration plays a major role in the development 
of severe disease and occurs as a result of both cytoadherence of IRBCs to capillary endo-
thelium [3, 7, 8] and the binding of IRBCs to uninfected erythrocytes (rosetting) [9, 10]. 
Adherence is mediated via knob-like structures at the surface of IRBCs [11] resulting from 
the deposition and aggregation of parasite proteins and their interaction with the host cell 
cytoskeleton underneath the RBC membrane [12, 13]. Studies have suggested that P. falci-
parum erythrocyte membrane protein 1 (PfEMP-1) expresses variant-specific epitopes and 
mediates adhesion to endothelium. CD36 is among the host ligands that have been found to 
mediate endothelial binding of IRBCs and has been identified in most field isolates [8, 14-
21]. 
 
CD36 is one of the most characterized host receptors for P. falciparum IRBCs. CD36 is an 
88-kDa glycoprotein expressed on endothelial cells, platelets, macrophages and dendritic 
cells, and participates in phagocytosis and lipid metabolism. However, it is not expressed on 
endothelial cells of brain capillaries. The gene encoding CD36 consists of 15 exons, and 
extends at least 32 kb on the q11.2 band of chromosome 7 in humans. As most P. falcipa-
rum field isolates bind CD36, CD36 is considered the major endothelial receptor for seques-
tration, although not all parasites bind this receptor [22, 23]. CD36 exons X–XII occur in 
numerous polymorphic forms in the Gambia and in Kenya and several of these forms are 
associated with susceptibility to cerebral malaria. A subsequently described polymorphism 
of exon X confers protection against severe anaemia in heterozygotes in Kenya by mecha-
nisms not clearly defined [24].   
 
The mechanism by which CD36 confers protection against malarial anaemia (MA) in chil-
dren is not clearly understood. This study was designed to determine role of cytoadherence 
in the protection of CD36 deficiency against MA in children below 5 years of age. In par-
ticular, we assessed the role played by CD36 deficiency in the development of MA in chil-
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dren. The study specifically explored the frequency of CD36 deficiency among children in 
malaria endemic areas and associations between CD36 deficiency and status of MA in chil-
dren and the role played by cytoadherence on the development of MA in children. 
 
Materials and methods 
Participants, recruitment and consent: Mothers were recruited among women presenting at 
Muheza Designated District Hospital for antenatal care in the third trimester or for delivery 
hospitalization. Mothers of prospective study children initially learned about the study 
through community meetings. Mothers who qualified for inclusion were requested to read 
and sign a consent form on behalf of their newborns. Verbal consent was given by those 
unable to read and write, followed by thumb stamp. Children whose mothers consented for 
participation, and whose mothers were willing to bring them fortnightly and when they are 
sick for sample collection were included in the study. Unwillingness to sign the informed 
consent form and to give samples when required were exclusion criteria for this study. In 
total, 155 children were recruited. Of these, 149 completed the follow up, and provided 204 
samples used for data analysis. Six children were dropped at different time points due to 
various exclusion criteria. 
 
Definition of categories: A malaria case was defined as a child testing positive for P. falci-
parum parasites with a fever (body temperature) of >38.5 °C and any of the typical malaria 
symptoms. MA was defined as a haemoglo+bin (Hb) concentration of ≤10 g/dl, in the pres-
ence of positive thin and/or thick blood smears at any parasitemia level. Non-anaemia (NA) 
was defined as an Hb concentration of >10 g/dl, in the presence of malaria parasites at any 
parasitemia level. Hb concentration was determined using a Cell-Dyn 1200® Haematology 
Analyser (Spectron Corporation, Burlington, WA, USA). In this study, an IRBC was con-
sidered to be a binder to CD36 if the number of IRBCs binding to CD36 was at least twice 
as much as the number of IRBCs binding to the control molecule, bovine serum albumin 
(BSA), observed under light microscope at 10 × magnification in 20 fields of the binding 
plate. This study was approved by both the Tanzanian and the Seattle Biomedical Research 
Institute (Seattle, WA, USA) Ethics Review Boards. 
 
Sample collection: We genotyped 155 children for the CD36 gene at the start of the follow-
up. The children were then followed for a period of 12 months from November 2003, for 
occurrence of malaria-associated anaemia. Only malaria positive blood samples were used 
in this study. Each collected sample was treated as a separate sample representing a different 
infection. Samples were collected as passive cases when a child presented with malaria. 
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Every time a sample was collected, Hb concentration was measured, and IRBCs cultured for 
binding assays. Approximately 1 ml of blood was collected by venipuncture into 10 ml 
vacutainers (Fisher Inc, USA) containing citrate phosphate dextrose (CPD) as anticoagulant, 
at a ratio of 1:10, CPD: blood. A blood drop from whole blood was placed on Whatman® 
filter paper strips (Whatman, USA) and stored at room temperature for genotyping. 
 
Parasites quantification and in vitro culture: Small volumes (5 µl) of blood were used to 
prepare a thick and thin smear for detection of malaria parasites. Slides were stained with 
Giemsa stain at pH 7.2. The number of IRBCs with asexual parasites was counted against 
2000 total red blood cells (both infected and non-infected) to obtain the percentage of IRBC. 
The infected blood was then diluted using a mixture of blood group O+ cells and AB sera 
from malaria non-immune volunteers to 3–5% IRBCs, and cultured in a complete media 
with RPMI 1640 (Gibco), 10% human sera, Pen-strep (Gibco) and Gentamycin (Gibco) for 
24 h at 37 °C, 5% CO2, humidified incubator, to allow them to develop into the mature form 
before subjected to binding assays to determine their CD36 binding phenotypes. 
 
Determination of parasite binding phenotype: Parasites (IRBCs) were allowed to develop 
into the mature form by in vitro culture before being subjected to binding assays to deter-
mine their CD36 binding phenotypes. Purified CD36 (20 µl) and BSA at a concentration of 
1 µg/ml (Sigma Chemicals Co. St Louis, USA) were placed onto a Petri dish and incubated 
overnight at 4 °C. Petri dishes were then blocked with 2% BSA for 30 min at 37 °C and 
washed three times with 1 × PBS (Dulbeco). The dishes were incubated with 5% Hematocrit 
of washed parasites for 30 min at 37 °C followed by a triple wash with PBS. Parasites on 
Petri dishes were fixed using 1% (w/v) Formaldehyde solution at room temperature for 
1 min, and then stained with 1% Giemsa stain for 1 min. The number of parasites binding 
onto each molecule in relation to those binding to BSA was determined by observing under 
light microscope at 10 × magnification in 20 fields of the binding plate. 
 
DNA extraction and PCR amplification of CD36: DNA extraction was performed using the 
Gentra DNA extraction protocol (Gentra Systems Inc, Minneapolis, USA) according to the 
manufacturer's instructions. DNA was used as 10% of the PCR reaction mix. Nested PCR 
was used throughout this experiment. The reactions were performed in 50 µl reaction tubes 
on a PTC-100 Programmable Thermal Controller (MJ Research Inc., USA). The primer 
sequences for the first PCR reaction were F: 5' ATG CTT GGC TAT TGA GT and R: 5' 
TAT CAC AAA TTA TGG TAT GGA CTG and those for the nested PCR were F: 5' CTA 
TGC TGT ATT TGA ATC CGA and R: 5' ATG GAC TGT GCT ACT GAG GTT ATT 
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CGT T. The nested primers were designed using DNAstar® software (Lasergene, Madison, 
USA). Distilled water was included in the control reactions instead of the isolated DNA. For 
both PCR reactions, the following PCR cycle was used: a initial denaturation step of 94 °C 
for 4 min followed by 45 cycles of 94 °C denaturation for 1 min, annealing at 55 °C for 30 s 
and elongation at 68 °C for 8 min. The first PCR reactions amplified fragments of 415 bp 
whereas the nested PCR reaction amplified fragments of 212 bp. 
 
Genotyping by RFLP and agarose gel electrophoresis: The nested PCR product (20 µl) 
from each sample were placed into a 50-µl microtubes followed by 1 µl of restriction en-
zyme NdeI (BioLabs Inc, New England, USA). The mixture was incubated for 4 h at 37 °C 
and then was heated at 65 °C for 1 min to stop enzyme activity. The CD36 gene has a wild-
type NdeI restriction site, 5'-CA/TATG. This single nucleotide mutation eliminates the in-
herent restriction site. Thus, NdeI digestion of the wild-type CD36 allele gave two frag-
ments, 148 bp and 64 bp, whereas the homozygous mutant was not cut and thus was a single 
fragment of 212 bp. The heterozygous allele gave a mixture of the three fragments from the 
wild-type and the mutant allele, i.e. 212, 148 and 64 bp fragments. Restriction digestion 
products, PCR products and molecular weight markers were subjected to agarose gel elec-
trophoresis in a 3.5% (w/v) agarose gel (Sigma Chemicals Co) containing 5 µl of 10 mg/ml 
ethidium bromide (Sigma Chemicals Co). PCR products, restriction digests and molecular 
weight markers were loaded onto the wells as 1 µl of 6 × loading dye (0.2% bromophenol 
blue, 0.2% xylene cyanol, 60% glycerol and 60 mm EDTA) in 10 µl of sample, and run in 
1 × TE buffer at constant voltage of 120 V for 25–30 min. The DNA marker FX174/HinfI 
(BioLabs Inc) with fragment size range from 24 to 726 bp was used to determine the various 
band sizes for the samples. 
 
Statistical analyses: For categorical (nominal) data, chi-square correlation tests were used to 
compare expected and observed frequencies for (genotypes, binding patterns and MA) pa-
rameters using SPSS version 14.0.1 (SPSS Inc., USA) computer software. Unpaired t-test 
comparisons of means were used to compare mean Hb readings among different genotypes. 
 
Results 
Frequencies of CD36 alleles and CD36 binders: Results for CD36 genotyping and IRBC 
binding profiles are presented in Fig 1 and Table. The gel presented in Fig 1 shows an aga-
rose gel for the PCR-RFLP of genotyped CD36 gene for the CD36 T1264G mutation. Table 
1 summarizes the frequencies of different CD36 genotypes among children. Results show 
that out of the 204 genotyped children, 176 (86.3%) children had the wild-type allele, 22 
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(10.8%) children were heterozygous for the studied mutation and 6 (2.9%) children were 
homozygous for the CD36 mutation studied. 
 
 
 
 
 
 
 
 
 
Figure 1: Agarose gel showing restriction fragments for CD36 alleles. Lanes 1, 20, 21 and 
38: molecular marker with the following band size (bp) (top–bottom): 726, 713, 553, 500, 
(427, 417, 413 together), 311, 249 200, 151, 140, 118, 100, 82, 66, (48, 42, 40 together), 
and 24 bp. Lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, 22, 24, 26, 28, 30, 32 and 34: undigested 
nested PCR product. Lanes 3, 5, 9, 11, 13, 15, 17 19, 23, 25, 27, 29: wild-type CD36 allele 
with two bands of 148 and 64 bp. Lanes 7 and 31: heterozygous for CD36 allele with three 
bands of 212, 148 and 64 bp. Lane 35: homozygous mutant with one band of 212 bp. Lanes 
36 and 37: control samples (distilled water) digested and undigested, respectively.  
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Figure 2: Overall results for CD36- IRBC binding phenotypes. IRBC samples were either 
binders or non-binders if the number of CD36 binding IRBC were twice as much (or more) 
as the number of IRBC binding to BSA, tested on the same plate. 
 
 
 
 
 
 
 
 
Figure 3: Binding phenotypes of IRBCs isolated from different CD36 genotypes to CD36. 
The y-axis shows the number of anaemic cases from both binders and non-binder IRBCs to 
CD36. The binding phenotype was found to be statistically associated with occurrence of 
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MA among children using the Fisher's exact test (P < 0.01). MA, malarial anaemia, NA, 
non-anaemia.  
 
 
 
 
 
 
 
 
Figure 4: Mean haemoglobin (Hb) levels among different genotypes of CD36. Bars repre-
sent the mean (mean ± SE) Hb level (g/dl) for each CD36 genotype. All means were statisti-
cally different from one another (P < 0.01). 
 
Table 1:  Frequencies of CD36 genotypes and binders in each category  
 
 
 
 
 
Data presented in column A: Numbers indicate the number of children that fall in each 
genotype (Wild-type, Heterozygous and Homozygous mutant). Numbers in parentheses show 
the percentage of respective genotypes out of 204 typed children. Column B: Data in col-
umn B show the number of IRBC samples binding to CD36. Numbers in parentheses indi-
cate the respective percentage of binder IRBC samples in each genotype. 
 
  Frequency 
 A B 
 Genotype Genotype frequency (%) 
Wild-type 176 (86.3) 124 (70.5) 
Heterozygous 22 (10.8) 20 (10.8) 
Homozygous 6 (2.9) 0 (0.0) 
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Discussion and conclusions 
The absence of data that intimately defines, at the molecular level, the host–parasite inter-
face during infection with malaria parasites leaves a major gap in our understanding of the 
critical phenomena that lead to severe malaria, particularly in children. The only available 
information provides statistical associations between polymorphisms that occur in genes 
encoding host proteins used by malaria parasites as ligands of cytoadherence and severe 
malaria. Consistent with previous observations in Kenya and The Gambia [22], results from 
this study show CD36 to be the major ligand for cytoadherence of field isolates of P. falci-
parum. In line with previous findings elsewhere [25-29], we have shown in our study that 
the prevalence of CD36 deficiency in Muheza, Tanzania is (2.9%). 
 
A small proportion of IRBCs from CD36 deficient children bound to the purified CD36 
protein. Binding to CD36 has been shown to be highest when IRBC used were from chil-
dren with the wild-type CD36 allele. This association between CD36 genotypes and parasite 
adherence to CD36 in our study was found to be statistically significant. The association 
between IRBC binding phenotype and occurrence of MA provides a direct explanation that 
failure of adherence of IRBC to vascular endothelial cells may be responsible for reduced 
occurrence of MA. The findings in this study suggest that protection against MA in CD36 
deficient children is most likely to be a result of changes (absence/reduction) in IRBC ad-
herence to vascular endothelial CD36 receptors. 
 
As CD36 deficient children do not express the CD36 receptor, it is likely that CD36 defi-
ciency alters the ability of IRBCs to bind to CD36. A reduction/absence of in vivo IRBC 
adherence to CD36 may result into a reduction in the number of sequestered, agglutinating 
and rosetting IRBC and non-infected RBC, which would result to resistance to reduction of 
number of circulating erythrocytes due to parasite-induced hemolysis. This phenomenon is 
reflected as normal Hb level, and thus absence of anaemia. This is the first study that has 
linked polymorphisms in the CD36 gene, genotype-specific, IRBC CD36 binding profiles 
and MA. 
 
Apart from acting as a receptor for P. falciparum-infected IRBC, CD36 serves as an impor-
tant molecule in modulating host immunity. CD36 is expressed on endothelial cells, plate-
lets, macrophages and dendritic cells and participates in phagocytosis and lipid metabolism 
[30-36] all of which are crucial processes of life. This may partly explain the mechanisms 
by which a polymorphism that protects against a severe malarial syndrome (MA) is kept at a 
relatively low and stable frequency in the study population and elsewhere. The results of 
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this study focus on the contribution of CD36 polymorphisms to the development of MA in 
children. The deficiency of CD36 on immune cells is most likely to interfere with immune 
processes, including phagocytosis of ageing RBCs, which may have significant implications 
in terms of Hb levels, aberrant lipid metabolism, predisposition to atherosclerosis insulin 
intolerance and many other fatal conditions [33, 37, 38]. 
 
A delicate equilibrium is therefore likely to exist between the protective role of CD36 defi-
ciency and reduced CD36 adherence against MA and its predisposition to other equally fatal 
diseases. This observation calls for future studies to better explain how CD36 deficiency 
may influence host immunity, and ways in which such deficiency modulates the clinical 
outcomes of fatal syndromes. 
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General discussion 
 
Interpretation of the results  
Chloroquine has been a useful antimalarial drug for decades, but parasite resistance to this 
drug has led to policy changes in most malaria-endemic countries. Tanzania, for example, 
changed its policy from chloroquine to an antifolate drug combination, sulphadoxine-
pyrimethamine (SP) for first-line treatment of uncomplicated malaria in August 2001. In 
addition, SP is used to control malaria in pregnancy: as part of antenatal care, pregnant 
women are provided with repeated curative doses of SP. Surveillance for antifolate-resistant 
parasites in the field was important to keep tracking the spread and intensity of drug resis-
tance. Monitoring drug resistance through regular exploration of gene mutations pertaining 
to drug resistance bears critical importance. Results from surveillance of SP resistance para-
site genetic markers have led to a policy change in Tanzania in late 2006 from SP as an in-
terim first-line drug to artemether-lumefantrine (Coartem). Both effective drugs and natu-
rally acquired immunity play important roles in controlling malaria. Such immunity is ac-
quired in endemic areas through continued or repeated exposure to malaria infection.  
 
In the immune defence against infection with Plasmodium falciparum, many innate factors 
were found to be involved. Genetic polymorphisms in the innate immune response of the 
host during falciparum malaria results in a partial protection against the development of 
severe disease. Thalassaemia trait, sickle cell anaemia, glucose-6-phosphate dehydrogenase 
(G6PD) deficiency may partially protect against disease. The acquired resistance, on the 
other hand, is slow to develop and the underlying immune mechanisms involved are still 
only partially understood. It is believed that acquired immunity requires repeated exposure 
to malaria infection, possibly with different variants of the parasite. In areas of stable trans-
mission, neonates are protected for the first 6 months of age by maternal antibodies, fol-
lowed by a periods of increased susceptibility during which immunity is only slowly ac-
quired. Depending on the level of transmission anti-parasite immunity appears around 10 
years of age. Adults tend to get less severe disease and parasite densities are usually lower 
than in children..  
 
A combined efficient innate and adaptive immune response is essential for limiting Plasmo-
dium falciparum multiplication in its host’s blood or at least to prevent the progression of 
infection to (severe) disease. The importance of protective immunity is evident from the fact 
that many people in endemic areas are infected yet symptom-free. This protective immunity 
can possibly be influenced by micronutrient deficiencies. Zinc plays a critical role in multi-
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ple enzyme systems that are involved in gene expression, cell division and growth, and im-
munological functions. Zinc determination in plasma is difficult to link to the zinc status in 
the individual. Supplementation with zinc and observing the response is the most reliable 
method to diagnose zinc deficiency. Based on available evidence and the guidelines for a 
survey design, zinc deficiency and low zinc status were defined as plasma zinc concentra-
tions <9.9 µmol/L and <10.7 µmol/L, respectively. Zinc deficiency has been found to result 
in an increased risk and severity of a variety of diarrhoeal diseases, acute respiratory infec-
tions and possibly malaria. We therefore hypothesized that supplementation with zinc and 
other micronutrients would boost the capacity of the immune system to brandish a protec-
tive response to falciparum malaria. To study this hypothesis, we adopted technical and con-
ceptual advances to analyse the immune capacity in vitro without the need to wait for actual 
challenging the individuals with infectious organisms. This enabled us to assess various 
immunological parameters reflecting the capacity of monocytes to mount innate immune 
response, induction of T-cell subpopulations and alterations in cytokine-mediated immune 
regulation, and alterations in malaria-specific antibodies and their isotypes in the serum. 
 
The studies described in thesis were conducted in Tanzanian preschool children, with the 
following aims: 
1. To assess the prevalence of resistance-associated mutations on dhfr (dihydrofolate 
reductace) and dhps (dihydropteroate synthase) genes of the infectious pathogen, P. 
falciparum, and their relation to the risk of drug resistance to SP. 
2. To assess the effect of nutrient deficiencies on cytokine responses of innate immu-
nity to Plasmodium falciparum. 
3. To assess the effect of nutrient deficiencies on adaptive immune responses to Plas-
modium falciparum, measured as T-cell responses to in vitro stimulation with cul-
tured Plasmodium falciparum-infected red blood cell preparations. 
4. To assess associations between markers of micronutrient status and plasma levels of 
malaria-specific immunoglobulins. 
5. To assess associations between the endothelial receptor molecule CD36 deficiency, 
Plasmodium falciperum adherence in vitro on purified CD36 molecules and anaemia 
status among children in a malaria endemic region. 
 
Mutations in the dhfr and dhps genes alter the conformational structure of some crucial en-
zymes that are involved in the synthesis of parasite DNA. SP is a drug combination that was 
designed to produce an intracellular state of folic acid deficiency so that folate-dependant 
enzymes involved in DNA synthesis and cell division are inhibited, thereby killing the para-
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site. Mutations in those genes can induce parasite resistance to SP. The field work for our 
study (January-August 2002) was conducted shortly before the formal introduction of SP as 
the first-line treatment for uncomplicated malaria (August 2002). Even so, we found that 
11% of treatments resulted in failure within 14 days of follow-up (Chapter 2). These find-
ings and subsequent reports [1-4] provide support for the decision by late 2006 of Tanzanian 
policy makers to change from SP to artemether-lumefantrine (Coartem) as the first-line anti-
malarial drug. The problem of drug resistance by the malaria parasite has been compounded 
by similar problems of resistance by the mosquito vector to insecticides used for bednet 
impregnation. Thus improving nutrition to boost immunity against malaria remains to be a 
promising control strategy in endemic areas. 
 
The findings presented in Chapter 3 show variable effects of micronutrient deficiencies on 
innate cytokine responses. Previous studies have shown the immunoregulatory potential of 
zinc [5-12]. Our results concur with previous reports that zinc deficiency is associated with 
increased production of malaria-extract induced and monocyte-derived inflammatory cyto-
kines (TNF-α and IL-1β) that can be restored through zinc supplementation [8, 11, 12]. Our 
results contradict reports, however, that deficiency in zinc resulted in a reduced production 
of TNF-α. It can be derived from these contradictory findings that zinc deficiency might be 
causing an imbalance in cytokine production [13]. This is critical in malaria because in-
creased inflammatory cytokine levels are widely associated with pathological consequences 
of the disease. The association between magnesium and innate cytokine regulation, particu-
larly in malaria, had not been studied before. In our study, we found a relative increase in 
IL-10 concentration in magnesium deficiency as compared to zinc deficiency. 
 
In Chapter 4, effects of micronutrients deficiencies are assessed on T-cell responses that, 
based on their associated cytokine profile, are indicated by type I and type II. The results 
concur with previous reports that zinc deficiency is typically associated with the production 
of signature type I cytokines, like IFN-γ, that results in a cell-mediated immune response [8, 
15]. By contrast, magnesium deficiency appeared more associated with signature type II 
cytokines, notably IL-13. IL-13 production coincides with the generation of a humoral im-
mune response [15], and is particularly associated with isotype switching from IgG to IgE 
[16-18]. This may be critical because IgE contributes to protection against malaria, but also 
to disease severity [17, 19]. Collectively, our findings indicate that deficiencies in zinc and 
magnesium may lead to an imbalance between type I and type II responses, which may be 
associated with poor protection or even pathology. Iron deficiency anaemia was found to be 
associated with variable changes in concentrations of both type I and type II cytokines, par-
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ticularly in children with malaria infection. 
 
The associations between zinc deficiency and plasma antibody responses to malaria are re-
ported in Chapter 5. Specifically, the study determined the plasma concentrations of IgM, 
total IgG, and malaria-specific IgG subclasses to provide the profile of a specific antibody 
response to malaria antigens. The malaria-specific IgG3 concentration was predominantly 
high in both zinc deficiency and zinc replete groups although the levels were relatively 
higher in zinc deficient than in zinc replete individuals. The malaria status, both in asympto-
matic and symptomatic children, was always associated with increased IgG3 concentrations, 
and the change was always associated with an age dominating in ‘older’ (3–5 yrs) as com-
pared to younger age (< 3 yrs of age). The dominance in IgG3 responses is in agreement 
with previous reports that this IgG subclass is the main antibody class conferring protection 
against malaria parasites [20-25]. We report that the association of at least one cytophilic 
with one non-cytophilic IgG subclass may be crucial in conferring protection at least in zinc 
deficiency and this association is also influenced by age. This is because at younger age the 
IgG1 and IgG4 classes were dominant and IgG2 and IgG3 were more prevalent in older 
children providing the probability of the latter to be protective [26, 27] in relatively older 
children. These suggestions needs further studies but largely reflect an imbalance in anti-
body responses due to zinc deficiency following a similar effect as previously observed in 
T-cell cytokine responses. This is not surprising as the isotype switching potential of the 
malaria-specific B-cells is largely dependent on exposure to helper T-cell derived cytokines. 
Our study specifically underscores the notion that the variation in profiles of IgG subclasses 
are the combined result of zinc deficiency, malaria status and an age < 5 yrs. These findings 
support the idea that zinc (and other micronutrients) may influence the malaria-specific im-
mune response at all steps ranging from the induction of the response to the generation of 
effector mechanisms by cells and antibodies [8, 28]. 
 
Our findings from chapters 3-5 can be presented in a model showing possible impacts of 
nutrient deficiencies on a range of immune responses to malaria parasites (figure 1). 
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Figure 1: Different points in the network of the proposed immune response to malaria para-
sites where possible effects of zinc deficiency are noticed; 1: impaired activation, phagocy-
tosis; 2: impaired killing activity; 3: decreased production of IL-2 and IL-2 receptors; 4: 
impaired MHC class II expression; 5: impaired T-cell differentiation; 6: impaired produc-
tion of anti-inflammatory cytokines by Tr cells (modified from: Stevenson & Riley [14]). 
 
Previous reports have proposed a stepwise fashion in P. falciparum-parasitized erythrocytes 
cytoadherence within the microvasculature, reflecting a synergistic activity between recep-
tors. According to Ho and White [29], parasite ligands expressed on the surface of infected 
erythrocytes interact with endothelial receptor CD36, and in synergy with intercellular adhe-
sion molecules-1 (ICAM-1), P-selectin and vascular adhesion molecule-1. Consequently, 
cytoadherence may activate intracellular signalling pathways of mediators, particularly cyto-
kines, which can influence the outcome of infection. CD36 participates in phagocytosis and 
lipid metabolism and is known to be the major endothelial receptor molecule for field iso-
lates of Plasmodium falciparum. A T1264G mutation in exon X of the gene leads to defi-
ciency of CD36. Chapter 6 explored the association between this CD36 deficiency, P. falci-
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parum in vitro adherence with purified CD36, and anaemia in children. The findings indi-
cate the protective role of CD36 deficiency against the development of malarial anaemia in 
children, which may be mediated through reduced cytoadherence of infected red blood cells 
to vascular endothelium. These findings necessitate a more focused study on the nature of 
the protective mechanisms that could be exploited and combined with malaria interventions 
to limit severe forms of malaria. 
 
From the results of this thesis, we have generated a model that represents the effects of zinc 
and magnesium deficiencies on the generation of the immune response in the course of ma-
laria infection (figure 2). In this model, we propose that following an infection with malaria, 
of the presence of a zinc deficiency can induce Th1 cell activation with subsequent produc-
tion of mainly type I signature cytokines (TNF-α, IL-12 and IFN-γ) which activate and in-
duce B-cells, in a series of events to produce antibody switching from IgM to IgG1 and 
IgG3 subclasses. IgG3 is responsible for malaria parasite clearance (Chapter 5). On the 
other hand, we hypothesise that malarial infection under conditions of magnesium defi-
ciency will lead more towards a Th2 response phenotype through the production of IL-5, IL-
10 and IL-13. IL-13 is well known for its pathological role through induction of IgG4 and 
IgE isotype switching and CD23 expression by human B cells [17-19]. In malaria, Th2 re-
sponses will induce B-cells to produce IgM switching to IgG2, IgG4 and possibly IgE. As 
discussed in Chapter 5, IgG2 may be involved in protection against malaria in association 
with IgG3, but IgG4 and IgE may be associated with the development of disease. It is im-
portant to note that while zinc deficiency showed insignificant changes in innate cytokine 
responses (Chapter 3) in the absence of infection but a high cytokine response in malaria 
infection, magnesium deficiency seemed to associate with increased IL-10 levels independ-
ent of a malaria infection. 
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Figure 2: Proposed model for the effects of zinc and magnesium deficiencies on immune 
responses in the course of infection by the malaria parasites. Iron deficiency anaemia varia-
bly influenced production of cytokines especially depending on malaria infection status (+/-
). Dashed line: negative effects; solid line: positive effects. 
 
Intervention strategies 
Micronutrient deficiencies have been widely regarded as contributing factors to morbidity 
from infections. Several studies have indicated a reduction in disease morbidities and mor-
talities as the result of micronutrient supplementation. Nutrient deficiencies lower the resis-
tance to infection. Conversely, fever from infection speeds depletion of calories and thus 
nutrients by influencing satiety centres that control appetite in the brain. As a result, loss of 
appetite and other symptoms (e.g. weakness, nausea and mouth lesions) limit the ability to 
eat. Programmes that prevent or control infection (e.g. immunization, improvement in hy-
giene and sanitation, safe water supply, and access to medicine and medical care) can all 
indirectly improve nutrition status. This thesis evaluated the impact that some micronutri-
ents may have on the immune response to malaria focusing on both innate and adaptive re-
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sponses. The intervention strategies should focus on precise selection of specific nutrient 
components given in combination at proper dosages and with suitable supplementation 
vehicles. Preschool children are the primary beneficiaries from such supplementation, but 
one of the main operational problems is that infants and toddlers have problems with swal-
lowing tablets or capsules that are conventionally used to supplement minerals and vita-
mins. The International Research on Infant Supplementation (IRIS) initiative has been 
evaluating newly created supplementation vehicles in the form of chewable tablet-cookies 
and nutrient-dense spreads suitable for use in tropical environments. The efficacy, safety 
and acceptability is being evaluated in populations of children where this study was carried 
and the initial results are promising. Another possibility is the breeding and dissemination 
of new staple crop varieties with high concentrations of micronutrients. This has the poten-
tial to create an entirely new, safe, low-cost and self-sustaining approach to deliver micro-
nutrients to poor farmer families that are difficult to reach through alternative approaches. 
Biofortification focusing on single nutrients or at most a few nutrients will be rewarding 
especially those which have shown potential impacts on the immune response to malaria as 
reported in this thesis. Malaria vaccine programmes should consider incorporating at least 
few micronutrients that have shown the potential to boost the immune response to malaria, 
like zinc, and to strengthen protection against the manifestation of  clinical disease. 
 
Potential challenges for micronutrient interventions 
Nearly half of the world’s population suffers from deficiencies in vitamins and minerals. 
Development of effective strategies for increasing the intake of micronutrients by people, 
most of them being the poor, bears a critical importance. The concern is how to produce 
strategies that are cost effective, acceptable and the most likely to succeed. Distribution of 
dietary supplements can be very efficacious in the short term. This approach may be diffi-
cult to sustain, however, because of poor adherence to supplementation, particularly if sup-
plements cause unpleasant side effects, cost, and difficulties in the distribution of supple-
ments. The best strategy would thus be fortification of staple foods with vitamins and min-
erals. This has been used and has proven to be successful in many developed countries; it 
can be used also in developing countries but can only be used with centrally processed 
foods and probably has limited impact in rural self-sustaining populations. Another strat-
egy could be the use of nutritionally enhanced staple food crops through conventional 
breeding or genetic engineering (‘biofortification’). These strategies could be very reward-
ing but may require relatively high initial capital investments. The main potential chal-
lenge is the acceptance of biofortified foods. Genetically modified foods have been facing 
wide spread problems of ethical and public acceptance. There have also been concerns that 
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genetically modified foods can cause allergic reactions or other health hazards. Community 
education and sound scientific advice to policy authorities is needed to clear misconceptions 
and to promote the use of these promising approaches.   
 
Potential challenges from parasite and vectors genetic factors 
Several host and parasite genetic factors will determine the fate of malaria infection and its 
consequences. Drug resistance of the parasite has been critical in malaria control. In addi-
tion, the extensive diversity in parasite surface proteins, which are the targets for the induc-
tion of the protective immune responses, and this combination proved to be catastrophic for 
malaria control. Malarial parasites are capable of evading the induction of a protective im-
munity by displaying an unprecedented level of antigenic variation, and in addition have 
developed several specific genetic mutations that confer resistance to the employed antima-
larial drugs. Integrated disease control is furthermore hindered by the resistance of Anophe-
les gambiae – the most important malaria vector in Africa – to commonly used insecticides, 
the inability of transgenic mosquitoes to compete under field condition and the ban of previ-
ously effective insecticide (DDT). In this context, the strengthened immune response to ma-
laria through micronutrient supplementation could still be a preferable potential strategy 
particularly in poor communities. Our findings show potential associations between nutrient 
deficiencies and cytokine responses although they lack sufficient evidence to warrant devel-
opment of public health interventions as a strategical measure to improve body’s immune 
defence as yet. However, the study provides insights for further research that can bring this 
goal within reach. More large scale dietary intervention studies at the community level can 
substantiate and elaborate on the findings described in this thesis. 
 
Potential challenges from host genetic factors 
An emerging challenge in chapter 3 is the IL-12B gene promoter polymorphisms that have 
been detected in Tanzania, and that have been reported to be associated with low IL-12 pro-
duction and increased malaria mortalities in children [33]. Suboptimal levels of IL-12 in 
early phases of infection may result in delayed or reduced triggers of subsequent cellular 
responses to infection. These polymorphisms may underestimate the real IL-12 cytokine 
response that could be expected under normal conditions. With the results of chapter 5, the 
recently reported ethnicity difference in malaria-specific antibody subclasses [27] poses a 
challenge on the variability in the response to malaria that can be expected in the population. 
This is in addition to the differences due to micronutrient deficiencies. Some genetic poly-
morphisms like those occurring in TNF-α and TLR-genes are challenging the potency of the 
immunological reactions. For example, it has been recently reported that single nucleotide 
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polymorphism haplotypes of TNF-α genes will result into significantly higher plasma levels 
of TNF-α [34]. Strong TNF-α responses have furthermore been associated with intestinal 
blockade of iron absorption leading to its systemic deficiency. On the other hand, the re-
ported TLR-4-mediated response to malaria in vivo and the polymorphisms on the TLR-4 
genes and their association with severe disease [35] are potential challenges to intervention 
programs aimed at correcting such nutrient deficiencies. Research efforts should be directed 
to address these challenges together with possible contribution of Th17 cells that produce a 
potential inflammatory cytokine IL-17 that may also contribute to malaria severity in en-
demic countries. 
 
Conclusion 
Despite the variable effects of micronutrients on several parameters of the immune response 
to malaria, the findings from all chapters in this thesis, add to our current knowledge of how 
useful micronutrient supplementation can become part of malaria control programs. In the 
face of the prevailing malaria parasite resistance potential to conventional antimalarial 
drugs, and given the potential development of protective immunity in endemic areas, the use 
of micronutrients supplementation may become an option for prevention, especially in 
young children.  
 
Recommendations for future research 
The potential effects of zinc and magnesium in boosting effective malaria-specific immune 
response as shown in Chapters 3 – 5 may help poor communities to prevent malaria. How-
ever, large scale dietary intervention trials are needed to confirm the medical importance of 
the findings that zinc deficiency and possibly magnesium, influence the balance in the pro-
duction of crucial cytokines that play a role in limiting the dangers of malaria. Focusing on 
supplementation trials may be rewarding in providing sufficient evidence for policy changes 
towards complementary strategies for malaria control programs, but more emphasis should 
be placed on elucidating the underlying mechanisms by which micronutrients interact with 
or promote the development of effective innate and adaptive responses. In addition, African 
countries should support the development of research facilities so that most of advanced 
immunological researches can be near the field, where malaria occurs. 
 
Food fortification of staple foods with vitamins and minerals, particularly those found to be 
deficient, should ideally, be implemented in developing countries. Lay people should be 
educated about the advantages of such programs, not only because they may improve the 
nutritional quality of foods but also because they may provide protection from malaria. Ac-
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ceptance of nutritionally enhanced staple food crops through genetic engineering has been 
debated among scientists and lay people. Sufficient evidence and clarification, will be re-
warding if focused on populations in need. Fortification of locally acceptable foods, and 
dietary modification to consume greater amounts of animal products and less phytates may 
contribute to better zinc and iron nutritional status. Focused researches on improving or de-
signing the best supplementation vehicles should be sought to suit children, because these 
are at highest risk of malaria and other infectious diseases. With expected goals clearly ex-
plained to the community in need of the service, whatever useful strategy will hopefully be 
acceptable.  
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This thesis aimed at investigating the role of genetic and nutritional factors that affect the 
immune response to malaria in Tanzanian children. The introductory chapter (Chapter 1) 
reviews the importance of nutritional deficiencies, particularly of zinc, and presents the hy-
pothesis that such deficiencies lead to impaired immunity and contribute to the burden of 
malaria. The chapter also describes current efforts to prevent malaria through intermittent 
preventive treatment, both in infants (IPTi) and pregnant women (IPTp). Sulfadoxine-
pyrimethamine is still used for first-line treatment of uncomplicated malaria, or, in many 
countries, to prevent malaria and anaemia in pregnancy. In malaria endemic areas, develop-
ment of resistance to previously valuable antimalarial drugs has been continuously reported 
for decades. Thus our initial longitudinal study aimed at measuring the prevalence of resis-
tance-associated mutations on dihydrofolate reductase (DHFR) and dihydropteroate syn-
thase (DHPS) genes (dhfr and dhps) that confer parasite resistance to sulphadoxine-
pyrimethamine (SP) that was used as an interim antimalarial drug after chloroquine resis-
tance. Although SP resistance-associated point mutations were highly prevalent, we ob-
served an adequate parasite response to SP (Chapter 2). We speculated that the impact of 
the dhfr and dhps mutations on SP resistance may be dependent at least in part on the pro-
tective immunity that has developed in response to frequent exposure to infection and may 
be weighed down by host immunity in endemic areas and thus impacts in the continued use 
of the drug for treatment of malaria. The impact of other drugs with similar mechanisms of 
action used as antibiotics in selecting mutations responsible for SP resistance needs there-
fore to be studied for their modulating activity of the immune response. These findings un-
derscore the relevance to further study the crucial involvement of the immune system in the 
development of protection against malaria but also affecting the efficacy of treatment mo-
dalities of malaria in various African conditions. 
 
In the subsequent cross-sectional studies, we assessed the effect of deficiencies of zinc and 
magnesium as well as iron deficiency anaemia on malaria-specific cytokine responses in-
dicative of innate immunity to Plasmodium falciparum (Chapter 3). In this study, we used 
Plasmodium falciparum-parasitised red blood cells (pRBCs) as antigens for in vitro stimula-
tion of peripheral blood mononuclear cells (PBMCs). Cytokines were measured in the su-
pernatant of cultured PBMCs after 24 hours of stimulation. Zinc deficiency was associated 
with a marked increase in monocyte-derived TNF-α concentration in children with malarial 
infection but not in their uninfected peers. In children with malarial infection, iron defi-
ciency anaemia was associated with elevated concentrations of TNF-α, whereas magnesium 
deficiency in children without malaria seemed to be associated with increased concentra-
tions of IL-10. Our findings reflected plasticity in cytokine profiles of monocytes reacting to 
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malaria infection under conditions of different nutrient deficiencies. Following the observa-
tion of the variable impact of micronutrients on innate cytokines, we evaluated the profile of 
both type I and type II cytokines and whether they were influenced by nutritional and ma-
laria status (Chapter 4). The cytokine measurements were performed at day 7 of stimulation 
anticipating that this timing was optimal for measuring effects on these cytokines mainly 
derived from activated T-cells. The results indicated a variable influence of nutrient defi-
ciencies on increased cytokine response with zinc deficiency and iron deficiency anemia 
having greater impact on type I and magnesium deficiency on type II cytokines. The subse-
quent study evaluated the plasma levels of naturally acquired antimalarial antibodies of vari-
ous IgG subclasses plus the total IgG and IgM levels and whether they were associated with 
zinc deficiency based on preceding chapters (Chapter 5). The results indicated a high vari-
ability in antibody levels with zinc deficiency, varying with age of the affected child. IgG3 
appeared to be predominant across all age subgroups within < 5 yrs aged children providing 
clues that IgG3 might confer immune protection to malaria under conditions of zinc defi-
ciency. Chapter 6 explored the association between CD36 deficiency, P. falciparum in vi-
tro adherence on purified CD36 and anemia in children. CD36 is a receptor that occurs on 
the surface of activated immune cells and vascular endothelial cells and participates in 
phagocytosis and lipid metabolism. We hypothesized that it could play a fundamental role in 
cytoadherence of erythrocytes that are parasitized by Plasmodium. Our results showed that 
CD36 deficiency was associated with protection against the development of malarial anemia 
in children and that it may be mediated through reduced cytoadherence of infected red blood 
cells to vascular endothelium.  
 
These studies demonstrate that despite antimalarial drug resistance, there is a potential for 
optimizing the immunological protective capacity in the population to confer parasite clear-
ance that can be variably influenced by micronutrient status. Improving nutritional status in 
this population could be rewarding not only to increase protection to malaria but possibly 
also to other infections. 
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In dit proefschrift worden de bijdragen van genetische en nutritionele factoren onderzocht 
op hun vermogen de immuunrespons tegen Plasmodium falciperum malaria in Tanzaniaanse 
kinderen te beïnvloeden. Het inleidende hoofdstuk (Hoofdstuk 1) word teen overzicht gege-
ven van het belang van dieet gebonden nutritionele deficiënties, in het bijzonder van zink, 
en wordt de hypothese ontwikkeld dat dergelijke deficiënties leiden tot verstoorde immuni-
teit die bijdraagt aan de ziektelast van malaria infecties. In dit hoofdstuk worden eveneens 
de huidige vormen van therapeutische interventies beschreven via zogenaamde intermitte-
rende preventieve behandeling bij zowel jonge kinderen (IPTi) als zwangere vrouwen 
(IPTp). Sulfadoxine-pyrimethamine wordt nog steeds in vele landen gebruikt als eerstelijns 
behandeling van ongecompliceerde malaria of om malaria en daaraan geassocieerde bloed-
armoede (anemie) tijdens de zwangerschap te voorkomen. In endemische malariagebieden 
wordt al gedurende vele jaren het probleem gerapporteerd van opkomende resistentie ont-
wikkeling tegen voorheen goed werkende antimalaria medicatie. In onze eerste longitudina-
le studie werd de prevalentie bepaald van resistentie geassocieerde mutaties in de genen die 
coderen voor dihydrofolate reductase (DHFR) en dihydropteroate synthase (DHPS) (dhfr 
and dhps) en die de parasieten resistentie bepalen tegen sulphadoxine-pyrimethamine (SP) 
dat gebruikt werd als interim antimalaria medicatie na de ontwikkeling van resistentie tegen 
chloroquine. Ofschoon aan SP resistentie geassocieerde puntmutaties veelvuldig voorkwa-
men vonden we dat de parasiet een adequate respons ontwikkelde tegen SP (Hoofdstuk 2). 
Wij speculeren dat het belang van de dhfr en dhps mutaties bij de ontwikkeling van SP re-
sistentie (gedeeltelijk) berust op de beschermende immuniteit die in respons op veelvuldige 
blootstelling aan infectie optreedt op de jonge kinderleeftijd. Tegelijkertijd wordt deze be-
schermende immuniteit in endemische gebieden onderdrukt en maakt daarmee het continue 
gebruik van deze behandeling van malaria met SP noodzakelijk. Het belang van andere me-
dicatie met vergelijkbare werkingsmechanismen als antibioticum om mutaties te selecteren 
die verantwoordelijk zijn voor SP resistentie dient daarom onderzocht te worden op het ver-
mogen de beschermende immuunrespons te moduleren. Deze bevindingen onderstrepen het 
belang om de cruciale rol van het immuunsysteem nader te onderzoeken voor het opwekken 
van bescherming tegen malaria maar ook de beïnvloeding van de effectiviteit van de behan-
deling van malaria onder condities in Afrika. 
 
In de hierop volgende cross-sectionele studies hebben wij het effect onderzocht van zink- en 
magnesiumdeficiëntie in combinatie met ijzer deficiëntie anemie op de malaria-specifiek 
geïnduceerde cytokinenresponsen die indicatief zijn voor de aangeboren immuniteit tegen 
Plasmodium falciperum infectie (Hoofdstuk 3). In deze studie hebben we Plasmodium fal-
ciparum-geparasiteerde rode bloed cellen (pRBCs) als antigeen gebruikt voor de in vitro 
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stimulatie van perifere bloed mononucleaire cellen (PBMCs) van jonge kinderen. De cytoki-
nes werden gemeten in het kweeksupernatant van PBMCs na 24 uur stimulatie. Zink defici-
entie bleek geassocieerd aan een sterke stijging in het van monocyten afkomstige cytokine 
TNF-α bij kinderen met een malaria infectie maar niet bij kinderen zonder deze infectie. Bij 
kinderen met een malaria infectie bleek ijzer deficiëntie anemie geassocieerd aan een ver-
hoogde concentratie TNF-a, terwijl magnesium deficiëntie in kinderen zonder malaria infec-
tie geassocieerd bleek te zijn aan verhoogde productie van het anti-inflammatoire cytokine 
IL-10. Onze bevindingen reflecteren de plasticiteit in de cytokinenprofielen van monocyten 
die verschillend reageren op malaria infectie afhankelijk van de nutriënt deficiëntie van het 
desbetreffende kind. Na het vaststellen van de variabele invloed van micronutriënten op de 
productie van cytokines die de innate immuniteit reflecteren, hebben wij het profiel van type 
I (IFN-γ) en type II (IL-5, IL-13) cytokines en de invloed daarop van malaria infectie en 
micronutriënt status onderzocht (Hoofdstuk 4). De cytokinenmetingen werden uitgevoerd 
na 7 dagen stimulatie waarbij de effecten op de uitgroei en differentiatie van geactiveerde T-
cellen waarneembaar zijn. De resultaten geven aan dat er een variabele invloed is van mi-
cronutriënt deficiëntie op de cytokinenproductie waarbij zinkdeficiëntie en ijzer deficiëntie 
anemie leiden tot een verhoogde productie van type I cytokines, terwijl magnesiumdeficiën-
tie de productie van type II cytokines verhoogt. Vervolgens hebben wij de plasmaspiegels 
van verschillende typen malaria-specifieke antistoffen bepaald die via natuurlijk voorko-
mende infecties waren gevormd. Speciaal is er gekeken naar malariaspecifieke antistoffen 
van de IgG subklassen en naar totale IgG en IgM antistoffen en of deze geassocieerd waren 
aan zink deficiëntie gebaseerd op voorgaande onderzoeken (Hoofdstuk 5). De resultaten 
gaven aan dat zinkdeficiëntie leidt tot een grote mate van variabiliteit in antistofspiegels bij 
de individuele kinderen en dat deze spiegels afhankelijk blijken te zijn van de leeftijd van 
het kind. Malariaspecifieke antistoffen van de IgG3 klasse waren dominant in alle leeftijds-
groepen van kinderen jonger dan 5 jaar waarbij aanwijzingen werden verkregen dat IgG3 
antistoffen immuunbescherming tegen malaria kunnen geven onder zinkdeficiëntie condi-
ties. In Hoofdstuk 6 hebben wij de associatie onderzocht tussen CD36 deficiëntie, P. falci-
parum in vitro adherentie aan gezuiverd CD36 en het optreden van ijzer deficiëntieanemie 
bij jonge kinderen. CD36 is een receptor die voorkomt op het oppervlak van geactiveerde 
immuuncellen (zoals dendritische cellen en macrofagen), erytrocyten en vasculaire en-
dotheelcellen en die participeert in fagocytose en lipide metabolisme. Wij onderzochten de 
hypothese dat CD36 een fundamentele rol zou kunnen spelen in cytoadherentie van erytro-
cyten die geïnfecteerd zijn met Plasmodium. Onze resultaten toonden aan dat CD36 defici-
entie geassocieerd was aan bescherming tegen de ontwikkeling van malaria geïnduceerde 
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anemie en dat dit mogelijk een gevolg was van gereduceerde cytoadherentie van geïnfec-
teerde rode bloedcellen aan het vasculaire endotheel.  
 
Deze studie laat zien dat er in de populatie van Afrikaanse kinderen een grote potentie aan-
wezig is om via optimalisatie van de immunologische bescherming tegen infectie met Plas-
modium falciperum malaria parasieten te verkrijgen ondanks het voorkomen van resistentie 
van de parasiet tegen de gebruikte geneesmiddelen en dat deze potentie verschillend beïn-
vloed wordt door de micronutriënt status van het individuele kind. Het verbeteren van de 
voedingsstatus van deze populatie kan daarmee de aanwezige beschermende immuniteit 
tegen malaria infectie versterken en wellicht ook tegen andere infecties.  
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